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PREAMBLE 
In recent years, knowledge in the field of medical sciences has been 
expanding more rapidly than ever before. For centuries medicine was a 
static discipline, based on the paradigm of humoral pathology. After the 
opening of the human body in the Renaissance the apodictic concepts 
of the Antics were gradually abandoned and replaced by insights based 
on observation and measurable data. The development of the natural 
sciences gave an impetus to the developing medical science, and medical 
classification and nosology were based mainly on clinical signs and 
symptoms, and on pathology. 
Modern techniques in electrophysiology, radiology, chemistry, bioche-
mistry, and pathology changed fundamentally our concepts of etiology 
and pathophysiology. Especially, immunology, molecular genetics and 
biochemistry hold great promise for the future. As a result of these 
developments, classical nosology also in neurology changed, and new 
nosological entities arose not primarily based on pathological criteria. 
Leigh syndrome constitutes an example of a neurological disorder to 
which newly developed techniques have brought new insights. Originally 
described as a progressive neurological degenerative disorder of unknown 
etiology, the diagnosis was based on pathologic criteria (subacute necro-
tizing encephalomyelopathy). It is nowadays incorporated in the, also 
biochemically characterized, mitochondrial encephalomyopathies. In the 
future it will probably be possible to classify these degenerative and 
progressive disorders according to their DNA pathology. 
Despite all these technical developments the clinician's diagnostic efforts 
are still guided initially by patient history, and observation of clinical signs 
and symptoms. This clinical nosology must be integrated in new classi-
fication systems. 
With expanding knowledge the fabric of medical science steadily becomes 
more complex and intricate. Although it has become impossible for the 
clinician to master the whole field of basic sciences that bring out the 
new developments, it is the task of the clinician to evaluate and integrate 
these new developments into the medical practice of every day. With this 
concept in mind, the present study of Leigh syndrome has been undertaken 
by a practising neurologist to bring together and integrate established 
knowledge and new insights and concepts to a state of the art. 
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CHAPTER I 
INTRODUCTION, AIM AND OUTLINE 
OF THE STUDY 
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LEIGH SYNDROME: A MITOCHONDRIAL ENCEPHALO-
MYOPATHY 
The role of mitochondria in human pathology remained obscure during 
a long time. The first report of a patient with a myopathy and an abnormal 
mitochondrial function was published in 1959.' In 1962, Luft et al2 reported 
on the same patient, a 35-year-old woman who suffered from an euthyroid 
hypermetabolism and a mild myopathy. In muscle biopsy they found 
morphologically abnormal mitochondria and a defective mitochondrial 
function due to uncoupling of respiration and phosphorylation in these 
mitochondria. Price3 used the term mitochondrial myopathy to indicate 
a clinical condition characterized by muscle weakness and fatigue, asso­
ciated with morphological or biochemical mitochondrial abnormalities. 
The histopathological hallmark of the mitochondrial myopathies is the 
ragged-red fiber.4 The ragged-red appearance consists of subsarcolemmal 
and intermyofibrillary purplish blotches on the modified Gomori trichrome 
stain,5 caused by abnormal accumulation of mitochondria. Excessive 
accumulation of lipid droplets may overshadow the mitochondrial changes. 
In the past, much attention has been paid to the often peculiar morpho­
logical mitochondrial alterations, such as abnormalities of mitochondrial 
cristae or paracrystalline inclusions in the intramitochondrial space.6 
However, classification of mitochondrial myopathies based only on clinical 
and morphological criteria was unsatisfactory. 
With the finding of biochemical errors of energy metabolism in several 
types of mitochondrial myopathies a classification based on biochemical 
abnormalities has appeared: "9 
1. defects of substrate transport, e.g. carnitine deficiency and carnitine 
palmitoyltransferase deficiency, 
2. defects of substrate utilization, e.g. pyruvate dehydrogenase complex 
deficiency, 
3. defects of the respiratory chain, e.g. NADH dehydrogenase deficiency 
or cytochrome с oxidase deficiency, 
4. defects of the energy transducing and conserving system, e.g. hyper-
metabolic myopathy or myopathies with 'loose coupling'. 
In the clinical spectrum of mitochondrial myopathies three subgroups have 
been identified:10 
1. chronic progressive external ophthalmoplegia and limb weakness, 
2. proximal weakness with fatigability, 
3. predominantly or exclusively central nervous system disease. 
The fact that in some patients with a mitochondrial myopathy also a central 
nervous system involvement was present, led Shapira et al' to propose 
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the concept of mitochondrial encephalomyopathies: a group of complex 
multisystem disorders with structurally and/or functionally abnormal 
mitochondria in brain and/or muscle. The group of mitochondrial en-
cephalomyopathies encompasses the syndromes of Leigh,12 of Alpers,13 
of dysmyelination,9 of myoclonus epilepsy with ragged-red fibers 
(MERRF),14 and of mitochondrial myopathy, encephalopathy, lactic aci-
dosis and strokelike episodes (MELAS).15 
Leigh syndrome or subacute necrotizing encephalomyelopathy is a pro-
gressive and often fatal neurological disorder, preferentially affecting young 
children.The clinical picture of Leigh syndrome shows a great variability. 
The diagnosis is still based on well-defined neuropathological criteria, but 
because a biopsy of the afflicted central nervous system areas is not feasible 
during life, the diagnosis can only be made by postmortem examination 
of the central nervous system. In the last decade Leigh syndrome was 
found to be associated with several defects of pyruvate metabolism or 
of the respiratory chain, and therefore it can be classified in the group 
of mitochondrial encephalomyopathies. 
AIM AND OUTLINE OF THE STUDY 
This study intends to provide a review of the literature data concerning 
Leigh syndrome and to present results of own investigations in patients 
with Leigh syndrome, with special emphasis on the clinical and biochemical 
aspects of the disorder. 
The most important questions this study aims to answer are: 
1. Can a better characterization of the clinical picture of Leigh syndrome 
be achieved? 
2. Is it possible to distinguish clinically distinct subgroups within the 
spectrum of Leigh syndrome? 
3. What is the contribution of technical (neurophysiological, neuroradio-
logical and biochemical) investigations to diagnosis and to insight into 
the pathophysiology of Leigh syndrome? 
4. Is it possible to formulate better criteria for a diagnosis of Leigh 
syndrome durante vitam? 
The results of a literature study of 173 patients with proven Leigh syndrome 
are presented in Chapter II. This extensive survey provides data on clinical, 
genetic, biochemical and therapeutic aspects of the syndrome. In the other 
chapters (III-X) of our study the results of own investigations are presented. 
Within our patient group it was possible to distinguish a clinical subgroup 
with a distinct picture of parkinsonism in 3 patients. The value of 
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neurophysiological studies in Leigh syndrome was assessed in 12 patients 
(Chapter IV) and the value of an intravenous pyruvate loading test in 
9 patients (Chapter V). Two patients with a proven and one patient with 
a suspected NADH dehydrogenase deficiency, as well as one patient with 
a partial cytochrome с oxidase deficiency (all in muscle biopsy material) 
are reported (Chapters VI-IX), and in one family a defect in oxidative 
metabolism was restricted to brain (Chapter X). Comparison of our results 
with literature data, contributions of our publications to the general concept 
and diagnosis of Leigh syndrome, and aspects of pathophysiology and 
antenatal diagnosis as well as future perspectives are discussed in Chapter 
XL 
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CHAPTER II 
LEIGH SYNDROME 
A Review of the Literature 
P.M.M. van Erven, J.P.M. Gillessen, E.M.W. Eekhoff, 
F.J.M. Gabreëls, W.H. Doesburg, W.A.J.G. Lemmens, 
J.L. Slooff, W.O. Renier and W. Ruitenbeek 
Clinical Neurology and Neurosurgery 
(accepted for publication) 
ABSTRACT 
Results of a literature survey of 173 patients with Leigh syndrome are 
presented, with emphasis on signs and symptoms in relation to age at 
onset, contributions of technical investigations to the diagnosis, patho-
physiology, genetic considerations and therapeutic aspects. Based on this 
study we are of the opinion that it is possible to come to a diagnosis 
of 'most probable Leigh syndrome' durante vitam on the combination 
of clinical signs and symptoms, autosomal recessive mode of inheritance, 
association with a defect of energy metabolism, and CT or MRI abnor-
malities. 
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INTRODUCTION 
Since the first description by Dennis Leigh in 1951,1 over 200 case reports 
of subacute necrotizing encephalomyelopathy (SNE) or Leigh syndrome 
have been published. The pathology of SNE is well-documented.2,3 Clinical 
signs and symptoms, and course of the disease show considerable variability 
and do not allow a diagnosis of Leigh syndrome. Although in recent years 
several biochemical abnormalities of energy metabolism4"7 that were 
associated with and possibly causally related to Leigh syndrome have been 
elucidated, the definite diagnosis still rests on pathologic findings. 
We performed a literature survey of 173 cases of pathologically proven 
Leigh syndrome,1"6,8""1 with emphasis on clinical presentation, results of 
neurophysiological, radiological, chemical and biochemical investigations, 
pathophysiology, genetics and therapy. First a synopsis of the pathology 
of Leigh syndrome is given, and then the results of our study will be 
presented. 
PATHOLOGY 
The lesions, that usually destroy gray and white matter without predilection, 
may be evident on macroscopic examination as focal gray-brown disco-
lorations or cystic softenings in brainstem and medulla oblongata, or 
bilaterally symmetrical 'butterfly' lesions in periaqueductal region and 
tegmentum.2 These often sharply punched-out lesions may be seen in various 
parts of the central nervous system (CNS). The incidence of lesions with 
regard to the main anatomical divisions of the central nervous system 
in the cases reviewed by Montpetit et al3 is as follows: brainstem 98%, 
cerebrum 92%, spinal cord 74% and cerebellum 58%. The structures that 
show the highest incidence of lesions are brainstem tegmentum (92%), 
basal ganglia (67%), visual system (65%), substantia nigra (64%) and 
thalamus (51%). Apart from the tegmentum, brainstem lesions are often 
seen in midbrain tectum, ventral part of the medulla oblongata, and inferior 
olives. The spinal cord lesions are localized mainly in the anterior horns, 
dorsal columns and pyramidal tracts (Fig 1). In the cerebellum, dentate 
nucleus and corpus medulläre show the highest incidence of lesions. Lesions 
rarely occur in cerebral or cerebellar cortex and mamillary bodies. 
Histopathologically the changes consist of spongy necrosis with glial 
reactions and vascular proliferation. The lesions show a spongy loosening 
and vacuolation or even microcystic disintegration of the nervous paren-
chyma. Breakdown of myelin is almost constantly present in the lesions 
with microcystic spongiosis. A microglial reaction accompanies the dis-
integration of gray and white matter. A moderate to marked increase of 
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cytoplasmic and gemistocytic astroglia and a loss of Oligodendroglia are 
present in most of the lesions. The vessels are dilated and there is an 
increase in the number of capillaries and precapillaries often with endothelial 
proliferation. Nerve cells and axons are remarkably preserved in the necrotic 
areas (Fig 2). 
Ultrastructural studies of the CNS reveal axonal swelling and degene-
ration, loosening of myelin lamellae with formation of vacuoles, and 
hypertrophy and hyperplasia of capillaries with endothelial prolifera-
tion.83,84'"2 Structural mitochondrial abnormalities of the CNS have, to 
our knowledge, never been reported in Leigh syndrome. 
In peripheral nerve signs of myelin loss and axonal degeneration have 
been described.16'30·40'52'82 
In muscle 'ragged-red' fibers have been reported in 2 patients.75'105 On 
electronmicroscopy of skeletal muscle of these patients accumulation of 
mitochondria and mitochondrial enlargement, proliferation of cristae and 
paracrystalline inclusions are seen. In another patient mitochondrial 
enlargement was reported in heart muscle.113 
Rutledge et al108 reported a series of 12 patients with Leigh syndrome 
of whom 7 had a hypertrophic cardiomyopathy, an infrequent abnormality 
in the other case reports.11·1218·40·75·84'113·114 
The CNS lesions in Leigh syndrome closely resemble those of Wernicke's 
disease in topographical distribution and histopathology. In Leigh syn-
drome, however, hemorrhage is very rare and the mamillary bodies are 
rarely involved, and the substantia nigra and basal ganglia are often affected, 
whereas the opposite holds true for Wernicke's disease. But on morpho-
logical grounds it is not possible to come to a definite distinction between 
the two entities.76 
Fig 1. Spinal cord (hematoxylin-eosin, x8.3). Extensive microcystic degeneration. 
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Fig 2. Detail anterior horn (hematoxylin-eosin, bar = 50 μπι). Spongy dystrophy, vascular 
proliferation (arrows) and relative sparing of motor neuron cell. 
CRITERIA OF SELECTION OF LITERATURE PATIENTS 
We selected a total of 173 patients. In 165 patients the diagnosis was 
proven on pathologic examination, and in 8 patients the diagnosis was 
confirmed in a sib. Age at onset, clinical signs and symptoms, and course 
of the disease had to be adequately described. 
We divided the 173 patients in 4 groups according to age at onset: neonatal 
(n=20; 0-4 weeks), early infantile (n=81; 4 weeks-1 year), infantile (n=48; 
1-4 years) and juvenile (n=24; 4-16 years). Adolescent ( n = l ) 1 1 4 and adult 
( n = 1 3 ) 9 5 " 2 ' " - 1 2 1 patients were not included in the study because in some 
of them there were serious doubts considering the correctness of the 
diagnosis.118 Pathology, clinical signs and symptoms, and course of the 
disease in the adolescent and adult patients, however, seem essentially the 
same as in the juvenile patients. 
SEX RATIO 
Numbers of patients and sex ratios in each group are shown in Table 
1. There is a preponderance of males over females, that becomes more 
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pronounced with increasing age at onset. In the adult onset patients, 
however, the sex ratio is 1.0. As the mode of inheritance is presumably 
autosomal recessive (see 'genetic considerations'), equal numbers of male 
and female patients would be expected. The sex ratios of the first three 
age groups are, more or less, compatible with this hypothesis (p = 0.49, 
0.18 and 0.18 respectively, sign test), but that does not hold true for the 
juvenile group (p = 0.01, sign test). 
Table 1. Age distribution and sex ratio of 173 Leigh patients from the literature 
Neonatal 
Early infantile 
Infantile 
Juvenile 
Total 
0 - 4 w 
4 w - 1 y 
1- 4 y 
4 - 1 6 y 
0 - 1 6 y 
π (%) 
20 (12) 
81 (46) 
48 (28) 
24 (14) 
173 
M 
2 
3 
3 
4 
3 
F 
3 
2 
2 
1 
2 
M = male; F = female. 
AGE AT ONSET AND SURVIVAL 
Leigh syndrome presents preferentially in very young children (median 
age at onset 0.8 years) (Table 1). The age at death, documented in all 
deceased patients (n=165) has a median of 2.1 years. In Table 2, median 
time of survival after onset of symptoms is presented. The duration of 
the disease actually ranges between a few hours (in the neonatal and early 
infantile groups) and one or more decades (Table 2). 
Table 2. Median and maximum time of survival (duration of illness) after onset of disease 
Median survival* Maximum survival* 
M + F M F M + F 
Neonatal 0.9 1.0 0.6 9.0 
Early infantile 0.9 0.9 0.8 19.5 
Infantile 0.9 0.9 0.9 11.5 
Juvenile 5.5 4.8 8.0 33.0 
*years; M = male; F = female. 
SYMPTOMATOLOGY AT ONSET 
Signs and symptoms at onset of 169 patients are summarized in Table 
3. Feeding problems encompass dysphagia, inadequate sucking, regurgi­
tation, anorexia and periodic vomiting. It can be a presenting complaint, 
especially in the younger children, or develop later in the course of the 
illness and is even quite often a terminal phenomenon. Eye signs and 
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symptoms consist of blindness, optic atrophy, diminished pupillary reaction 
to light, mild ophthalomoplegia, strabismus, nystagmus and jerky eye 
movements. Irregular respiration and periods of hyperventilation, apnea 
and frequent sighing are the main respiratory problems. Ataxia, dysdi-
adochokinesis, hypermetria and explosive speech indicate cerebellar in-
volvement. Extrapyramidal signs are hypokinesia, rigidity, dystonia, athe-
tosis, choreoathetosis and ballism. 
According to Pincus122 the onset of the disease is insidious in 71%, 
subacute in 14% and acute in 15%. Seizures, sometimes status epilepticus, 
and coma are often seen in cases with acute presentations. 
Table 3. Signs and symptoms at onset of Leigh syndrome (%) 
Feeding problems 28 
Motor retardation 27 
Hypotonia 22 
Eye signs and symptoms 18 
Mental retardation 12 
Seizures 8 
Respiratory problems 7 
Cerebellar signs 7 
Pyramidal signs S 
Extrapyramidal signs 3 
Coma 2 
THE COURSE OF THE DISEASE 
The course of the disease122 is chronic and unremitting in 55%, chronic 
and remitting in 28%, subacute and unremitting in 15%, and acute and 
unremitting in 2%. 
In Table 4, symptomatology in the course of the disease of all patients 
is summarized. Height is below the 10th percentile in 17% of the children 
and skull circumference in 5%. The most frequent signs and symptoms 
are presented for the different age groups. It can be seen from Table 4 
that eye signs and symptoms show the same incidence in all age groups. 
Pyramidal, cerebellar, extrapyramidal and cardiac signs show an increasing 
incidence with increasing age. Respiratory problems, motor retardation 
and feeding problems show a gradual decrease in incidence with increasing 
age at onset. Deafness, that is often considered one of the clinical hallmarks 
of Leigh syndrome, is encountered in only 7% of the patients. Disturbances 
of cardiac rhythm constitute the main part of cardiac signs and long lasting 
periods of tachycardia and bradycardia are reported. The hypertrophic 
cardiomyopathy108 is often asymptomatic or only a systolic murmur is 
heard. 
As the cause (or one of the causes) of death a neurogenic disturbance 
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Table 4. Signs and symptoms in the course of the disease in relation to age at onset 
Neonatal 
(n=20) 
Early infantile 
(n=81) 
Infantile 
(n=48) 
Juvenile 
(n=24) 
All age groups 
(n=173) 
Eye signs and symptoms 
ophthalmoplegia 
nystagmus 
optical atrophy 
loss of vision 
diminished pupillary reaction 
abnormalities of retina/macula 
Respiratory problems 
irregular respiration 
apnea periods/terminal 
hyperventilation 
Hypotonia 
Pyramidal signs 
extensor response 
hyperreflexia 
hypertonia 
paresis 
Motor retardation/deterioration 
Feeding problems 
anorexia 
vomiting 
weight loss 
Exercise intolerance/fatigue 
Infections (decompensation/deterioration) 
60% 
65% 
77% 81% 
25% 
30% 
25% 
25% 
25% 
5% 
30% 
50% 
15% 
31% 
32% 
26% 
21% 
21% 
5% 
68% 
56% 
24% 
11% 
68% 
60% 
60% 
60% 
25% 
30% 
40% 
40% 
25% 
55% 
35% 
50% 
68% 
59% 
40% 
44% 
28% 
35% 
26% 
6% 
43% 
35% 
35% 
54% 
52% 
54% 
79% 
46% 
31% 
25% 
15% 
21% 
4% 
54% 
35% 
13% 
42% 
33% 
50% 
42% 
4% 
17% 
54% 
33% 
21% 
8% 
36% 
32% 
29% 
23% 
19% 
6% 
69% 
49% 
30% 
12% 
61% 
35% 
25% 
15% 
23% 
29% 
35% 
25% 
29% 
42% 
50% 
42% 
38% 
29% 
42% 
46% 
17% 
33% 
8% 
58% 
55% 
47% 
39% 
32% 
32% 
27% 
18% 
37% 
35% 
30% 
Table 4. (continued) 
Neonatal Early infantile Infantile Juvenile All age groups 
(n=20) (n=81) (n=48) (n=24) (n=173) 
Cerebellar signs 22% 65% 54% 39% 
ataxia 20% 20% 
dysarthria 4% 
Mental retardation 
Seizures 30% 45% 
generalized 15% 36% 
partial (focal) 20% 20% 
Extrapyramidal signs 21% 
rigidity/akinesia 6% 
chorea 9% 
athetosis/dystonia 6% 
tremor 1% 
Cardiac signs and symptoms 10% 15% 
Deafness/hearing loss 5% 10% 
Sensibility disorder 3% 
31% 
25% 
19% 
21% 
2% 
6% 
56% 
15% 
17% 
10% 
10% 
6% 
2% 
50% 
33% 
46% 
25% 
8% 
12% 
46% 
33% 
25% 
17% 
25% 
13% 
13% 
4% 
37% 
36% 
24% 
18% 
7% 
5% 
34% 
10% 
27% 
17% 
9% 
8% 
6% 
2% 
of respiration is mentioned in 44%, sudden coma e.c.i. in 26%, pneumonia 
and cardiac disorder both in 12%, and hyperpyrexia in 3%. The cause 
of death is stated unknown in 36%. 
TECHNICAL INVESTIGATIONS 
NEUROPHYSIOLOGICAL STUDIES 
In 50% of the patients described in literature, results of electroencepha-
lography (EEG) and in 18% results of electromyography (EMG) and nerve 
conduction velocity studies are mentioned. Evoked potentials (VEP/BAEP) 
are recorded in only 5 patients. The three patients mentioned by Hecox 
et al123 of whom two had BAEP abnormalities, are not included in our 
series of 173 patients because description of the clinical data of the patients 
is lacking. 
The neurophysiological findings in the literature patients are presented 
in Table 5. As can be seen from this table there are no constant or specific 
EEG abnormalities. Diffuse slowing and epileptic manifestations of various 
nature are seen most often. Nerve conduction velocities, measured in 24 
patients, are reduced in 11 (46%). In only a few patients (3/22) EMG 
shows a myopathic picture. Evoked potentials are normal in 2 and abnormal 
in 3 patients. 
RADIOLOGICAL INVESTIGATIONS 
In a number of Leigh patients it is possible to demonstrate the cerebral 
lesions on CT scan and magnetic resonance imaging (MRI). MRI is much 
more sensitive than CT scan, in that it can visualize multifocal abnormalities 
in some cases, where CT scan fails to detect any abnormal findings.124"126. 
The most constant finding in Leigh syndrome is that of bilateral 
radiolucent or hypodense regions in the basal ganglia, most often localized 
in the putamina.88,97'103'126"130. Bilateral symmetrical low density areas in 
the thalamus, throughout the midbrain and adjacent to the fourth ventricle 
and scattered throughout the cerebral cortex have also been reported.103,125 
These findings are dynamic and may vary with time.131 
Bilateral low density areas in the lentiform nuclei are also encountered 
in other pathologic states, such as Wilson's disease,132 postanoxic states,133 
carbon monoxide134 and methylalcohol poisoning,135 and (familial) stri-
atonigral atrophy.88 
CT/MRI abnormalities in the basal ganglia region do not necessarily 
clinically present with extrapyramidal signs. This fits in with the finding 
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Table 5. Electrophysiological studies in 173 Leigh syndrome patients in the literature 
EEG (n=87)· 
EMG (n=31): 
VEP(n=4): 
BAEP (n=l). 
Normal 
Diffuse slowing 
Focal slowing 
Increase of amplitude 
Dysrhythmia 
Epileptic manifestations 
- generalized spikes 
- paroxysms 
- focal spikes 
- spike and wave complexes 
- hypsarhythmia 
Electromyography: 
Nerve conduction velocities: 
Normal 
3 
4 
4 
4 
2 
Normal 
Denervation 
Myopathy 
Normal 
Reduced: motor+sensory 
motor 
sensory 
Not ehcitable over right occipital cortex 
Not ehcitable 
Right ear: normal, left ear: not ehcitable 
31 
29 
6 
4 
2 
17 
17 
2 
3 
13 
11 
3 
1 
2 
1 
1 
(1) 
of pathologic lesions in the basal ganglia in 65% of the cases in the series 
of Montpetit et al3 while only 12% of the patients manifested extrapyramidal 
signs. 
CHEMICAL AND BIOCHEMICAL STUDIES 
In 1965, Worsley et al33 described lactic acidosis in familial Leigh syndrome. 
In the series of 173 patients, serum pyruvate levels are measured in only 
21 patients and show an increase in 20 patients. Serum lactate levels are 
increased in 27 out of 33 patients, and serum alanine levels in 10 out 
of 12 patients. Cerebrospinal fluid (CSF) pyruvate, lactate and alanine 
levels show an increase in 5 out of 5, 5 out of 6, and 6 out of 6 patients 
respectively. In CSF there is an increase in protein level in about half 
of the patients. In Table 6 the most important chemical findings in serum, 
CSF and urine are summarized. 
Since the first report by Hommes et al4 of a pyruvate carboxylase (PC) 
deficiency in liver associated with Leigh syndrome, there have been several 
reports on deficiencies of pyruvate metabolism and respiratory chain defects 
in liver, muscle, kidney, brain and fibroblasts in Leigh patients. Several 
other authors"0,136,137 have linked PC deficiency with pathologically proven 
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Table 6. Results of biochemical studies in Leigh syndrome 
Serum CSF Urine 
Increased pyruvate level 
Increased lactate level 
Increased alanine level 
Increased protein level 
20(21) 
27(33) 
10(12) 
5(5) 
5(6) 
3(4) 
41 (85) 
3(5) 
1(2) 
6(6) 
In parentheses the total number of patients in whom the results of the particular chemical 
study were mentioned. 
SNE, but methods and interpretation of findings remain controversial.138,139 
Deficiencies of the pyruvate dehydrogenase complex (ронс),5·106'107'109'140'141 
a defective activation of PDHc9 4 '4 2 and defects of the respiratory chain, 
i.e. cytochrome с oxidase6'143144 and NADH-CoQ oxidoreductase,7 have 
been found in association with Leigh syndrome (Fig 3). Deficiencies of 
pyruvate metabolism or respiratory chain defects restricted to the CNS 
have never been reported in Leigh syndrome. All the deficiencies reported 
in Leigh syndrome (PC, PDHc, cytochrome с oxidase and NADH-CoQ 
oxidoreductase) have in common that even a severe deficiency can occur 
without evidence of SNE.1 4 5 1 4 8 
NADH 
latty acids 
KD H j 
ketone bodies 
glucose 
NADH 
FADH2 
lactate 
ψ | NADH - CoO - c y t b e , — c y t c — cyl a a 3 — О г 
Fig 3. The formation of pyruvate from nutnents, and the role of the Krebs cycle and respiratory 
chain in the catabohsm of pyruvate (see text for further explanation). 
1 = pyruvate carboxylase, 2 = pyruvate dehydrogenase complex, 3 = ^-oxidation of fatty 
acids, 4 = NADH dehydrogenase, 5 = FADH2 oxidizing proteins, 6 = cytochrome с oxidase. 
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PC, PDHc and the respiratory chain are located in the mitochondria 
and their deficiencies give rise to a disturbance of mitochondrial metabolism. 
Mitochondrial dysfunction is the common denominator in the so-called 
mitochondrial myopathies,149'150 a clinically and biochemically heteroge-
neous group of disorders characterized by structurally or numerically 
abnormal mitochondria or by abnormal functioning of mitochondria. In 
the clinical spectrum of the mitochondrial myopathies three syndromes 
can be distinguished:151 1) chronic progressive external ophthalmoplegia 
(CPEO) and limb weakness, 2) proximal weakness with fatigability, and 
3) predominantly or exclusively CNS disease. As it became generally 
recognized that CNS disease is a prominent feature in a subgroup of the 
mitochondrial myopathies, Shapira et al152 expanded the concept of 
mitochondrial myopathy to mitochondrial encephalomyopathy. The mi-
tochondrial encephalomyopathies show CNS and muscle involvement, 
associated with abnormalities in mitochondrial metabolism and/or mor-
phology. Leigh syndrome is one of these mitochondrial encephalomyo-
pathies. Other representatives of this group are the syndromes of Alpers,153 
dysmyelination,150 myoclonus epilepsy associated with ragged-red fibers 
(MERRF),154 and the so-called MELAS syndrome,155 which stands for 
mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike 
episodes. 
The close resemblance of the lesions in SNE and Wernicke's disease 
prompted research of thiamine metabolism in Leigh syndrome. In 1969, 
Pincus et al55 discovered in vitro inhibition of the mitochondrial enzyme 
thiamine pyrophosphate-adenosine triphosphate phosphotransferase by 
urine and serum of a patient with SNE. Thiamine triphosphate (TTP) 
was absent in the brain of their patient and they presumed this was caused 
by a so-called 'inhibiting factor'. Later the same authors reported low 
values of TTP in SNE brains, roughly correlating with the sites of the 
brain lesions.156 The urine inhibitor test, however, failed to prove a specific 
biochemical marker for antemortem diagnosis of Leigh syndrome because 
it has a 6% false-positive rate, and no inhibiting factor could be dem-
onstrated in 6 out of 29 patients.157 
GENETIC CONSIDERATIONS 
Leigh syndrome is generally considered to be a familial degenerative 
disorder with an autosomal recessive mode of inheritance.158,159 Arguments 
in favour of an autosomal recessive mode of inheritance in our patient 
group are a parental consanguinity in 8 families and the familial occurrence 
of Leigh syndrome in both sexes in 56 families, in which only one generation 
is afflicted. In these 56 families there are 56 probands, 53 sibs who are 
21 
also affected, and 108 healthy sibs. When the index cases are omitted, 
33% (53/161) of the sibs in these families are affected, which is significantly 
more (p = 0.01) than would be expected in autosomal recessive inheritance. 
The reason for this increased number of affected sibs is not clear to us. 
There is a bias of ascertainment because those families with 2 or more 
affected sibs are more likely to be published. In 12 families with healthy 
and affected sibs, the sex of the affected children is recorded and there 
is a boy-girl ratio of 1.0. An X-linked mode of transmission was postulated 
by Benke et al1 0 4 in two halfbrothers with Leigh syndrome who had different 
fathers. The existence of X-linkage in some cases of Leigh syndrome might 
explain the preponderance of males in our series (see 'sex ratio'). In the 
same sibship, cases with a different age at onset occur and thus there 
are no genetic grounds for a division of Leigh syndrome in four age groups 
according to age at onset. 
An interesting new perspective in the transmission of certain respiratory 
chain defects is formed by the maternal inheritance of mitochondrial 
defects.160 Some of the components of the respiratory chain, e.g. subunits 
of cytochrome с oxidase are coded for by mitochondrial DNA.1 6 1 In the 
formation of the zygote almost all the mitochondria are contributed by 
the ovum.162 So, mitochondrial properties are inherited from the mother. 
This maternal or mitochondrial type of inheritance can be distinguished 
from the Mendelian type of inheritance by involvement of subsequent 
generations with a higher number of affected individuals in each generation 
than expected in autosomal dominant diseases, and involvement of both 
sexes in contrast to X-linked recessive transmission.163 Maternal inheritance 
has not yet been conclusively documented in Leigh syndrome, but it is 
probable that it is present in some cases.164 Maternal inheritance has been 
reported in MERRF syndrome,154,165 one of the mitochondrial encepha-
lomyopathies. 
THERAPEUTIC CONSIDERATIONS 
No causal treatment of the condition is available so far, and no controlled 
trials have been performed with substances or drugs that were reported 
to be benificial in patients with disturbances of pyruvate metabolism or 
the respiratory chain, clinically presenting as mitochondrial (encephalo)-
myopathies. Apart from general measures as a low carbohydrate diet to 
prevent exacerbations from carbohydrate sensitivity in PC and PDHc 
deficiencies,166 the therapeutic efforts in patients with disturbances of 
pyruvate metabolism or respiratory chain are aimed at circumventing the 
deficient enzyme, or at optimizing enzyme function by pharmacological 
doses (of precursors) of cofactors. 
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In ketotic states (starvation, high fat ketogenic diet), brain tissue can 
utilize ketone bodies produced by the liver in direct proportion to their 
concentrations in the arterial blood.167 Ketogenic diet provides clinical and 
biochemical improvement in some patients with PC and PDHc deficien-
166,168,169 
cies. 
In PC deficiency, administration of additional glutamine and aspartate, 
both precursors of oxaloacetate, can be helpful.136'147'170 Administration 
of the PC cofactor biotin seems to be ineffective.66171 
In PDHc deficiency, administration of thiamine (a cofactor of the first 
enzyme of the PDH complex) and a-lipoic acid (a cofactor of the second 
enzyme of the PDH complex) can be considered. These compounds, alone 
or in combination, have been administered with variable re-
sults>4,36,.68,.69,172,.73 
Recently, favourable results have been reported from therapeutic efforts 
in respiratory chain deficiencies.174'175 Riboflavin, a precursor of the flavin 
moiety of flavoproteins, appears to be of benefit in patients suffering from 
a reduced activity of one of the many flavoproteins, for example in patients 
with a NADH-CoQ oxidoreductase deficiency176 and in patients with a 
multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria type II).177 
FINAL REMARKS 
We performed a literature study on 173 pathologically proven Leigh 
patients. The sex ratio of 4 : 1 (Table 1) in the juvenile onset group deviates 
significantly from the expected 1 : 1 . We have no explanation for this 
phenomenon, nor for the preponderance of males in the whole group of 
173 patients. X-linked inheritance, that might explain this male excess, 
has only been documented once in Leigh syndrome, and our findings 
confirm the autosomal recessive mode of inheritance of Leigh syndrome. 
Signs and symptoms show a great variability, which is not surprising 
considering the variable topography of the pathologic lesions. However, 
there is a cluster of signs and symptoms (Tables 4 and 5) that, although 
not pathognomic, is encountered often in Leigh syndrome. The division 
of the patients in this study in 4 groups according to age at onset, does 
not intend to suggest that there exist distinct neonatal, early infantile, 
infantile and juvenile forms of Leigh syndrome. Clinical signs and symp-
toms, the results of biochemical studies and the lack of true breeding 
do not support the concept of distinct age-related subgroups of Leigh 
syndrome. The group with a juvenile age at onset, however, can be separated 
from the rest in that the disease in these children runs a much more 
protracted course and median survival is much longer than in the other 
groups (Table 2). 
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Neurophysiological studies do not contribute to the diagnosis. Cerebral 
CT scan and MRI can show bilateral hypodense areas in the basal ganglia 
region. 
Leigh syndrome has been firmly associated with a number of deficiencies 
in the mitochondrial energy metabolism. Morphological or functional 
mitochondrial abnormalities are characteristic of the group of mitochon-
drial myopathies and one of its subgroups, with predominantly or mainly 
CNS disease, the mitochondrial encephalomyopathies. Leigh syndrome 
belongs to this latter group. 
A disturbance of pyruvate metabolism or a deficiency of the respiratory 
chain often lead to an elevation of the levels of lactate and pyruvate in 
serum, CSF and urine. Determination of the levels of lactate and pyruvate 
in body fluids is therefore of utmost importance when a patient is suspected 
of Leigh syndrome (Table 6). 
In the future much more insight into the pathogenesis of the mitochon-
drial (encephalo)myopathies will be gained when the biochemical defects 
can be identified at a molecular level. Another promising development 
is that of in vivo phosphorus magnetic resonance spectroscopy (31P-NMR), 
that has proven useful in the noninvasive diagnosis of mitochondrial 
myopathies, in monitoring therapeutic improvements in mitochondrial 
myopathies,178 and in defining the pathophysiological basis of these 
disorders.179 
Despite all recent developments, the definite diagnosis of Leigh syndrome 
still rests on pathologic findings. But, in our opinion, it is possible to 
come to a clinical diagnosis of most probable Leigh syndrome on the 
basis of the following criteria: 1) signs and symptoms, 2) autosomal recessive 
mode of inheritance, 3) disturbance in energy metabolism, 4) bilateral 
hypodense areas in the basal ganglia region on CT or MRI. 
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ABSTRACT 
Three patients are reported with a neurological disorder in whom hypo-
kinesia and rigidity are the most prominent clinical manifestations. On 
CT-scan and MRI, two patients show bilateral lesions in the striatum, 
mainly in the putamen, and the third patient shows bilateral lesions in 
the postenor limb of the internal capsule. Chemical investigations suggest 
a disturbance of pyruvate metabolism in all three patients. In skeletal muscle 
of two patients a disturbance of pyruvate oxidation was established. In 
one patient it was caused by a NADH dehydrogenase defect. The signs 
and symptoms, the bilateral lesions in the striatum in two patients, and 
the association with a disturbance of pyruvate metabolism justify clas-
sification of these patients as mitochondrial encephalomyopathies, resem-
bling Leigh syndrome. Therefore in infantile and juvenile patients presenting 
with parkinsonism, a mitochondrial encephalomyopathy must be consi-
dered and the mitochondrial energy metabolism should be investigated. 
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INTRODUCTION 
The mitochondrial encephalomyelopathies constitute a group of neuromus-
cular disorders associated with defects in mitochondrial metabolism or 
structure (Shapira et al, 1977; Gabreëls et al, 1984). Representatives of 
this group are the syndromes of Leigh (Hommes et al, 1968; Farmer et 
al, 1973; Willems et al, 1977; Van Erven et al, 1985) and Alpers (Cabreéis 
et al, 1984), dysmyelination (Sengers et al, 1984), Kearns-Sayre syndrome 
(Karpati et al, 1973), myoclonus epilepsy with 'ragged-red fibres' (Fukuhara 
et al, 1980), and the MELAS syndrome, an acronym which stands for 
mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike 
episodes (Pavlakis et al, 1984). These syndromes vary considerably in clinical 
signs and symptoms, but they all show cerebral spongiosis, although to 
a varying extent and with different localisation (Walter, 1983). 
The diagnosis of Leigh syndrome or subacute necrotizing encephalomyel-
opathy rests on characteristic pathologic findings in brainstem, spinal cord, 
and basal ganglia, especially the striatum (Jellinger and Seitelberger, 1970). 
Ante mortem diagnosis of probable Leigh syndrome can be made when 
clinical signs and symptoms indicate involvement of the above mentioned 
parts of the central nervous system (CNS) (Pincus, 1972) and when a 
disturbance of pyruvate metabolism is present (Van Erven et al, 1987). 
The presence of bilateral hypodensities in the basal ganglia in CT scanning 
or abnormal signal intensities in magnetic resonance imaging (Hall and 
Gardner-Medwin, 1978) can further support the clinical diagnosis. 
In this report we present three patients with a mitochondrial enceph-
alomyopathy and a clinical diagnosis of Leigh syndrome, in whom 
hypokinesia and rigidity constitute the initial and most prominent clinical 
manifestations. 
CASE REPORTS 
In none of the cases there is parental consanguinity. Family histories are 
unremarkable and do not contain evidence of neuromuscular or central 
neurological disorders. 
Case 1 
The pre-, peri- and postnatal periods of this boy are normal. Apart from difficulties in 
feeding, his early development is uneventful. He reaches motor milestones with some delay. 
At the age of 2 years he can walk alone, but is clumsy. At that age, exercise intolerance 
and slow recovery after infections (otitis, bronchitis) become apparent. Because of slowly 
progressive deterioration of motor abilities over the years he is presented at our department 
at age 7 years. 
On examination marked hypokinesia with a stooped posture and semiflexion of the 
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extremities are sinking Full scale IQ is normal Height is 123 cm (P50), weight is 20 kg 
(PIO) and head circumference is 50 5 cm (P20) General examination is normal except for 
periods of paroxysmal tachypnoea and tachycardia There is a strabismus divergens of the 
nght eye, a first-grade horizontal nystagmus on looking to the right, and a rotatory nystagmus 
on looking upwards. Fundoscopy is normal Speech is soft, slow, monotonous and somewhat 
slurred He shows a generalized ngidity of muscle tone with a mask-like face and a marked 
hypokinesia with start hesitation, but tremor is not apparent Dystonie movements of the 
trunk are occasionally seen. A cerebellar type of ataxia and dysmetna of the extremities 
are apparent. There is no sensory loss Tendon reflexes are hyperactive. Plantar reflexes 
show an extensor response. He is wheelchair-bound but can walk a few small steps 
Case 2 
This male patient is born after an uncomplicated pregnancy and delivery. Early psychomotor 
development is normal Motor milestones are reached in due time, but motor performance 
is always slow and clumsy At the age of 8 years, a deterioration of motor function appears 
He often falls and speech becomes soft and slurred. On intercurrent infections a marked 
deterioration of speech and motor function appears, followed by a slow recovery. 
On examination at the age of 9 years we see a small, pale boy with thin, atrophic muscles, 
a mask-like face and a stooped posture with flexion of arms and legs, who functions on 
a normal mental level Height is 124 cm (P5), weight is 21 kg (P2 5) and head circumference 
is 53 cm (P50). General examination is normal except for frequent sighing and periods of 
tachy- and bradycardia. Visual acuity is sufficient, but fundoscopy reveals a bilateral optic 
atrophy. Speech is soft, slow, monotonous and slurred He walks with shuffling, small steps 
and has start hesitation There is a generalized rigidity of muscle tone with a cogwheel 
phenomenon, more marked on the left side Tremor is not apparent. The limbs are ataxic 
There are no sensory disturbances. Tendon reflexes are hyperactive, more markedly on the 
left, and plantar reflexes show an extensor response. 
At the age of 14 years, only a slight progression of hypokinesia and ngidity is noted. 
Case 3 
This male patient's medical history is unremarkable until age 14 years when changes in 
his conduct with social withdrawal and aggressive behaviour, associated with a loss of motor 
abilities, exercise intolerance and deterioration on intercurrent infections, become manifest. 
On examination at the age of 17 years, we see a small, thin boy with a masklike face 
and a parkinson-like stooped posture with flexion of arms and legs, who functions on a 
normal mental level Height is 163 cm (P2.5), weight is 41 kg (P2 5) and head circumference 
is 52.5 cm (PÍO) Irregular breathing with frequent sighing and bouts of sinus tachycardia 
of 140 beats/min and sinus bradycardia of 50 beats/min are noted Fundoscopy is normal. 
There is a strabismus convergens of the nght eye. Eye movements are jerky with loss of 
smooth pursuit. There is a marked hypokinesia, and a generalized ngidity with a cogwheel 
phenomenon. Tremor is not apparent, but the hands show athetotic movements. When 
walking, one remarks start hesitation, small steps and a mild broad-based gait. Speech is 
soft, monotonous and slurred. There is generalized muscular weakness. Ataxia and intention 
tremor indicate cerebellar involvement. There are no sensory disturbances. Tendon reflexes 
are hyperactive with bilateral extensor plantar responses. 
TECHNICAL INVESTIGATIONS 
Neurophysiological studies (electroencephalogram, electromyogram, nerve 
conduction velocity studies, visual evoked potentials, brainstem auditory 
evoked potentials and median nerve somatosensory evoked potentials) are 
normal in all patients. 
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Electrocardiography and echocardiography are unremarkable in our 
patients. 
NEURORADIOLOGICAL INVESTIGATIONS 
Neuroradiological investigation consists of cerebral computed tomography 
(CT) and magnetic resonance imaging (MRI) in all patients. A four-vessel 
angiography is performed in two patients, and is normal in both. 
CT scans in patients 1 and 2 show bilateral symmetrical hypodense areas 
in the putamen. In patient 2 there is also diffuse central and cortical atrophy 
of the cerebral hemispheres and cerebellum. In patient 3 there are no 
abnormalities (Figs 1-3). 
The MRI scans are performed on a super-conducting 0.5 Tesla Philips 
scanner, and are directed to the striatum because of the hypokinesia and 
rigidity of our patients. Axial sections are performed through the striatum 
using both Ti- and T2-weighted pulse-sequences. In one section a mixed-
mode sequence is used for determination of Ti and T2 relaxation times 
(IR: TE 50 ms, TI 500 ms, TR 1500 ms; SE: TE 50 ms, TR 1000 ms; 
four echos) (Mills et al, 1984; Orthendahl et al, 1984; Brown et al, 1985; 
Kjos et al, 1985). 
MRI investigation of the striatum of patient 1 demonstrates hypo-
intensive grey matter abnormalities bilaterally in the putamen and in the 
head of the right caudate nucleus on the calculated Ti image. These 
abnormalities are hyper-intensive on the calculated T2 image (Fig 1). In 
patient 2 identical lesions are found bilaterally in the putamen (Fig 2). 
In patient 3 the calculated T2 image shows hyperintensive areas bilaterally 
in the posterior limb of the internal capsule (Fig 3). In Table 1 calculated 
T] and T2 values of the putamen are compared with similar values of 
the thalamus. In children above age 2 years Ti and T2 values of cerebral 
tissue in a magnet of 0.5 Tesla are in the same range as in adults: 600 
± 100 ms and 100 ± 20 ms respectively (mean ± SD) (Bottomley et al, 
1984; Bydder and Young, 1985; Komiyama et al, 1987). 
LABORATORY INVESTIGATIONS 
STANDARD INVESTIGATIONS 
Results from blood and urinary studies, including haematologic evaluation, 
renal, hepatic, thyroid and adrenal functions, serum protein, serum protein 
electrophoresis and Immunoelectrophoresis are normal. Other normal 
values include serum pH, рСОг and bicarbonate, serum lipids, short-chain 
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Fig 1. (Case 1). A, CT image. Hypodense areas in the putaminal regions. B, calculated Ti image. Hypointensive areas in the putaminal regions 
and head of the right caudate nucleus. C, calculated T2 image. Hyperintensive areas in the putaminal regions and head of the right caudate 
nucleus. 
Fig 2. (Case 2). A, CT image. Hypodense areas in the putaminal regions. B, Ti-weighted image (SE: TE 30 ms, TR 400 ms). Hypointensive 
areas in the putaminal regions. С, calculated Ti image. Hyperintensive areas in the putaminal regions. 
Fig 3. (CaseS). A, CT image. Normal densities in the regions of the basal nuclei. B, calculated Ti image. Normal intensities in the regions 
of the basal nuclei. C, calculated T2 image. Hypointensive areas bilaterally in the posterior limb of the internal capsule. 
Table 1. Calculated Τ, and Τ2 relaxation times (in ms at 0 5 Tesla) in putamen and thalamus 
Patient 1 
Patient 2 
Patient 3 
Control subjects 
thalamus 
putamen 
thalamus 
putamen 
thalamus 
putamen 
left 
right 
left 
right 
left 
right 
left 
right 
left 
right 
left 
right 
CT 
N 
N 
Ρ 
Ρ 
Ν 
Ν 
Ρ 
Ρ 
Ν 
Ν 
Ν 
Ν 
Ν 
MRI 
Ν 
Ν 
Ρ 
Ρ 
Ν 
Ν 
Ρ 
Ρ 
Ν 
Ν 
Ν 
Ν 
Ν 
Τ,* 
1087І100 
1035І136 
518±65 
590±196 
1428±451 
1382І358 
1479±232 
1430±135 
568І46 
527±50 
640±40 
690±41 
600І100 
Τ2* 
86±6 
86±6 
231±15 
215±27 
90±9 
95±8 
370±38 
336±115 
87±7 
89±5 
93±5 
91±7 
100±20 
Ν = normal imaging, Ρ = pathological imaging, * values ± 1 SD 
fatty acids and carnitine (total and free), growth hormone, thiamine, 
pyndoxine, cobalamine, creatine kinase, copper, zinc, manganese and 
caeruloplasmin, lysosomal enzymes in leucocytes, urinary copper excretion 
and organic acids and amino acids in urine. Levels of homovamllic acid 
(HVA) and vanylmandelic acid (VMA) in CSF and 24 h urine sample 
are normal. Appropnate studies ruled out immunologic and chronic 
infectious diseases, and disorders caused by toxic agents. 
In cerebrospinal fluid (CSF), cell number, protein content, protein 
electrophoretic and immunoelectrophoretic patterns, mineral concentra­
tions and levels of HVA and 5-hydroxyindole acetic acid (5HIAA) are 
normal. 
EXAMINATION OF ENERGY METABOLISM 
Serum levels of glucose are normal in all patients. Levels of pyruvate and 
lactate, and the lactate/pyruvate ratios in serum and CSF are shown in 
Table 2. Serum lactate level shows an intermittent elevation in patient 
2. In all patients there is an elevation of CSF pyruvate and lactate levels. 
Levels of acetoacetate and /3-hydroxybutyrate are normal in serum and 
CSF. 24 h lactate excretion in urine is elevated in patient 1 (148 and 405 
дтоі/ттоі creatinine; normal <100 дтоі/ттоі creatine) and normal 
in the other patients. Moderate physical exercise (walking for a few minutes) 
leads to a marked increase in serum lactate and pyruvate levels in all 
patients. Only patient 3 shows an abnormal lactate response to oral glucose 
tolerance loading (1.75 g/kg) as lactate reaches a level of 2300 μιηοΐ/ 
1 (normal 450-1700 μιηοΐ/ΐ), while in all three patients glucose and pyruvate 
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responses are normal. After intravenous pyruvate loading (500 mg/kg) 
(Dijkstra et al, 1984), pyruvate response is abnormal in case 2, while lactate 
response is abnormal in all patients (Fig 4). 
Magnetic resonance spectroscopy is not performed in our patients. 
Table 2. Lactate and pyruvate levels in serum and cerebrospinal fluid 
Serum Cerebrospinal fluid 
Pyruvate* Lactate* Ratio L/P Pyruvate* Lactate* Ratio L/P 
Patient! 115-139 
Patient 2 131-158 
Patient 3 81-120 
1270-1410 
1520-2130 
810-1160 
9.7-11.9 
10.4-13.5 
9.7-10.0 
197-238 
180 
154 
3750-5050 
3690 
3210 
18.9-21.2 
20.5 
20.8 
Controls 
(n=200) 60-155** 460-1720** up to 15.0 85-132**· 1200-1600*** up to 15.0 
* /imol/l; ·* P 2, - P,, 5; *** Mean ± 2 SD. 
6000, 
| 5000 
9 4000 
« 
^* 
с 
ΰ 3000 
с 
О 
υ 
S 2000 
υ 
я 
E 1000 
0) 
w 
Case 1 
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Minutes after loading infusion 
90 
Fig 4. Lactate response to pyruvate loading (500 mg/kg). 
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BIOCHEMICAL STUDIES 
MATERIALS AND METHODS 
Enzymatic studies are performed in cultured fibroblasts, and in liver and 
muscle tissue, obtained at biopsy. Oxidative metabolism in fibroblasts is 
evaluated by measuring the 14C02 production rate from [l-14C]pyruvate 
and [2-14C]pyruvate (Willems et al, 1978), and the activities of cytochrome 
oxidase (Cooperstein and Lazarow, 1951) and citrate synthase (Srere, 1969). 
Pyruvate carboxylase activity is measured in liver homogenate (Utter and 
Keech, 1963), using a regenerating system for acetyl-CoA (Henning and 
Seubert, 1964). Oxidation of [l-14C]pyruvate by liver is measured according 
to Willems et al (1977) in the presence of 1 mmol/l malate. Pyruvate 
oxidation rate, and activities of citric acid cycle and respiratory chain are 
evaluated by measuring 14C02 production from [l-14C]pyruvate and [U-
14C]malate in fresh muscle homogenate (Bookelman et al, 1978b). The 
capacity of muscle to generate adenosine triphosphate (ATP) and creatine 
phosphate (CrP) is investigated under conditions in which adenylate kinase 
is inhibited (Ruitenbeek et al, 1981). In muscle homogenate, stored at 
-70oC, activities of citrate synthase, cytochrome с oxidase, succinate: 
cytochrome с oxidoreductase (Fischer et al, 1985), N A D H O : oxidore-
ductase (Fischer et al, 1986b) and NADH:Qi oxidoreductase (Fischer et 
al, 1986b) are measured. Cytochrome content (Bookelman et al, 1978a) 
is measured in isolated muscle mitochondria in the presence of succinate 
and cyanide, and subsequently in the presence of antimycin A (1 μξ). 
Protein is assayed according to Lo wry et al (1951). 
RESULTS 
Pyruvate oxidation in fibroblasts is normal in all patients. In liver tissue, 
pyruvate carboxylase activity is normal in the 2 patients measured (patients 
1 and 3). The rate of pyruvate oxidation by liver tissue is normal in patient 
1 but decreased in patient 2 (21 nmol '"COi/h/mg protein; controls 45 
- 205). Biochemical studies in muscle tissue (see Table 3) reveal that 
cytochrome levels are normal in all patients. In patient 1, pyruvate oxidation 
rate and ATP + CrP production rate from pyruvate is mildly reduced 
when expressed on basis of protein, but when expressed on basis of citrate 
synthase, the results are normal. So, a clear disturbance is not found. 
In patients 2 and 3, oxidation rates for pyruvate and malate are decreased, 
as is ATP + CrP production from pyruvate. In patient 3, the activities 
of NADH:Qi and NADH:02 oxidoreductase are reduced. 
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Table 3. Results of biochemical studies in tissues 
Oxidation (600 g supernatant) 
[l-14C]pyruvate + malate 
[l-'4C]pyruvate + carnitine 
[U-14C]malate + pyruvate + malonate 
[U-14C]malate + acetylcamitine + malonate 
[U-"C]malate + acetylcamitine + arsemte 
ATP Metabolism (600 g supernatant) 
ATP + CrP production from pyruvate 
Enzyme activities (600 g supernatant) 
Citrate synthase 
Cytochrome с oxidase 
Succinate cytochrome с oxidoreductase 
NADH:0 2 oxidoreductase 
NADH Q, oxidoreductase 
Cytochromes (isolated mitochondria) 
Cytochrome аа
у 
Cytochrome b 
Cytochrome с + с, 
Cytochrome с oxidase 
Patient No. 
1 
212' 
356' 
340' 
351' 
291' 
29212 
183 
191' 
369« 
382« 
5346 
2.607 
2 
123 
151 
150 
156 
91 
1214 
100 
647 
405 
482 
2 70 
3 
69 
103 
69 
69 
34 
496 
57 
166 
224 
8.55 
5.05 
486 
488 
531 
4 26 
Controls 
Range 
273-705 
266-941 
320-996 
317-1155 
198-274 
3354-9993 
27-77 
73-284 
22-84 
14-45 
8.7-25.3 
271-585 
317-511 
365-923 
129-3 43 
No 
20 
20 
20 
20 
19 
20 
18 
39 
18 
12 
11 
14 
14 
14 
16 
1
 nmol 14C02/h/mg protein,
2
 nmol/h/mg protein, ' mU/mg protein,4 nmol cytochrome с 
reduced/min/mg protein,s nmol NADH oxidized/min/mg protein;6 pmol/mg protein; 
7
 U/mg protein. 
HISTOPATHOLOGIC STUDIES 
In all patients, histochemical studies of quadriceps muscle tissue, obtained 
by biopsy, show no abnormalities. No 'ragged-red fibres' are noted in 
the trichromie stained sections, and no Sudan-black positive droplets are 
seen. Immunohistochemical studies of cytochrome oxidase reveal no 
abnormalities. Ultrastructural studies also show no abnormalities. 
THERAPY 
Therapy with L-Dopa and benseraside (Madopar®) did not result in any 
improvement in our patients. 
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DISCUSSION 
We report three sporadic patients with a progressive degenerative neu-
rological disorder. The clinical picture is dominated by severe hypokinesia 
and rigidity, although in two patients slight athetotic or dystonic movements 
are seen. The association of dystonia and parkinsonism in untreated 
patients, as is seen in our patients, albeit uncommon, has been reported 
more often (Katchen and Duvoisin, 1986; Lewitt et al, 1986). Our patients 
show frequent sighing and abrupt changes in respiratory and cardiac rate. 
Pyramidal and cerebellar signs are present in all three and ocular signs 
in two patients. Their clinical status deteriorates markedly on intercurrent 
infections, followed by slow recovery. Cognitive functioning is normal and 
there are no epileptic manifestations. Neurophysiological studies reveal 
no abnormalities. Cerebral CT and MRI show bilateral putaminal lesions 
in patients 1 and 2, lesions of the head of the right nucleus caudatus 
in patient 1, and bilateral lesions of the internal capsule in patient 3. 
Chemical investigations of serum, urine and CSF reveal as most conspicuous 
findings an elevation of CSF lactate, pyruvate and lactate-pyruvate ratio, 
a marked increase in serum lactate and pyruvate levels after a moderate 
physical exercise, and an abnormal lactate response to pyruvate loading 
in all patients. These abnormalities point to a disturbance of pyruvate 
metabolism. In liver and muscle tissue, no histochemical or ultrastructural 
abnormalities are seen, but biochemical studies reveal a NADH dehydro-
genase deficiency in patient 3 (Table 3). A disturbed functioning of the 
respiratory chain could be a possible cause for the reduced pyruvate 
oxidation rate found in patient 2. As the cytochrome content is normal, 
the defect must be localised at the level of the NADH dehydrogenase 
or at the level of coenzyme Q (Fischer et al, 1986a). At the time of the 
muscle biopsy, enzyme assays for this part of the respiratory chain were 
not yet available. In patient 1 no biochemical abnormalities are found 
in muscle tissue. A defect of oxidative metabolism restricted to brain is 
possible in this patient. 
Our patients are suffering from a mitochondrial encephalomyopathy 
according to the definition of Shapira et al (1977). 
The differential diagnosis of CT scan abnormalities similar to the 
putaminal lesions seen in our patients and in other patients with Leigh 
syndrome (Hall and Gardner-Medwin, 1978) is considerable. Moreover, 
the differential diagnosis is not necessarily restricted to parkinson-like 
hypokinetic-rigid syndromes. Depending on the kind and extension of 
lesions in various parts of the striopallidum, the resulting functional 
disorders may be associated with a variable symptomatology of postural 
disorders and involuntary movements, that can manifest in kaleidoscopic 
symptoms, while in other cases the pathological lesions are not necessarily 
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associated with any clinical symptoms at all. This also holds true for Leigh 
syndrome (Montpetit et al, 1971; Sipe, 1973). Bilateral parkinsonian rigid 
hypokinesia and dysarthria, as seen in our patients, is called the pseu-
dobulbar syndrome (Denny-Brown, 1962). Hypokinesia can be regarded 
as the primary symptom of nigrostriatal failure (Denny-Brown, 1962; 
Marsden, 1982), while rigidity can be considered as caused by pathological 
changes in the putamen and the release of pallidofugal discharge (Martin, 
1965). The pseudobulbar syndrome may be caused by infarcts (Denny-
Brown, 1962), which are sometimes visible on CT scan (Tolosa and 
Santamaria, 1984; Friedman et al, 1986), by methanol (Bourrât et al, 1986) 
or by carbon monoxide intoxication (Klawans et al, 1982). None of these 
causes seem to be present in our patients. 
Putaminal CT lesions are associated with dystonia in the patients of 
Burton et al (1984), in patients with familial dystonia with optic atrophy 
(Marsden et al, 1986; Novotny et al, 1986) and in some cases of infantile 
bilateral striatal necrosis (Goutières and Aicardi, 1982). The clinical data 
of the two children described by Burton et al (1984) are compatible with 
Leigh syndrome. Familial dystonia with optic atrophy is excluded in our 
patients because of the exclusive dystonic syndrome in such patients. 
Infantile bilateral striatal necrosis may also be associated with hypokinesia, 
rigidity or a mixture of extrapyramidal symptoms (Miyoshi et al, 1968; 
Roessmann and Schwartz, 1973; Roytta et al, 1981). Goutières and Aicardi 
(1982) divide the syndrome of infantile bilateral striatal necrosis into three 
subgroups: 1) those of definite or probable Leigh syndrome, 2) cases of 
familial degeneration of the striatum with an insidious onset and a slow 
progressive course, and 3) cases which present with abrupt neurological 
dysfunction following an acute systemic illness. The distinguishing feature 
with our patients is the presence of mental retardation and the absence 
of metabolic features of Leigh syndrome. Our patients show features of 
both the first and the third subgroup: metabolic abnormalities strongly 
suggest Leigh syndrome, and there is a deterioration during systemic 
illnesses. Because the latter phenomenon is frequently seen in patients with 
Leigh syndrome (Table 4), the first and the third subgroup of Goutières 
and Aicardi may be identical. Wilson disease (Williams and Walshe, 1981) 
and anoxia (Aicardi et al, 1985), which also may cause putaminal CT 
abnormalities and extrapyramidal symptoms, have been excluded in our 
patients. 
Hallervorden-Spatz syndrome (Dooling et al, 1974) and juvenile Hun-
tington chorea (Jongen et al, 1980) are always characterized by a rapidly 
progressive mental deterioration and, to our knowledge, there are no CT 
abnormalities in the putamen. Moreover, in Huntington chorea, there is 
a positive family history. In patients with Hallervorden-Spatz syndrome 
(2 own patients, unpublished data) and juvenile Huntington chorea (Jongen 
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et al, 1980) normal CSF lactate and pyruvate levels are found. None of 
our patients has a history of use of phenothiazines or butyrophenones, 
or drug abuse. 
Signs and symptoms of our patients are compatible with Leigh syndrome. 
In Table 4, signs and symptoms of our patients are compared with data 
from a literature study of 173 patients with proven Leigh syndrome, that 
show ocular signs, pyramidal and respiratory signs, and feeding problems 
in more than half of the cases. 
CT and/or MRI abnormalities bilaterally in the basal ganglia, most 
striking in the putamina and often associated with hemispheral or brainstem 
lesions have been reported in a number of proven and suspected Leigh 
patients (Hall and Gardner-Medwin, 1978; Ollivier and Diebler, 1980; 
Schwartz and Hutchinson, 1981, with additional remark of Weisberg, 1982; 
Chi et al, 1981; Burton et al, 1984; Onuma et al, 1986; Koch et al, 1985, 
1986; Davis et al, 1987). In none of these patients, however, the movement 
disorder is dominated by a parkinson-like hypokinetic rigid syndrome as 
seen in our patients. MRI is superior to CT in that it may show abnormalities 
not yet apparent in CT (Geyer et al, 1986; Koch et al, 1986; Onuma et 
al, 1986). In the putaminal regions of patients 1 and 2 the T2 relaxation 
times are significantly prolonged (Table 1), corresponding with abnormal 
CT and MRI images of those regions. The Ti values are abnormal only 
in patient 2. The calculated Ti and T2 values of the thalamus (Table 1) 
show normal T2 values and prolonged Ti values in patients 1 and 2 without 
any abnormality in CT or MRI images of this area. It might, therefore, 
be useful in suspected Leigh patients to calculate the Ti and T2 values 
of clinically relevant areas even if MRI pictures are not abnormal. However, 
it is not necessary that basal ganglia abnormalities can be visualized by 
Table 4. Signs and symptoms of our patients compared with signs and symptoms of 173 pro-
ven Leigh patients (age at onset between 0 to 16 years) from the literature and with a sub-
group of 24 juvenile Leigh patients (age at onset between 4 to 16 years) from the literature 
Feeding problems 
Repiratory signs and symptoms 
Cardiac signs and symptoms 
Ocular signs 
Pyramidal signs 
Extrapyramidal signs 
- hypokinesia-ngidity 
- dystonia 
Cerebellar signs 
Exercise intolerance 
Deterioration on infections 
Patient No. 
1 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
2 
-
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
3 
-
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
Patients from 
literature 
(n=173) 
55% 
69% 
18% 
78% 
61% 
24% 
9% 
6% 
39% 
47% 
39% 
Juvenile patients 
from literature 
(n=24) 
42% 
54% 
25% 
79% 
88% 
46% 
25% 
13% 
54% 
50% 
42% 
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CT or MRI in Leigh syndrome, as we found no evidence of such 
abnormalities in four other cases of proven Leigh syndrome. 
Leigh syndrome has been associated with various types of mitochondrial 
deficiencies. Deficiencies of pyruvate carboxylase (Hommes et al, 1968), 
pyruvate dehydrogenase complex (Farmer et al, 1973), cytochrome с oxidase 
(Willems et al, 1977), NADH dehydrogenase (Van Erven et al, 1985), and 
a disturbance in the activation of the pyruvate dehydrogenase complex 
(DeVivo et al, 1979) have been reported in Leigh syndrome. 
In conclusion, signs and symptoms, the association with a disturbance 
of pyruvate metabolism and the bilateral putaminal lesions on CT and 
MRI make the clinical diagnosis of Leigh syndrome in these patients highly 
probable. 
We would like to stress that in children with a disorder presenting with 
hypokinesia and rigidity, especially if accompanied with basal ganglia 
lesions on CT or MRI, mitochondrial energy metabolism should be 
investigated in order to evaluate the possibility of Leigh syndrome. In 
these patients, lactate and pyruvate levels of serum and CSF should be 
measured. In some cases a pyruvate loading test can also provide useful 
information (Van Erven et al, 1987). 
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ABSTRACT 
We performed neurophysiological studies in 12 patients with the Leigh 
syndrome (6 pathologically confirmed and 6 clinically diagnosed). The 
results are compared with data derived from a literature survey of 173 
Leigh syndrome patients. We found no positive contribution of neuro-
physiological studies towards the diagnosis of the Leigh syndrome. 
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INTRODUCTION 
The Leigh syndrome (1) is one of the so-called mitochondrial enceph-
alomyopathies (2). The latter are a group of degenerative neurological 
disorders associated with disturbances in mitochondrial energy metabolism 
and/or morphologically abnormal mitochondria. A definite diagnosis can 
only be made on post mortem examination of the central nervous system. 
The pathological abnormalities are well-defined and consist of symmetrical, 
bilateral, sharply demarcated areas of spongy degeneration and demyeli-
nation, characterized by vascular, endothelial and glial proliferation, with 
relative sparing of the neurons (3). The highest incidence of involvement 
is shown by the brainstem tegmentum, basal ganglia, spinal cord and 
cerebellum (4). No specific diagnostic tests are available. Apart from the 
diagnosis of a disturbance of pyruvate metabolism, the value of chemical 
and biochemical investigations lies in the exclusion of other metabolic 
diseases, deficiencies, intoxications, and endocrinologie and immunologic 
disorders. 
Neuroradiological abnormalities are not specific: the bilateral hypoden-
sities in the basal ganglia region seen on cerebral CT scanning (S) are 
also found in Parkinson disease, carbon monoxide poisoning and Wilson 
disease. 
In order to investigate ihe diagnostic value of neurophysiological studies 
in this category of patients, we performed electroencephalography (EEG), 
electromyography (EMG) and nerve conduction velocity studies, and 
measured evoked potentials (visual evoked potentials, VEP; brainstem 
auditory evoked potentials, BAEP; short latency somatosensory evoked 
potentials, SSEP) in 12 patients with the Leigh syndrome (6 pathologically 
confirmed and 6 clinically diagnosed). 
PATIENTS AND METHODS 
PATIENT SELECTION 
We studied 12 patients. In patients 1 and 3, and a sib of patient 2, the 
clinical diagnosis of the Leigh syndrome was confirmed on pathological 
examination. Patients 4, S and 6 are sibs of patient 3. So, the diagnosis 
is proven in patients 1 to 6. For patients 7 to 12, who suffer from 
mitochondrial encephalomyopathies, we made a clinical diagnosis of 'most 
probable Leigh syndrome' on the basis of a combination of three pa-
rameters: clinical signs and symptoms, autosomal recessive mode of 
inheritance, and disturbance of pyruvate metabolism. The signs and 
symptoms in our patients are summarized in Table 1. They are compared 
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Table 1. Summary of the clinical data of our patients* compared with the percentages derived from a literature study of 173 Leigh syndrome patients 
Patient No. 1 2 3 4 5 6 7 8 9 10 11 12 Total Literature 
(%) (%) 
4 
2 
M 
p, 
Ρ, 
Ν 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
-
+ 
+ 
-
9 
6 
M 
Ν 
Ν 
Ν 
_ 
+ 
-
+ 
+ 
-
+ 
-
-
+ 
+ 
-
14 
0 
F 
Ν 
Ν 
Ν 
_ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
25 
92 
83 
58 
100 
50 
83 
43 
8 
58 
100 
43 
55 
69 
18 
78 
61 
24 
39 
69 
36 
47 
39 
37 
* Patients 1 to 6: diagnosis confirmed; patients 7 to 12: most probable Leigh symdrome. 
t = deceased; M = male; F = female; Ρ = percentile; N = normal; + = present; - = absent; ± = mild. 
Age (yrs) 
Age at onset (yrs) 
Sex 
Height 
Weight 
Skull circumference 
Feeding problems 
Respiratory signs and symptoms 
Cardiac signs and symptoms 
Ocular signs 
Pyramidal signs 
Extrapyramidal signs 
Cerebellar signs 
Hypotonia 
Seizures 
Exercise intolerance 
Decompensation on infection 
Mental retardation/deterioration 
17t 
4 
F 
N 
N 
N 
-
+ 
-
+ 
+ 
-
-
-
-
_ 
+ 
-
8 
1 
F 
Ρ,ο 
Pio 
PIO 
+ 
+ 
+ 
-
+ 
-
+ 
-
-
+ 
+ 
-
17t 
6 
M 
N 
N 
N 
-
+ 
+ 
-
+ 
-
+ 
-
-
-
+ 
-
24 
3 
M 
Ν 
Ν 
Ν 
-
+ 
+ 
-
+ 
+ 
+ 
+ 
-
_ 
+ 
+ 
23 
9 
F 
Ν 
Ν 
Ν 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
± 
20 
4 
F 
Ν 
Ν 
Ν 
-
+ 
+ 
-
+ 
-
+ 
+ 
-
_ 
+ 
-
17 
8 
Μ 
P2.S 
Ρ2 5 
Ρ,ο 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
-
13 
9 
Μ 
Ρ5 
Ρ2 5 
Ν 
-
-
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
-
7 
1 
Μ 
Ν 
Ν 
Ν 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
± 
with the results of a literature study of 173 proven Leigh syndrome patients, 
with a median age at onset of 0.83 years and a median age at death of 
2.08 years. The differences in the occurrences of signs and symptoms in 
our patients can be explained by the differences in age and the chronic 
protracted course of the disease in all our patients. In all patients there 
were strong indications of a disturbance of pyruvate metabolism: CSF 
pyruvate and/or lactate levels were elevated in all patients but one (patient 
11), and the pyruvate loading test (6) was disturbed in all patients. 
Biochemical studies of tissues were performed in 9 patients and defects 
in mitochondrial energy metabolism were found in 7 (Table 2). 
METHODS 
EEGs were recorded on a 21-channel Siemens Mingograph, with silver-
chloride cup electrodes placed according to the international 10-20 system. 
EEG recordings were made under standard conditions: 30 minutes of 
wakeful rest with closed eyes, and then photic stimulation and two periods 
of hyperventilation for 3 minutes. The EEG was considered non-disturbed 
when there was age-adequate dominant activity with little dispersion, good 
spatial differentiation, good reaction at eye opening, normal quantities 
of variants and other activities, and no spikes or instability of activities. 
A Medelec MS 6 was used for EMG and nerve conduction velocity studies. 
EMG was performed with DISA concentric needle-electrodes. Nerve 
conduction velocities were recorded with surface silver-chloride disc elec­
trodes. In all patients, nerve conduction velocity studies of the peroneal 
and sural nerves, Η-reflexes over the soleus muscles and electromyography 
of the distal and proximal muscles of the legs were performed. Evoked 
potentials were recorded with a Nicolet Pathfinder II, using the protocols 
summarized in Table 3. For normal values of evoked potentials, see Colon 
et al (7,8). 
RESULTS 
In 5 patients there were EEG abnormalities. Four had slight diffuse 
nonspecific abnormalities, such as dysrhythmia and slight slowing. One 
patient showed focal (right temporal) 2У2-3/8 high amplitude discharges 
with polyspike bursts, and generalized paroxysmal epileptic activity. 
The results of EMG and nerve conduction velocity studies were normal 
in all patients, except in sibs 3, 4 and 5. These 3 patients showed motor 
and sensory neuropathy of the legs beginning with an increase in distal 
motor and sensory latencies, and at a later stage, a decrease in motor 
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Ç£ Table 2. Results of biochemical studies in tissues 
Patient No. 
1 
2 
3 
7 
8 
9 
10 
11 
12 
N = normal; I 
Fibroblasts 
Pyruvate 
oxidation 
N 
-
N 
N 
N 
N 
N 
N 
-
= decreased; - = 
Liver 
Pyruvate 
carboxylase 
N 
N 
N 
N 
-
N 
N 
N 
-
:
 not measured. 
Table 3. Evoked potential protocols 
Stimulating 
Stimulation 
Band pass 
Analysis time 
Sensitivity 
Number of stimuli 
Electrodes 
VEP (flash) 
Muscle 
Pyruvate 
oxidation 
I 
i 
_ 
-
I 
_ 
\ 
\ 
-
(eyes open, wakeful rest) 
OD and OS 
Flash 0.2 ms (0.1 J at 30 cm) 
0.30/s 
Random 
1 - 500 Hz 
800 ms* 
100 or 200 μν 
100 (twice) 
0z-A 2 
Pyruvate, malate ATP 
oxidation 
N 
N 
BAEP 
production 
I 
-
N 
1 
J 
N 
1 
J 
i 
(eyes open, wakeful rest) 
AD and AS 
Click 0.1 ms 
70 dB HL 
11. l/s 
(80 dB SPL) 
Rarefaction 
Regular 
150 - 3000 Hz 
16 ms* 
20 MV 
1000 (twice) 
preauricular R -
preauricular L -
С
г 
- С
г 
Respiratory chain defect 
NADH dehydrogenase deficiency 
NADH dehydrogenase deficiency 
N 
NADH dehydrogenase deficiency 
N 
N 
no localized defect 
no localized defect 
cytochrome oxidase deficiency 
SSEP (short latency) 
(eyes open, wakeful rest) 
Median nerve (wrist) 
Electrical 0.1 ms 
Twitch level 
3.1/s 
Regular 
5 - 1000 Hz 
200 ms* 
200 μν 
1000 (twice) 
5Я£77^зАірм 
С, or C4 
* 25% prestimulus interval incorporated into indicated analysis time. 
nerve conduction velocities (peroneal nerves 30 m/s). In the arms, they 
showed distal motor and sensory neuropathy of a much lesser degree. 
EMG in these patients showed high amplitude, polyphasic motor unit 
potentials of long duration: a picture compatible with a chronic neurogenic 
lesion. 
Sural nerve biopsy specimens from patients 3 and 5 showed a chronic 
process of axonal degeneration, with a near total loss of myelinated and 
also, but to a lesser extent, unmyelinated fibers. Incidental Wallenan 
degeneration was seen, but no segmental abnormalities. 
VEP were recorded in 9 patients and were normal in all cases. 
BAEP were normal in all 10 patients studied. 
SSEP were found to be normal in 7 patients and not elicitable in 1 
patient (polyneuropathy), and were not investigated in the other 4 patients. 
An example of evoked potential recordings in a patient with proven Leigh 
syndrome (patient 2) is presented in Fig 1. 
The results are summarized in Table 4. 
DISCUSSION 
We performed clinical neurophysiological studies (EEG, EMG and nerve 
conduction velocities, VEP, BAEP and SSEP) in 12 patients with mito-
chondrial encephalomyopathy of the Leigh type. 40% showed EEG 
Table 4. Summary of results of electrophysiological studies in 12 patients with the Leigh syn-
drome 
Patient No. 
it 
2 
3t 
4 
5 
6 
7 
8 
9 
10 
11 
12 
EEG 
slight diffuse slowing 
N 
N 
slight diffuse nonspecific 
disturbance 
slight diffuse slowing 
N 
N 
N 
N 
N 
slight diffuse nonspecific 
disturbance 
focal (right temporal 
region) and generalized 
epileptic activity 
EMG/nerve 
conduction 
N 
N 
polyneuropathy 
polyneuropathy 
polyneuropathy 
N 
N 
N 
N 
N 
N 
N 
VEP 
-
N 
-
N 
N 
N 
N 
-
N 
N 
N 
N 
BAEP SSEP 
_ 
N 
-
N 
N 
N 
N 
N 
N 
N 
N 
N 
-
N 
-
not elicitable 
-
_ 
N 
N 
N 
N 
N 
N 
N = normal; - = not performed; f = deceased. 
61 
SjuV/Div Visual Evoked Potentials 
O z - A 2 
80 ms > Div 
Brainstem Auditory Evoked Potentials (left earl 
0 3 μ ν 'Div 
А , - С , . 2 " '-ζ 
А
і - с
г 
1 6 ms Div 
Right Median Nerve Somalosensory Evoked Potentials 
5/uV/Div (short latency! 
CV" A; 3 " л 2 
SC,:- А; 5 - я 2 
20 ms/Div 
Fig 1. Recordings of normal VEP, BAEP and median nerve SSEP in patient 2. The protocols 
are summarized in Table 3. For normal values, see Colon et al (7,8,). 
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abnormalities, all of which involved nonspecific phenomena, and axonal 
polyneuropathy was found in three sibs, in one of whom no median nerve 
SSEP were elicitable. The other studies showed normal results. 
173 pathologically proven Leigh syndrome patients in the literature were 
surveyed (10)(Table5). For 50% (n=87) the EEG findings and for 18% 
(n=31) the EMG findings were mentioned. VEP were recorded in 2% (n=4) 
and BAEP in 0.5% (n=l). We found no mention of SSEP recording in 
the Leigh syndrome. 
EEG was unremarkable in 31 patients, and showed epileptic discharges 
in 17, and diffuse or focal abnormalities, of which diffuse slowing was 
the most frequent (n=29), in 43. In 8 patients, EEG was normal initially 
and became abnormal during the course of the disease. EMG was normal 
in 17 patients. Two patients showed denervation and myopathic features 
were found in 3. Nerve conduction velocities were normal in 13 patients 
and reduced in 15. Distinction between motor and sensory nerve conduction 
was only seldom made. VEP were normal in 2 patients and disturbed/ 
non-elicitable in 2. BAEP were disturbed in 1 patient. Three patients 
mentioned in a report by Hecox et al (9) were not included m our series 
of 173 patients, because a description of the patients is lacking. Normal 
BAEP were recorded in 1 patient, tested at age 3 months, and abnormalities 
Table 5. Electrophysiological studies in 173 Leigh syndrome patients in the literature 
EEG (n=87): 
EMG(n=31): 
VEP (n=4): 
BAEP(n=l). 
Normal 
Diffuse slowing 
Focal slowing 
Increase of amplitude 
Dysrhythmia 
Epileptic manifestations 
- generalized spikes 
- paroxysms 
- focal spikes 
- spike and wave complexes 
- hypsarhythmia 
Electromyography: 
Nerve conduction velocities: 
Normal 
3 
4 
4 
4 
2 
Normal 
Denervation 
Myopathy 
Normal 
Reduced: motor+sensory 
motor 
sensory 
Not elicitable over right occipital cortex 
Not elicitable 
Right ear normal; left ear: not elicitable 
31 
29 
6 
4 
2 
17 
17 
2 
3 
13 
11 
3 
1 
2 
1 
1 
(1) 
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of interwave intervals were present in responses obtained from 2 patients 
at age 1 and 6 years respectively. 
Many difficulties arose as to the interpretation of the results of the 
literature study. Descriptions of findings are often inadequate, incomplete 
and/or unhomogeneous. The median age at death of the 173 patients studied 
was 2.08 years. Interpretation of EEG is notably difficult in these often 
very young patients. Furthermore, the EEGs were often recorded in relative 
inactive phases of the disease. In a considerable number of patients there 
was acute onset or aggravation of symptoms, leading to death in a few 
days. In such cases, hardly any EEGs were recorded, but there was often 
mention of epileptic seizures or status epilepticus. Most of the patient 
reports appeared before 1972; this could explain the paucity of EMG and 
evoked potential recordings. 
Although the findings in our patients, a subgroup with a relatively late 
onset and chronic progressive course of the disease, cannot be compared 
with those in the patients mentioned in the literature, they support the 
concepts that EEG abnormalities are nonspecific, and that EEG does not 
contribute to the diagnosis. 
EMG and nerve conduction disturbances are rare in our patients (3 
sibs), contrary in the cases of the patients mentioned in the literature (Table 
5)· 
In our patients, the afferent sensory pathways are clinically intact and 
the symptomatology arises from efferent structures (Table 1). The intactness 
of the central sensory pathways explains the lack of evoked potential 
abnormalities. 
From our results we conclude that neurophysiological studies did not 
contribute to the diagnosis of the Leigh syndrome in our patients. Their 
relevance lies rather in the elimination of other differential diagnostic 
possibilities. 
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ABSTRACT 
Diagnosis of defective pyruvate metabolism can present difficulties in 
clinical practice. In search of a diagnostic procedure that can give a clear 
indication of a disturbance of pyruvate metabolism, we have developed 
an intravenous pyruvate loading test. The loading test was applied to 9 
patients with Leigh syndrome. Results and characteristics are described. 
The test proved to be a sensitive procedure to detect disturbances in pyruvate 
oxidation. The intravenous pyruvate loading test can be a useful tool in 
the diagnosis of mitochondrial (encephalo)myopathies. 
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INTRODUCTION 
The variability in clinical presentation and the lack of specific laboratory 
tests make defects of pyruvate metabolism often a difficult diagnostic 
problem in clinical practice. In the screening of these patients assessment 
of pyruvate and lactate levels of serum under standard conditions, upon 
fasting, after exercise, and after oral glucose loading, play an important 
role, as well as pyruvate and lactate levels of cerebrospinal fluid (CSF) 
and 24-h urine lactate excretion. Often, however, these relatively simple 
diagnostic procedures provide insufficient information. Sometimes even, 
all the results are normal but a defect in oxidative metabolism is found 
on biochemical studies in tissues nonetheless. 
In recent years, defects of oxidative metabolism have been described 
in a number of patients with Leigh syndrome (Hommes et al, 1968; Farmer 
et al, 1973; Willems et al, 1977; Van Erven et al, 1985). In search of a 
procedure that can give direct indication of a disturbance of pyruvate 
metabolism - or in a broader sense of oxidative metabolism - we performed 
an intravenous pyruvate loading test (Dijkstra et al, 1984) on 9 patients 
with Leigh syndrome (3 confirmed, 6 most probable), with elevation of 
lactate and pyruvate levels in body fluids and/or an established defect 
of pyruvate metabolism in liver or muscle tissue. 
CRITERIA OF PATIENT SELECTION 
The diagnosis of subacute necrotizing encephalomyelopathy (SNE) or Leigh 
syndrome rests on pathologic findings. Since no biopsy of afflicted central 
nervous system (CNS) areas is possible and since there is no specific test 
available, durante vitam only the probability of Leigh syndrome can be 
assessed after endocrinologie, immunologic and chronic infectious diseases, 
deficiencies, disorders caused by toxic agents, degenerative and other 
metabolic diseases have been ruled out by appropriate studies. Based on 
own experience and on the literature, it is, in our opinion, possible to 
come to a clinical diagnosis of 'most probable' Leigh syndrome when the 
following criteria are met: 
(1) Signs and symptoms that arise mainly from the brain regions that 
show the highest incidence of the typical lesions on pathologic examination: 
midbrain, hindbrain and spinal cord, basal ganglia, cerebellum and optical 
system (Montpetit et al, 1971; Pincus, 1972), 
(2) Disturbance of pyruvate metabolism (Hommes et al, 1968; Farmer 
et al, 1973; Willems et al, 1977; Van Erven et al, 1985). Pyruvate metabolism 
is considered disturbed when pyruvate and/or lactate levels of CSF, serum 
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or urine are elevated, or when a disturbed pyruvate oxidation is found 
in biochemical studies of tissue samples, 
(3) Autosomal recessive mode of inheritance (McKusick, 1978). 
We studied 9 patients with Leigh syndrome. In one patient the clinical 
diagnosis was confirmed on pathologic examination (patient 1, Van Erven 
et al, 1985). Two patients had sibs who died of pathologically confirmed 
Leigh syndrome (patients 2, Van Erven et al, 1986, and 3). The other 
6 patients matched the criteria listed above and were classified 'most 
probable' Leigh syndrome (patients 4-9). The mean age at which the 
pyruvate loading test was performed was 13 years (range, 5-17 years). 
Clinical data of our patients are presented in Table 1. 
Extensive routine and specific chemical and biochemical investigations 
yielded normal results in all patients. EEG showed a generalized epileptic 
predisposition in patient 9. Nerve conduction velocity studies revealed an 
axonal polyneuropathy in patients 3 and 8, and cerebral CT scan showed 
bilateral hypodensities in the basal ganglia area in patients 4, 5 and 6. 
Histochemical and ultrastructural studies in muscle tissue were performed 
in all patients. No Sudan black-positive droplets were seen in histochemical 
studies. 'Ragged-red' fibers were seen in the trichromic-stained section in 
patient 9. Ultrastructural studies revealed no mitochondrial abnormalities. 
Table 1. Summary of clinical data of patients 
Patients 1, 2 and 3· diagnosis confirmed, Patients 4 to 9 most probable Leigh syndrome 
Patient No 
Age (yrs) 
Age at onset (yrs) 
Sex 
Height 
Weight 
Skull circumference 
Feeding problems 
Respiratory signs and symptoms 
Cardiac signs and symptoms 
Ocular signs 
Pyramidal signs 
Extrapyramidal signs 
Cerebellar signs 
Hypotonia 
Seizures 
Exercise intolerance 
Decompensations on infections 
Mental retardation/deterioration 
1 
17t 
4 
F 
N 
N 
N 
-
+ 
-
+ 
+ 
-
-
-
-
-
+ 
-
2 
8 
l'A 
F 
Ρ,ο 
PIO 
P.0 
+ 
+ 
+ 
-
+ 
-
+ 
-
-
+ 
+ 
-
3 
24 
3 
M 
Ν 
Ν 
Ν 
-
+ 
+ 
-
+ 
+ 
+ 
+ 
-
-
+ 
+ 
4 
17 
8 
Μ 
P2S 
Ρ2 5 
Ρ.ο 
-
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
-
5 
13 
9 
Μ 
Ps 
Ρ25 
Ν 
-
-
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
-
6 
7 
i Vi 
M 
Ν 
Ν 
Ν 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
± 
7 
4 
2 
Μ 
Ps 
ρ, 
Ν 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
-
+ 
+ 
-
8 
9 
6 
Μ 
Ν 
Ν 
Ν 
-
+ 
-
+ 
+ 
-
+ 
-
-
+ 
+ 
-
9 
14 
0 
F 
Ν 
Ν 
Ν 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
t = deceased, M = male, F = female; P= percentile, N = normal, + = present; - = absent; 
+ = mild. 
70 
METHODS 
Pyruvate metabolism was assessed by determination of the levels of pyruvate 
and lactate, and their ratios in serum and CSF, and by measuring 24-
h lactate excretion in urine. All patients underwent an oral glucose tolerance 
test (GTT) (1.75 g/kg) with concomitant measuring of lactate and pyruvate. 
PYRUVATE LOADING TEST 
Informed consent was obtained from all patients, or their parents, and 
controls. The pyruvate loading test was performed after an overnight fast: 
500 mg sodium pyruvate/kg body weight was administered in a period 
of 10 min using a 0.91 M sodium-pyruvate solution. Antecubital venous 
blood samples were drawn from the other arm before and at 5, 15, 30, 
60 and 90 min after infusion. Glucose, pyruvate, lactate and alanine were 
measured in all samples. Nine healthy adult volunteers (mean age, 29 years; 
range, 20-43 years) and 14 children (mean age, 10 years; range, 4-17 years) 
formed the controls. The control children were suffering from progressive 
heredodegenerative neurologic disorders (e.g. spinal muscular atrophy, 
lateral sclerosis, progressive polyneuropathy and heredoataxia). In all 
children a disturbance of pyruvate metabolism was included in the 
differential diagnosis. Pyruvate and lactate levels were normal in body 
fluids and also after oral glucose loading. Biopsies of muscle and sural 
nerve were performed in all children, and morphologic and biochemical 
investigations revealed no abnormalities of pyruvate metabolism. Adults 
and children showed the same response after pyruvate loading. Some 
subjects both in the control and in the patient group had slight complaints, 
e.g. tachycardia, headache, trembling, nausea, perspiration and fatigue 
during the first 15 min after pyruvate infusion. 
BIOCHEMICAL STUDIES IN TISSUES 
Pyruvate oxidation and citric acid cycle activity in fibroblasts were 
determined by measuring lAC02 production from [l-14C]pyruvate and [2-
l4C]pyruvate (Willems et al, 1978). Pyruvate carboxylase activity was 
measured in liver tissue homogenate (Utter and Keech, 1963). Pyruvate 
oxidation in liver tissue was determined by measuring I4C02 production 
from [l-l4C]pyruvate according to Willems et al (1977). Pyruvate oxidation 
rate and activities of citric acid cycle and respiratory chain were evaluated 
in muscle homogenate by measuring '"CO: production from [l-l4C]pyruvate 
and fU-l4C]malate (Bookelman et al, 1978). ATP production was measured 
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according to Ruitenbeek et al (1981). The activities of the enzymes 
cytochrome с oxidase, citrate synthase, succinate-cytochrome с oxidore-
ductase and carnitine palmitoyltransferase were measured in liver and/ 
or muscle tissue (Cooperstein and Lazarow, 1951; Srere, 1969; Schölte 
et al, 1979; Fischer et al, 1985). 
STATISTICAL ANALYSIS 
The logarithm of the pyruvate and lactate concentrations was used in the 
statistical calculations. This allows the use of standard statistical methods 
based on assumptions regarding homogeneity of variance and normality 
of distribution. Student's /-test for the unpaired case is used to judge, 
on each sampling time after infusion, the difference in the mean relative 
value of the serum concentration between the control group and the Leigh 
patient group. In order to determine to what degree the two groups can 
be discriminated by means of the pyruvate and lactate values, we used 
the Hotelling T2-test, followed by a classification technique based on the 
linear discriminant function originally introduced by Fischer (see Morrison, 
1967). For diagnostic aids we constructed a tolerance region for the control 
group on a combination of one response parameter of the lactate response 
and one parameter of the pyruvate response curve. 
RESULTS 
Lactate and pyruvate contents of body fluids are shown in Table 2. Serum 
pyruvate levels were normal or nearly normal in all patients. Serum lactate 
levels showed an intermittent increase in patients 1 and 5. CSF pyruvate 
and lactate levels were increased in all patients but one (patient 8). Lactate-
pyruvate ratio in CSF was normal in patients 8 and 9. 24-Hour lactate 
excretion in urine was clearly elevated in patients 6 and 7, and showed 
an intermittent elevation in patient 9. After oral glucose loading, lactate 
and pyruvate levels were elevated in patients 1 and 4. 
PYRUVATE LOADING TEST 
Glucose levels did not change significantly after pyruvate infusion. Alanine 
levels reached their maximum at 5 min after pyruvate infusion and 
normalized at 90 min. Mean alanine increase (about 200 μπιοΐ/ΐ) did not 
differ between controls and patients, and the response was similar in both 
groups. Relative serum pyruvate levels of the patient group were signi-
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Table 2. Lactate and pyruvate levels in serum and cerebrospinal fluid, lactate levels in 24-hour urine, and results of glucose tolerance tests of patients 
and controls 
Patient No. 
1 
2 
3 
4 
5 
6 
7 
В 
9 
Controls 
Serum 
Pyruvate* 
152-156 
118-126 
113-156 
81-120 
131-158 
115-139 
108-137 
90 
94-148 
60-155e 
Lactate' 
1600-2330 
1280-1700 
925-1540 
810-1160 
1520-2130 
1270-1410 
1000-1220 
950 
1380-1460 
460-1720° 
Cerebrospinal fluid 
Pyruvate' 
143-198 
90-153 
201 
154 
180 
197-238 
144-216 
98 
222 
85-132'' 
Lactate' 
2520-4470 
1520-1830 
3760 
3210 
3690 
3750-5050 
3120-3780 
1400 
1900 
1200-1600" 
Ratio L/P 
17.6-22.6 
12.0-16.9 
18.7 
20.8 
20 5 
18 9-21.2 
17.5-21.7 
13.3 
8.6 
up to 15.0 
24-hour lactate" 
excretion in urine 
_ 
52-91 
49 
36 
60-70 
148-405 
158-669 
31 
30-131 
< 1 0 0 
GTT + lactate 
and pyruvate 
t L + P 
N 
N 
t L + P 
N 
-
N 
-
N 
N = normal; t = increased; - = not performed 
" μτηοΙΛ; Vmol/mmol creatinine; ' Pi s - P97 5;4 mean ± 2 SD. 
ficantly higher at 5, 15, 30, 60 and 90 min after infusion compared with 
the control group (Table 3). The shape of the pyruvate curves was similar 
in both groups, unlike the shape of the lactate curves, where the patient 
group showed a slower rise and reached a peak-level at 15 min after infusion 
(tis) compared with a peak-level at 5 min (ts) in the control group. The 
peak-level reached similar values in patients and in controls. Between 15 
and 90 mm, relative lactate levels were significantly higher than in the 
control group (Table 3). Lactate-pyruvate ratios in the patient group were 
significantly lower than in the control group at tj and tis. 
Results of discriminant analysis are presented in Table 4. From these 
data it is clear that Leigh patients respond quite different from a control 
group with respect to the pyruvate loading test. In order to make this 
finding suitable for diagnostic purposes we had to construct some region 
Table 3. Mean pre- and postinfusion levels ± SD of pyruvate and lactate (μπιοΐ/ΐ), their 
mean relative serum levels, and lactate-pyruvate ratios 
Time (mm) Pre- and postinfusion levels Mean relative serum levels 
Controls Leigh patients Controls Leigh patients F' 
(n=23) (n=9) 
Pyruvate 
Prcinfusion 
5 
15 
30 
60 
90 
120 
121±7I 
1991 ±763 
528 ±218 
235 ± 7 2 
133 ± 3 4 
113±27 
98 ± 2 1 
126±26 
5323 ±2065 
1396 ±395 
435 ±133 
205 ± 7 3 
164±41 
138 ± 4 2 
1. 
20 7 
5 4 
2 3 
13 
1 1 
I 1 
Lactate 
Preinfusion 
5 
15 
30 
60 
90 
120 
1086 ±404 
3528 ±745 
2757 ±467 
1850 ±353 
1223±317 
1021 ±237 
881±211 
Lactate-pyruvate ratio 
Preinfusion 
5 
15 
30 
60 
90 
120 
10 1 ± 4 5 
2 1 ± 1 0 
5 8 ± I 9 
8 3 ± 1 8 
9 4 ± 1 8 
9 2 ± 1 . 3 
9 0 ± 1 3 
1169 ±357 
3831±1258 
4203 ±1061 
3192±1137 
2030 ±689 
1548 ±493 
1290 ±485 
9 . 2 ± 1 8 
0 8 ±0.3 
3 1 ± 0 7 
7 4 ± 1 . 8 
10 1 ±2.2 
9.4 ±2.1 
9 2±1.7 
1 
3.6 
2 7 
18 
12 
1.0 
10 
1* 
0 83 
0 0001 
0 0001 
0 22 
0.32 
0 88 
0 79 
' P-value according to Student's /-test, applied to the logarithm of (the serum concentration 
relative to the preinfusion concentration) 
ь
 P-value according to Student's Mest, applied to the logarithm of lactate-pyruvate ratio. 
1 
44 1 
113 
3.5 
17 
13 
1 1 
1 
33 
38 
2 8 
18 
14 
1.1 
0 001 
0 0003 
0 01 
0 08 
0.06 
0 88 
0.68 
0 005 
0.001 
0 0006 
0.005 
0 36 
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Table 4. Results of linear discriminant analysis control group (n=23) versus Leigh syndrome 
group (n=9) 
Variables used 
in the procedure 
D Number of misclassifications by resub-
stituting procedure according to standard 
linear discriminant function analysis 
Control group Leigh group 
LLQO) LLQJ, 
LLQS, L I ^ J 
Lfgo, Lro5, 
LPos, L P 1 5 
ι LLq, 
. LP90 
15 54 
12 13 
10 67 
8 88 
LL = logarithm of lactate level at specific time (00, 05, ,90 mm), LP = logarithm of pyru­
vate level at specific time (00, 05, , 90 min), D = Malanobis distance 
D 2 = ^ — — T 2 , in which T2 = Hotelling test statistic, n, = No of controls, n2 = No of 
η, η, 
Leigh patients 
L05-L15 ] 
-200 
β Controls n. 23 
* Patients n- 9 
Fig 1. Tolerance region (90%-90%) for the control group based on response parameters 
P|» ~ ° I5
 я п г
1 Mis - L I S π 
_ _ _ a n d _ í 5 _ P05(,5 
level 5 (15) mm after infusion 
Ρ - Ρ L   
M l 5
 and 0 5 — ^ Posiisi = pyruvate level 5 (15) mm after infusion, Losus, = lactacte 
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where we expect the response of the individual control patient will belong 
to with a certain probability. As statistics for the visualization of such 
a region we chose the difference in serum levels at ts and tis from both 
lactate and pyruvate response. The ellipsoidal tolerance region R is 
constructed (Fig 1), according to the method based on the multivariate 
normal distribution (Chew, 1966), in such a manner that the probability 
is 0.90 that R contains at least 90% of the individuals in the population 
of control patients from which our sample is supposed to be drawn at 
random. 
BIOCHEMICAL STUDIES IN TISSUES 
The results of biochemical studies have been summarized in Table 5. 
Pyruvate oxidation by cultured fibroblasts from all 7 patients measured 
was normal. Liver tissue of all patients measured showed a normal pyruvate 
carboxylase activity, while the rate of pyruvate oxidation was decreased. 
Oxidation of pyruvate and malate, and ATP production in muscle tissue 
had a decreased rate in 7 patients. In cases 1, 4 and 9, this could be 
explained by abnormalities in the respiratory chain. 
DISCUSSION 
An intravenous pyruvate loading test was performed in 9 patients with 
Leigh syndrome (3 confirmed, 6 clinical diagnosis). Preinfusion levels were 
the same for both patient and control groups. Leigh patients responded 
quite different to pyruvate loading compared to the control group. Patient 
response was very similar to the response of Friedreich patients as described 
by Dijkstra et al (1984). 
Pyruvate response was in all patients of the same shape as in controls, 
but pyruvate levels in the period from 5 to 30 min after administration 
were significantly elevated in patients when compared to controls (Table 
3). 
The lactate response curves differ in shape with the control curves in 
that, in all patients but one, the postinfusion level at tis is higher than 
the level at ts. This patient (patient 3), however, shows the highest lactate 
values of all patients at all spmpling points. 
With the use of the values at ts and tis it proved possible to construct 
a tolerance region for the control group (Fig 1), which proved its use 
for diagnostic purposes. As can be seen in this figure, one patient falls 
in the tolerance region for the controls, but this patient can also be 
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Table 5. Results of biochemical studies in tissues 
Patient No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Fibroblasts 
Pyruvate 
oxidation 
N 
N 
N 
N 
N 
N 
N 
-
Liver 
Pyruvate 
carboxylase 
N 
N 
N 
N 
N 
N 
N 
-
Muscle 
Pyruvate 
oxidation 
1 
J 
Γ 
-
i 
ι 
-
Pyruvate, inalate 
oxidation 
Ν 
Ν 
ATP production 
from pyruvate 
1 
N 
1 
J 
N 
i 
I 
1 
Respiratory chain defect 
NADH dehydrogenase deficiency 
NADH dehydrogenase deficiency 
N 
NADH dehydrogenase deficiency 
N 
N 
no localized defect 
no localized defect 
cytochrome oxidase deficiency 
N = normal; i = decreased; - = not measured. 
discriminated from the controls in that his lactate level rises after ts to 
reach a maximum at tis. 
The intravenous pyruvate loading test has in our patients a greater 
sensitivity than the oral glucose loading test, that yielded abnormal results 
in only 2 cases, and 24-h lactate excretion in urine that was permanently 
elevated in 2 patients and showed an intermittent rise in 1 other patient. 
In nearly all our patients, serum levels of pyruvate and lactate reflect the 
clinical activity of the disease process (Table 2). In a phase of clinical 
deterioration, pyruvate and lactate levels show borderline or clear elevations 
and in the interval between bouts the levels of pyruvate and lactate are 
normal. So it is important not to rely on one measurement. But even 
when measured in a phase of clinical deterioration, serum levels of pyruvate 
and lactate in our patients only seldom give a straight-forward indication 
of a disturbance of pyruvate metabolism. This is contrary to our findings 
in CSF, where 6 patients showed clear elevations of pyruvate and lactate 
levels, while in 2 patients the elevations were borderline and only one 
patient (patient 8) showed normal lactate and pyruvate values. This 
illustrates the independence of the CSF lactate level of the serum lactate 
level, the former reflecting directly brain pyruvate metabolism (Posner and 
Plum, 1967). 
In our opinion, the intravenous pyruvate loading test is a specific and 
sensitive procedure to detect disturbances of pyruvate metabolism in 
patients clinically suspected of so-called mitochondrial myopathies (Sengers 
et al, 1984) and mitochondrial encephalomyopathies (Shapira et al, 1977). 
In case of a strong clinical suspicion of a disturbance of pyruvate metabolism 
while routine investigations are not conclusive, as might be the case in 
quiet phases of the disease, the intravenous pyruvate loading test can have 
diagnostic value. If routine investigations indicate a disturbance of pyruvate 
metabolism, intravenous pyruvate loading test will give no additional 
information. 
We have no experience with pyruvate loading in patients with a pyruvate 
carboxylase deficiency. A normal loading test does therefore not exclude 
a pyruvate carboxylase deficiency. 
If pyruvate and lactate levels of serum and CSF, and 24-h urinary lactate 
excretion are normal, and oral GTT and intravenous pyruvate loading 
yield normal results, pyruvate oxidation must be considered undisturbed 
in muscle and brain tissue. 
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CHAPTER VI 
MITOCHONDRIAL 
ENCEPHALOMYOPATHY 
Association with an NADH 
Dehydrogenase Deficiency 
P.M.M. van Erven, F.J.M. Gabreëls, W. Ruitenbeek, 
W.O. Renier and J.C. Fischer 
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ABSTRACT 
A 17-year-old patient had a progressive hypokinetic-rigid syndrome and 
several other signs and symptoms that indicated central nervous system 
involvement. Biochemical studies revealed a reduced form of nicotinamide-
adenine dinucleotide dehydrogenase deficiency in skeletal muscle. Clinical 
signs and symptoms, and their association with an established defect of 
energy metabolism, led us to classify this disorder as a mitochondrial 
encephalomyopathy of Leigh's type. 
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INTRODUCTION 
Since the first description by Luft et al' of mitochondrial dysfunction in 
a patient with hypermetabolism and muscle weakness, steadily increasing 
numbers of morphologic, functional, and biochemical abnormalities of 
skeletal muscle mitochondria have been reported.2 Price3 termed this group 
of disorders 'mitochondrial myopathies'. Analogous to this concept, 
Shapira et al" described the mitochondrial encephalomyopathies, a group 
of disorders with central nervous system (CNS) and muscle involvement, 
associated with abnormalities in mitochondrial metabolism and/or struc­
ture. Representatives of this group are the syndrome of Alpers,5 dysmy-
elination,2 the syndromes of Leigh6-9 and Kearns-Shy,10 myoclonus epilepsy 
associated with 'ragged-red fibers'," and the so-called MELAS (mito­
chondrial myopathy, encephalopathy, lactic acidosis, and Лгокеііке epi­
sodes) syndrome.12 Our patient had a clinical diagnosis of Leigh's syndrome 
and the reduced form nicotinamide-adenine dinucleotide (NADH) dehy­
drogenase deficiency in muscle biopsy material. 
REPORT OF A CASE 
The patient is a 17-year-old boy, the only son of nonconsangumeous parents. The medical 
history of both parents and their families are unremarkable 
Psychomotor development was normal until age 14 years, when a slowly progressive 
disturbance of motor function, exercise intolerance, and muscular weakness appeared. His 
performance in school showed a considerable decline, and changes in his conduct, with 
social withdrawal and aggressive behavior, also developed 
Examination revealed a small, thin 17-year-old boy with a poor facial expression and 
a parkinsonhke posture with bending forward and semiflexion of arms and legs. His height 
was 163 cm (2 5th percentile); his weight was 41 kg (2.5th percentile), and his skull circumference 
was 52.5 cm (tenth percentile) There was no intellectual impairment, full-scale IQ (Wechsler 
Intelligence Scale for Children-Revised and Wechsler Adult Intelligence Scale) was 115. 
Irregular breathing with frequent sighing occurred, as did bouts of sinus tachycardia of 
140 beats per minute and sinus bradycardia of 50 beats per minute 
Speech showed a marked dysarthria Automatic movements were diminished, intentional, 
deliberate movements were slow and clumsy Investigation of muscle tone revealed a 
generalized rigidity with a cogwheel phenomenon No resting tremor was apparent, but the 
hands showed athetotic movements Gait was broad based with marked starting difficulty, 
and steps were small Eye movements were jerky with loss of smooth pursuit. Cerebellar 
involvement was indicated by ataxia, intention tremor, and dysdiadochokinesis There was 
generalized muscular weakness Tendon reflexes were hyperactive with bilateral Babinskfs 
signs The Oseretsky motor development and performance test showed his motor development 
level to be that of a 7-year-old. 
ELECTROPHYSIOLOGIC AND RADIOLOGIC INVESTIGATIONS 
Electroencephalogram, electromyogram and results from nerve conduction 
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velocity tests were normal. Somatosensory, brainstem auditory and visual 
evoked potentials fell within the normal ranges. Roentgenograms of skull, 
chest, hand, and vertebral column, and cerebral computed tomographic 
scans showed no abnormalities. Electrocardiogram was normal and the 
echocardiogram showed no signs of cardiomyopathy. 
ROUTINE AND SPECIFIC LABORATORY INVESTIGATIONS 
Results from standard blood and urinary studies, including hematologic 
evaluation, renal and hepatic functions, serum protein levels, serum protein 
electrophoresis, and Immunoelectrophoresis were normal. Values were also 
normal for the following: blood pH; carbon dioxide pressure and bicar-
bonate; serum lipids; short-chain fatty acids and carnitine (total and free); 
serum uric acid and ammonia; organic acids and amino acids in plasma 
and urine; lysosomal enzymes in leukocytes; creatine kinase; serum copper, 
zinc, manganese, and ceruloplasmin; urinary copper excretion; thyroid and 
adrenal functions; and blood levels of growth hormone, thiamine, pyri-
doxine, and cobalamin. Appropriate studies ruled out immunologic and 
chronic infectious diseases and disorders caused by toxic agents. In 
cerebrospinal fluid (CSF), cell number, protein content, protein electro-
phoresis and Immunoelectrophoresis findings, and values for homovanillic 
acid and S-hydroxyindolacetic acid, and minerals were normal. 
ENERGY METABOLISM 
Serum levels of glucose, pyruvate, lactate, /î-hydroxybutyrate, and ace-
toacetate were normal under resting conditions. The lactate-pyruvate and 
j8-hydroxybutyrate-acetoacetate ratios were normal. Urinary lactate excre-
tion was normal. Oral glucose tolerance test (1.75 g/kg) revealed a normal 
glucose and pyruvate response, but lactate level increased from 1,16 to 
2.3 mmol/L (1.16 to 2.3 mEq/L) (normal, up to 1.7 mmol/L [1.7 mEq/ 
L]). The McArdle-Fischbein ischemic exercise test13 yielded a normal rise 
of serum lactate and ammonia levels. Moderate physical exercise, eg, 
walking for a few minutes, gave a marked increase in serum lactate level 
to 4.74 mmol/L (4.74 mEq/L), in the serum pyruvate level to 0.22 mmol/ 
L (0.22 mEq/L) (normal, 0.06 to 0.16 mmol/L [0.06 to 0.16 mEq/L]), 
and in the lactate-pyruvate ratio to 21.5 (normal, up to 15), and a metabolic 
acidosis with a pH of 7.23 and a base excess of -12.4. After intravenous 
pyruvate loading (500 mg/kg),14 there was a normal pyruvate response, 
but lactate response was abnormal (Fig 1). 
The CSF glucose, acetoacetate and j3-hydroxybutyrate levels were normal 
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under resting conditions and after moderate physical exercise. The pyruvate 
level (0.15 mmol/L [0.15 mEq/L]; normal, 0.09 to 0.13 mmol/L [0.09 
to 0.13 mEq/L]) and the lactate level (3.21 mmol/L [3.21 mEq/L]; normal, 
1.2 to 1.6 mmol/L [1.2 to 1.6 mEq/L]) were elevated, with an increase 
of the lactate-pyruvate ratio (20.8; normal, up to 15). 
HISTOPATHOLOGIC STUDIES 
Histochemical studies of quadriceps muscle, obtained at biopsy, showed 
no abnormalities. No ragged-red fibers were noted in the trichromic-stained 
section; no Sudan black-positive droplets were seen. Ultrastructural studies 
revealed no mitochondrial abnormalities. 
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1. Lactate response to pyruvate loading (500 mg/kg). Preinfusion level 1.6 mmol/L 
mEq/L). 
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BIOCHEMICAL STUDIES 
METHODS 
Enzymatic studies were performed in cultured fibroblasts and in liver and 
muscle that were obtained at biopsy. Oxidative metabolism was evaluated 
in fibroblasts by measuring the radioactive carbon dioxide (14C02) pro­
duction rate from radioactive carbon 14 in the No. 1 position-labeled 
pyruvate ([l-14C]pyruvate) and [2-14C]pyruvate,15 and the activities of 
cytochrome oxidase and citrate synthase. Pyruvate carboxylase activity 
was measured in liver homogenate,16 using a regenerating system for 
acetylcoenzyme A.17 Pyruvate oxidation rate, and activities of citric acid 
cycle and respiratory chain were evaluated by measuring '"СОг production 
from [l-MC]pyruvate and malate uniformly labeled with 1 4C (malate 1 4C 
[ul]) in fresh muscle homogenate.18 The capacity of muscle to generate 
adenosine triphosphate (ATP) and creatine phosphate (CrP) was investi­
gated under conditions in which adenylate kinase was inhibited.19 In muscle 
homogenate, frozen at -70oC, carnitine content20 and activities of citrate 
synthase,21 cytochrome с oxidase,22 succinatexytochrome с oxidoreduc-
tase,23 NADHOz oxidoreductase,24 and NADH:Qi oxidoreductase24 were 
measured. Cytochrome content25 was measured in isolated muscle mito­
chondria in the presence of succinate and cyanide, and subsequently in 
the presence of antimycin A (1 μg). Protein was assayed according to 
Lo wry et al.26 
RESULTS 
In fibroblasts, oxidation rates were normal: [l-14C]pyruvate: 59 nmol/h.mg 
of protein (control range, 25 to 96 nmol/h.mg of protein; n=23); [2-
14C]pyruvate: 23 nmol/h.mg of protein (control range, 12 to 35 nmol/ 
h.mg of protein; п^ІЗ). Activities of cytochrome oxidase (22 mU/mg of 
protein [control range, 11 to 43 mU/mg of protein; n=15]) and citrate 
synthase (41 mU/mg of protein [control range, 26 to 63 mU/mg of protein; 
n=15]) were also within the normal ranges. In liver tissue, pyruvate 
carboxylase activity was normal: 19 mU/mg of protein (control range, 
13 to 40 mU/mg of protein; n=15). The 14C02 production rates from 
[l-14C]pyruvate and malate 1 4C (ul) by muscle homogenate showed a marked 
decrease under all experimental conditions (Table 1). The ATP + CrP 
production with pyruvate as substrate was also strongly decreased. The 
ratio of the ATP + CrP production to the arsenite-sensitive pyruvate 
oxidation27 was slightly decreased. Total carnitine content (carnitine and 
acylcarnitines) in muscle homogenate was normal: 3.1 μιηοΐ^ wet weight 
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Table 1. Results of biochemical studies in muscle tissue 
Controls 
Study* Patient Range Mean ± SD No. 
Oxidation (600 g supernatant) 
[l-MC]pyruvate + malate 
[l- l4C]pyruvate + carnitine 
Malate 1 4C (ul) + pyruvate + malonate 
Malate 1 4C (ul) + acetylcamitine + malonate 
Malate H C (ul) + acetylcamitine + arsenite 
ATP Metabolism (600 g supernatant) 
ATP + CrP production from pyruvate 
ATP + CrP production / pyruvate oxidation 
Enzyme activities (600 g supernatant) 
Citrate synthase 
Cytochrome с oxidase 
Succinate cytochrome с oxidoreductase 
NADH 0 2 oxidoreductase 
NADH.Q, oxidoreductase 
Cytochromes (isolated mitochondna) 
Cytochrome J J , 
Cytochrome b 
Cytochrome с + с, 
Cytochrome с oxidase 
69t 
103t 
6П 
m 34t 
496+ 
72 
57§ 
166§ 
2211 
8 51 
501 
486* 
488# 
531# 
4 26** 
273-705 
266-941 
320-996 
317-1155 
198-274 
3354-9993 
8.8-15 0 
48-146 
73-284 
22-84 
14-45 
8 7-25 
271-585 
317-511 
365-923 
1 29-3 43 
473 ±117 
504 ±169 
621±211 
575 ±220 
294 ±80 
5910±2168 
118 ±18 
77 ±33 
194 ±92 
50±18 
29 ±10 
18±5 
430 ±100 
400 ±90 
609 ±166 
2.34 ± 0 54 
20 
20 
20 
20 
19 
20 
20 
18 
39 
18 
12 
11 
14 
14 
14 
16 
* [l-'^C] indicates radioactive carbon 14 in the No 1 position-labeled, l 4 C (ul), uniformly la­
beled with 1 4C, ATP, adenosine, triphosphate, CrP, creatine phosphate, NADH, the reduced 
form of nicotinamide-adenine dinucleotide, Q,, ubiquinone-1 (analogon of coenzyme Q). 
t Nanomoles of l 4C02 per hour per milligram of protein. 
% Nanomoles per hour per milligram of protein. 
§ Milhumts per milligram of protein. 
|| Nanomoles of cytochrome с reduced per minute per milligram of protein. 
1 Nanomoles of NADH oxidized per minute per milligram of protein. 
# Picomoles per milligram of protein 
** Units per milligram of protein 
(control range, 2.7 to 4.6 pmol/g wet weight; n=21). The specific activities 
of the mitochondrial enzymes in muscle homogenate are also shown in 
Table 1. Citrate synthase, used as a mitochondrial reference enzyme, had 
a normal activity in muscle homogenate. Concerning the respiratory chain, 
normal activities for cytochrome с oxidase and succinatexytochrome с 
oxidoreductase and normal concentrations of the cytochromes were found. 
The activities of both NADHO: and NADH:Qi oxidoreductase, however, 
were decreased to 30% of mean control activity (Table 1). 
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COMMENT 
We present a 17-year-old patient with a progressive hypokinetic-rigid 
syndrome, athetosis of the hands, pyramidal and cerebellar signs, periodic 
hyperventilation, abnormalities of cardiac rhythm, and exercise intolerance. 
The abnormally high increase in the blood lactate level after oral glucose 
loading, in the lactate and pyruvate levels after moderate physical exercise, 
and in the lactate level after intravenous pyruvate loading are indications 
of a disturbance of pyruvate metabolism. The clearly decreased oxidation 
of pyruvate in muscle tissue confirms this (Table 1). A deficiency of the 
pyruvate dehydrogenase complex can be excluded, because in that case 
the oxidation of malate in the presence of acetylcarnitine as cosubstrate 
should be undisturbed. The oxidation rates of pyruvate and malate, 
however, were lowered under all conditions tested. This finding points 
to a defect in a pathway necessary for the oxidation of pyruvate and malate 
under all experimental conditions, eg, the respiratory chain. Indeed, the 
activity of NADH:02 oxidoreductase, reflecting the overall capacity of 
the respiratory chain (Fig 2),24 is too low (Table 1). The defect can be 
pinpointed to the NADH dehydrogenase (complex I) activity, as NADH:Qi 
oxidoreductase has a decreased activity, while all other components of 
the respiratory chain show normal activities and/or concentrations (Fig 
2). The increase in CSF lactate and pyruvate levels makes it likely that 
the same defect is present in the CNS. 
In fibroblasts, no abnormalities in the mitochondrial oxidative meta­
bolism could be demonstrated, which has its negative consequence for 
antenatal diagnosis. 
In the literature, several patients with complex I deficiencies have had 
their cases reported.9,28"36 In one of these patients,9 a deficiency of NADH 
dehydrogenase has been established recently by direct assay.24 To our 
knowledge, there is direct proof of an NADH dehydrogenase deficiency 
in only one other patient.35 Clinically, there is a myopathy without 
neurologic signs and symptoms in six patients, and in the other four 
patients,' ' ' signs and symptoms originate predominantly from the CNS. 
succinate 
dehydrogenase 
compta 
pyruvate 
л
 NADH »-
/ 
NADH dehydrogenase 
comptai 
CoQ • - |cyt be,| • - cyl с *~ [ c y t M j 
Fig 2. Scheme of respiratory chain. NADH indicates reduced form of nicotinamide-adenine 
dinucleotide, CoQ, coenzyme Q; cyt bei. cytochrome bei; cyt c, cytochrome c; cyt ааз, 
cytochrome aaj 
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Table 2. Summary of clinical signs and symptoms of our patient compared with results of a 
literature study of 24 proven juvenile Leigh patients 
Patient Literature 
Respiratory signs and symptoms 
Cardiac signs and symptoms 
Ocular signs 
Pyramidal signs 
Extrapyramidal signs 
Cerebellar signs 
Exercise intolerance 
Decompensation on infection 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
54% 
25% 
79% 
88% 
46% 
54% 
50% 
42% 
Of the latter group, one is suffering from Alpers' disease,32 and in two 
patients the diagnosis of Leigh's syndrome is proved.9,36 
In our patient and in some of the patients whose cases are reported 
in literature with a complex I deficiency,9,30,32,36 there are no gross structural 
mitochondrial abnormalities, while the other patients all show a wide range 
of morphologic mitochondrial abnormalities. This illustrates that there 
is no specific correlation between defects of mitochondrial metabolism 
and alteration in mitochondrial structure.37 
In our patient, a clinical and biochemical myopathy and CNS involvement 
are apparent. We consider him suffering from mitochondrial encephalo-
myopathy,4 compatible with Leigh's syndrome. Signs and symptoms 
combined with a proved defect of energy metabolism led us to this 
conclusion. In Table 2, signs and symptoms of our patient are compared 
with signs and symptoms of 24 patients with proved juvenile Leigh's 
syndrome (age at onset between 4 and 16 years) whose cases were derived 
from the literature. As can be seen in Table 2, extrapyramidal signs are 
present in half of the patients with juvenile Leigh's syndrome. 
Leigh's syndrome has been associated with deficiencies of pyruvate 
carboxylase,6 pyruvate dehydrogenase complex,7 cytochrome с oxidase,8 
NADH dehydrogenase,9 and a disturbance in the activation of the pyruvate 
dehydrogenase complex.38 
Until now, the cases of more than 30 patients with respiratory chain 
deficiencies have been reported.39 Recognition of clinical entities in electron 
transport chain defects is difficult, due to the great variability in clinical 
presentation of a defect and the relatively small number of patients whose 
cases have been reported until now. At present, classification can best 
be made on biochemical grounds. 
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ABSTRACT 
We studied a 17-year-old girl with subacute necrotizing encephalomye-
lopathy (Leigh syndrome). Lactate and pyruvate levels were increased in 
serum and cerebrospinal fluid. The oxidation rates of all substrates tested, 
i.e. pyruvate in liver, and pyruvate, malate and 2-oxoglutarate in muscle, 
were decreased, as was the production of adenosine triphosphate plus cre-
atine phosphate. Cytochrome content was normal. The data imply a defect 
in oxidative phosphorylation, outside the cytochrome region. 
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INTRODUCTION 
In 1951, Leigh (1) described a 7-month-old boy with a unique central 
nervous system pathology, which he termed subacute necrotizing enceph-
alomyelopathy (SNE, Leigh syndrome). The diagnosis still is neuropath-
ologic, characterized by spongy dystrophy of the neuropil, pronounced 
proliferation of endothelial cells in the walls of small blood vessels and 
relative sparing of neuronal cells. The lesions show a bilateral, often 
symmetrical, distribution and are found most characteristically in the 
tegmentum of the brainstem and walls of the third ventricle (2). 
Since the description of a pyruvate carboxylase deficiency in a patient 
with Leigh syndrome by Hommes et al (3) in 1968, several investigators 
have reported disorders of pyruvate metabolism or of the respiratory chain. 
Deficiencies of pyruvate carboxylase (3-8), the pyruvate dehydrogenase 
complex (9-17) and cytochrome с oxidase (18,19) have been described. 
Cooper et al (20) demonstrated a factor in body fluids that inhibits thiamine 
diphosphate-ATP phosphoryltransferase; it blocks in vitro synthesis of 
thiamine triphosphate, thus implicating abnormal thiamine metabolism 
as a pathogenic factor (21). 
We now describe a 17-year-old girl with the classic pathology of SNE, 
and an abnormal oxidative phosphorylation. 
CASE REPORT 
This patient was the youngest daughter of healthy, nonconsanguineous parents There were 
3 healthy siblings Her youngest brother lost vision for 5 years, with bilateral optical atrophy 
of unknown ongin In this case, neurological examination and routine chemical investigations 
revealed no abnormalities Lactate and pyruvate in serum and cerebrospinal fluid (CSF) 
were not measured At age 9, the boy was nearly blind and died in the course of an intercurrent 
infection Cerebral autopsy was not performed. 
Our patient showed normal development and had an uneventful medical history until 
age 4, when she was seen by a neurologist because she had had difficulty in walking for 
a few months Mild spasticity of both legs, hyperactive tendon reflexes of the legs, ankle 
clonus, and Babinski signs were seen Apart from slight bilateral horizontal nystagmus, clumsy 
gait was the only sign for the next 13 years There were no exacerbations on intercurrent 
infections No exercise intolerance was noted. 
At age 17, the gait disorder gradually became more pronounced, and the right arm and 
hand were paretic. There were no visual symptoms On examination, there was no intellectual 
impairment There was external ophthalmoplegia, with nystagmus of the left eye in all 
directions. Fundoscopy was normal. The right arm showed a mild paresis The paresis of 
the legs had increased. Tendon reflexes of the arms were also hyperactive 
Three months after onset of the exacerbation, she had difficulty in breathing and became 
comatose On artificial respiration, consciousness cleared in so far as she could carry out 
simple tasks, such as moving the limbs, but spontaneous breathing did not recover After 
a few days, coma gradually deepened, tendon reflexes were lost, but plantar responses remained 
extensor. Pupillary reflexes and brainstem reflexes could not be elicited After 16 weeks 
of artificial respiration, all treatment was stopped and the patient died. 
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ELECTROPHYSIOLOGICAL AND RADIOLOGICAL INVESTIGA­
TIONS 
A few days after the onset of coma, EEG showed diffuse slowing (1-3 
Hz) with no signs of focal pathology. EMG and nerve conduction velocities 
were normal. The blink reflex was normal during the first weeks, but 
gradually disappeared. No evoked potentials were recorded. Cerebral CT 
and 4-vessel angiography showed no abnormalities. 
ROUTINE AND SPECIFIC LABORATORY INVESTIGATIONS 
Results from standard blood and urinary studies, including hematologic 
evaluation, renal and hepatic functions, serum protein, and serum protein 
electrophoresis, were normal. Other normal studies included serum pH, 
рСОг and bicarbonate, serum glucose, serum lipids and short-chain fatty 
acids, organic acids and amino acids in plasma and urine, lysosomal 
enzymes, creatine kinase, serum copper and ceruloplasmin. Serum levels 
of lactate and pyruvate were measured several times and were normal 
or moderately elevated (Table 1); 24-hr urinary lactate excretion was normal. 
Appropriate studies ruled out endocrinological, immunological and chronic 
infectious diseases, deficiencies, and disorders caused by toxic agents. 
CSF cell count, protein content, protein electrophoresis and Immuno­
electrophoresis, minerals, glucose, acetoacetate, and /J-hydroxybutyrate 
were normal. Lactate and pyruvate levels were elevated, with an increased 
lactate-pyruvate ratio (Table 1). 
NEUROPATHOLOGIC EXAMINATION 
Macroscopic examination of brain and spinal cord revealed a spongy aspect 
of the walls of the third ventricle (Fig 1), the tegmental region of 
Table 1. Lactate and pyruvate levels in serum and cerebrospinal fluid (CSF) of patient and 
controls 
Lactate' Pyruvate' Ratio 
Lactate-Pyruvate 
106-200 8.0-15.0 
75-120 up to 15 
143-198 17.6-22.6 
85-132 up to 15 
' дтоі/і;b range, based on measurements in 4 samples. 
Serum Patient 950-2330 
Controls 600-1200 
(n=200) 
CSF Patient" 2520-4470 
Controls 1200-1600 
(n=200) 
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Fig 1. Spongy degeneration of the walls of the third ventricle. Klüver-Barrera. 
mesencephalon, pons and medulla oblongata, and the central part of the 
spinal cord. On light microscopic examination, the hypothalamic area, 
walls of the third ventricle, tegmental region of mesencephalon and pons, 
olivary nuclei, nucleus dentatus, medulla oblongata, and central part of 
the spinal cord showed pathological changes, characterized by micro va-
cuolization and cyst formation, proliferation of protoplasmic and fibrocytic 
astrocytes, and vascular and endothelial proliferation. Within the lesions, 
which had a punched-out aspect, the ganglion cells remained relatively 
intact. There were no hemorrhagic changes and no inflammatory signs. 
Histochemical and ultrastructural studies of the frontal cortex revealed 
no pathological changes. No mitochondrial abnormalities were seen. 
BIOPSY STUDIES 
All biopsy specimens were taken while the patient was in coma. 
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MORPHOLOGICAL STUDIES 
Microscopic and histochemical studies were performed on liver tissue. 
Histochemical and ultrastructural studies were performed on muscle tissue. 
BIOCHEMICAL STUDIES 
Material 
Biochemical studies were performed in liver and muscle homogenates, and 
in isolated muscle mitochondria. Two specimens of quadriceps muscle were 
available for biochemical studies, obtained one and two months, respec­
tively, after onset of coma. 
Methods 
Pyruvate metabolism in liver tissue. Pyruvate oxidation rate in a fresh liver 
tissue homogenate was studied by measuring 14C02 production from [1-
'"CJpyruvate (18). Pyruvate carboxylase (E.C.6.4.1.1) activity was measured 
in the same liver homogenate (22) after storage at -70oC, using a regenerating 
system for acetyl-CoA (23). 
Mitochondrial oxidative metabolism in muscle tissue. Pyruvate oxidation 
rate and activities of citric acid cycle and respiratory chain in fresh muscle 
homogenate were evaluated by measuring 14C02 from [l-14C]pyruvate, [1-
14C]2-oxoglutarate and [U-14C]malate (24). The capacity of muscle to 
synthesize adenosine triphosphate (ATP) and creatine phosphate was 
investigated under conditions in which the adenylate kinase activity was 
inhibited (25). In frozen muscle homogenate, carnitine content (26) and 
activities of carnitine palmitoyltransferase (E.C.2.3.1.21) (exchange reaction 
at 0.8 mM palmitoylcarnitine) (27), citrate synthase (E.C.4.1.3.7) (28) and 
cytochrome с oxidase (E.C.I.9.3.1) (29) were measured. The assay medium 
for succinate-cytochrome с oxidoreductase activity contained 0.05 mM 
cytochrome c, 2 mM KCN and 2 μg/ml rotenone. Extinction was followed 
at 550 nm; extinction coefficient used was 21.1 mM'.cm - 1 . The assay 
medium for succinate dehydrogenase (E.C. 1.3.99.1) activity contained 0.05 
mM dichlorophenolindophenol. Extinction was followed at 600 nm; ex­
tinction coefficient used was 19.1 тМЛспГ' . For measurement of succinate-
cytochrome с oxidoreductase and succinate dehydrogenase activity, muscle 
homogenates were preincubated with 20 mM succinate in 50 mM KP,, 
pH 7.4. The dehydrogenase activity was corrected for the activity of samples 
preincubated with malonate instead of succinate. Both assays were per­
formed at 250C. In isolated muscle mitochondria (24), cytochrome с 
oxidoreductase activity (29), cytochromes (30), and oxygen consumption 
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at 370C with 1 mM pyruvate and 1 mM malate as substrates (31), were 
measured. 
Protein determination. Protein was assayed according to Lowry et al (32). 
RESULTS 
MORPHOLOGICAL STUDIES 
Microscopic and histochemical studies of liver revealed no abnormalities. 
Histochemical and ultrastructural studies of quadriceps muscle showed 
no abnormalities, particularly no 'ragged-red fibers' were seen in the 
trichromie stained section, and electron microscopy revealed no abnormal 
mitochondria. 
BIOCHEMICAL STUDIES 
Pyruvate carboxylase activity in liver homogenate was normal (37.0 nmol/ 
min/mg protein; controls 28.2 ± 12.1, mean ± SD; n=16), and UC02 
production rate from [l-14C]pyruvate + malate was decreased (Table 2). 
14C02 production rate from [l-1'lC]pyruvate, [l-1'lC]2-oxoglutarate and [U-
HC]malate in muscle homogenate was markedly decreased (Table 2). ATP 
production with pyruvate, malate or 2-oxoglutarate as substrates was lower 
than in control muscle homogenates (Table 3). The ratio of the amount 
of ATP produced to the amount of pyruvate oxidized was not decreased 
(33). Total carnitine content (carnitine + acylcarnitines) in muscle ho­
mogenate was normal. The specific activities of the mitochondrial enzymes 
in muscle homogenate are shown in Table 4. Cytochrome с oxidase activity 
Table 2. Ы С 0 2 production from various
 l4C-labeled substrates in liver and muscle tissue ho­
mogenates of patient and controls 
Substrate 
Liver [l-14C]pyruvate + malate 
Muscle [l-MC]pyruvate + malate 
[l-14C]pyruvate + carnitine 
[l-NC]pyruvate + malate + malonate 
[U-^CJinalate + pyruvate + malonate 
[U-MC]malate + acetylcamitine + malonate 
[U-l4C]malate + acetylcarnitinc + arsenite 
[l-14C]2-oxoglutarate 
Patient 
13 6" 
Biopsy 1 
54· 
98 
31 
90 
108 
81 
134 
Biopsy 2 
73* 
143 
136 
Controls 
45-205 (n=13) 
243-729 (n=41) 
221-838 (n=39) 
214-687 (n=36) 
390-1172 (n=39) 
352-1155 (n=39) 
172-492 (n=36) 
341-1229 (n=15) 
* nmol/hr/mg protein. 
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Table 3. Adenosine triphosphate (ATP) plus creatine phosphate production after incubation 
of muscle homogenates of patient and controls with vanous substrates in the presence or ab­
sence of specific inhibitors 
Substrate Inhibitor 
Pyruvate + malate 
Acetylcarnitine + malate Arsenite 
2-Oxoglutarate Malonate 
* nmol/min/mg protein. 
Table 4. Activities of mitochondrial enzymes m 
Carnitine palmitoyltransferase 
Citrate synthase 
Cytochrome с oxidase 
Succinate - cytochrome с oxidoreductase 
Succinate dehydrogenase 
Patient 
42* 
21 
10 
muscle homogenates 
Patient 
0.23' 
44 
65 
7.3 
7.2 
Controls 
78-242 (n=13) 
36-69 (n=l l ) 
35-79 (n=6) 
of patient and controls 
Controls 
0 33-0 97 (n=14) 
27-77 (n=18) 
73-284 (n=39) 
11-36 (n=14) 
6-16 (n=6 ) 
' nmol substrate converted/min/mg protein 
in isolated muscle mitochondria was normal (1315 nmol/min/mg protein; 
controls 1288 - 3427, range; n=19). The contents of cytochrome b, с + 
ci and ааз were normal. Oxygen consumption by isolated muscle mito­
chondria with pyruvate and malate as substrates, was decreased to about 
one tenth of normal (2.5 Mg-atom O/hr/mg protein; controls 23.0 ± 4.8, 
mean ± SD; n=4). 
DISCUSSION 
Leigh syndrome can be transmitted as an autosomal recessive trait (34). 
It is likely, therefore, that this patient's brother, though presenting with 
a different clinical picture, also suffered from SNE. Optical atrophy and 
blindness have been reported in SNE (2). The insidious onset and the 
chronic unremitting course in our patient, ending with a subacute exa­
cerbation and coma, is seen in some cases of SNE (34,35). 
The intermittent rise of serum levels of lactate and pyruvate and, 
especially, the high CSF lactate and pyruvate levels in our patient pointed 
to a primary or secondary defect in pyruvate oxidation. 
Pyruvate oxidation was decreased in both liver and muscle. In muscle 
homogenate, ,4C02 production from malate and 2-oxoglutarate was de­
creased too. Furthermore, ATP production with these compounds as 
substrates was decreased. The efficiency of oxidative phosphorylation (i.e. 
the amount of ATP produced per molecule substrate oxidized) was not 
affected, indicating that muscle mitochondria were well coupled. Oxidation 
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rates remain lowered if expressed on base of mitochondrial marker enzymes. 
As the mutual ratios of these enzymes (Table 4) are normal, the low normal 
or decreased activities point to a low mitochondrial content in the 
homogenate, and not to one or more defective enzymes. 
These findings, combined with a very low O2 consumption and normal 
cytochrome levels in isolated mitochondria, can be explained by an 
abnormality in a common metabolic step (24,36). A defect in the NADH-
CoQ complex, in the ADP-ATP translocator, or in the Fi-ATPase activity 
has to be considered (Fig 2). As succinate-cytochrome с oxidoreductase 
and succinate dehydrogenase are not deficient (Table 4), a possible defect 
in the NADH-CoQ complex is restricted to the pathway in which the 
reduction equivalents are transported from NADH to CoQ, excluding CoQ 
itself. 
The high CSF lactate and pyruvate levels make it probable that oxidative 
phosphorylation is abnormal in brain as well as in liver and muscle. 
Ours is the first report of a defect in oxidative phosphorylation outside 
the cytochromes in a patient with Leigh syndrome. Several authors (36-
39) have described patients with defects in the first part of the respiratory 
chain, but the clinical picture in these cases differs from our patient in 
that a clinical myopathy is almost always present. 
Our findings stress again the fact that SNE is a syndrome of different 
causes, based on a defect in aerobic energy metabolism. 
succinate » 
pyruvate 
malate 
4 
/ 
NADH 
«-] cyt.., | — - 0 2 
cytoplasmic ADP cytoplasmic ATP 
Fig 2. Scheme of the electron flow through the mitochondrial respiratory chain, and the 
synthesis and transport of adenosine triphosphate (ATP). 
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ADDENDUM 
DEFECT OF NADH DEHYDROGENASE 
IN LEIGH SYNDROME 
P.M.M. van Erven, J.C. Fischer, F.J.M. Gabreëls, 
W.O. Renier, J.M.F. Trijbels and A.J.M. Janssen 
Acta Neurologica Scandinavica 1986;74:167 

LETTER TO THE EDITOR 
Recently, we reported a patient with Leigh syndrome in this journal (1). 
Biochemical studies gave indirect evidence of a NADH dehydrogenase 
deficiency. 
In skeletal muscle 600 χ g supernatant of this patient, stored at -70oC, 
we measured activities of NADH:02 oxidoreductase and NADHrQi oxi­
doreductase as described by Fischer et al (2). The NADHO: oxidoreductase 
activity was determined in the presence of cytochrome c. The rotenone-
sensitive NADH oxidation by both enzyme systems was determined at 
340 nm (2). NADH:02 oxidoreductase activity was 2.1 nmol NADH 
oxidized/min/mg protein (control range 4.5 - 22.9, n=7) and NADH:Qi 
oxidoreductase activity was 3.8 nmol NADH oxidized/min/mg protein 
(control range 10.6 - 22.1, n=7). NADHrCb oxidoreductase activity reflects 
the oxidizing capacity of the respiratory chain as a whole. The use of 
Qi, a water soluble coenzyme Q analogue, as electron acceptor allows 
a direct estimation of NADH dehydrogenase activity. 
The results of our study show that there is a defect in the NADH 
dehydrogenase, one of the possible causes previously proposed (1). This 
holds at least for skeletal muscle of the patient, but likely also for brain 
and liver tissue (1). 
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ABSTRACT 
Several disorders of oxidative metabolism have been described in association 
with subacute necrotizing encephalomyelopathy (SNE) or Leigh syndrome. 
We present an eight-year-old girl with a mild spastic paraparesis and clinical 
deterioration on intercurrent infections. One sib died of SNE proven by 
autopsy. Biochemical examination of muscle tissue points to a disturbance 
in the process of oxidative phosphorylation due to a disturbed oxidation 
of NADH. The biochemical disorders associated with SNE are reviewed. 
The relation of SNE to the concepts of encephalomyopathy and mito-
chondriopathy is discussed. 
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INTRODUCTION 
Subacute necrotizing encephalomyelopathy (SNE) or Leigh syndrome is 
a degenerative disorder of the central nervous system (Leigh, 1951). The 
diagnosis can only be confirmed by postmortem examination and is based 
on well-characterized neuropathologic criteria (Pincus, 1972). Clinical signs 
and symptoms, and course of the disease show a considerable variability 
(Pincus, 1972). 
Different defects of oxidative metabolism have been reported in asso-
ciation with Leigh syndrome (Hommes et al, 1968; Farmer et al, 1973; 
Willems et al, 1977). 
We present an eight-year-old girl, whose brother died of SNE. Inves-
tigation of aerobic energy metabolism in muscle tissue pointed to a dis-
turbance in the process of oxidative phosphorylation. 
CASE REPORT 
Our patient is the youngest daughter of healthy, nonconsanguineous parents She had an 
uneventful history until she was eighteen months of age At that time she began to walk, 
but soon it appeared that she had a spastic ataxic walking pattern One year later she was 
examined at our department. She was a small, nice looking thirty-one-month-old girl, 
functioning on a normal mental level Weight, height and skull circumference were less than 
the tenth percentile No dysmorphic features were present Internal examination was normal. 
Pulse rate under resting conditions varied between 90 and 180/min Mild exercise intolerance 
was evident. On neurologic examination the following abnormalities were noted· there was 
spasticity of the legs, and gait was spastic ataxic with bilateral circumduction and dysmetna 
Tendon reflexes of the legs were hyperactive and the plantar responses were extensor Between 
ages two and a half and eight years the clinical picture has remained fairly stable, though 
there have been a few temporary deteriorations on intercurrent infections, that required 
hospitalization These deteriorations were charactemed by aggravation of the neurologic 
disturbances, apathy, vomiting and Cheyne-Stokes respiration, total recovery usually taking 
a few months. 
Family history. The pedigree is shown in Figure 1 There were two spontaneous abortions 
at three months amenorrhea The oldest sib is a healthy fifteen-year-old girl The other 
sister had the same spastic ataxic walking pattern as our patient. At age three years, she 
got an otitis media with high fever. In one week she deteriorated rapidly, lapsed into coma 
and died of breathing insufficiency. Brain autopsy was not performed 
Patient's brother was noted to have an elevated muscle tone of the legs at age six weeks. 
This was attributed to a birth trauma caused by difficult delivery due to pelvic contraction. 
Motor development was slow but within normal range. At age twenty-one months, the boy 
went through a viral infection with high fever, after which he could not walk without help 
anymore There proved to be a pronounced spasticity of the legs, with hyperactive tendon 
reflexes and extensor plantar responses. Biochemical investigations of serum and cerebrospinal 
fluid (CSF) showed no abnormalities The levels of lactate and pyruvate were not measured. 
Twenty-four-hour urinary lactate excretion was normal. Radiologic examination of skull 
and vertebral column, and cerebral CT scanning, EEG and EMG were all normal At age 
three and a half years, again following an episode of high fever, the boy went into coma, 
preceded by a few seizures of the grand-mal type. Artificial respiration was necessary due 
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Fig 1. Pedigree of the family. 
to respiratory insufficiency. Six weeks later he died. At brain biopsy, an edematous brain 
was seen, weighing 1010 g, with the classical pathology of SNE. 
ELECTROPHYSIOLOGIC AND RADIOLOGIC INVESTIGATIONS 
EEG, EMG and nerve conduction velocities were normal. Evoked potentials 
(somatosensory evoked potentials, brainstem evoked potentials and visual 
evoked potentials) fell within the normal ranges. Radiograms of skull, 
chest and vertebral column, and cerebral CT scan showed no abnormalities. 
ECG and echocardiogram were normal. 
ROUTINE AND SPECIFIC LABORATORY INVESTIGATIONS 
Results from standard blood and urinary studies, including hematologic 
evaluation, renal and hepatic functions, serum protein, and serum protein 
electrophoresis, were normal. Other studies, including serum pH, pCOj 
and bicarbonate, serum glucose, serum lipids and short-chain fatty acids, 
organic acids and aminoacids in plasma and urine, lysosomal enzymes, 
creatine kinase, serum copper and ceruloplasmin, showed also normal 
results. Serum levels of lactate and pyruvate were normal or moderately 
elevated (Table 1); twenty-four-hour urinary lactate excretion was normal. 
Appropriate studies ruled out endocrinologie, immunologic and chronic 
infectious diseases, deficiencies, and disorders caused by toxic agents. 
CSF cell count, protein content, protein electrophoresis and immune-
electrophoresis, minerals, glucose, acetoacetate, and /?-hydroxybutyrate 
were normal. Lactate and pyruvate levels, and the lactate-pyruvate ratio 
were normal or moderately elevated (Table 1). 
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Table 1. Lactate and pyruvate levels in serum and CSF of patient and controls 
Patient Controls 
(n=200) 
Serum Lactate" 1280-1700 600-1200 
Pyruvate' 118-126 75-120 
Ratio lactate/pyruvate 10.2-14.4 up to 15 
CSF Lactate' 1520-1830 1200-1600 
Pyruvate* 90-153 85-132 
Ratio lactate/pyruvate 12.0-16.9 up to 15 
' μιηοΐ/ΐ. 
HISTOPATHOLOGIC STUDIES 
Biopsies were taken from quadriceps muscle, sural nerve and liver. 
Histochemical and ultrastructural studies of quadriceps muscle showed 
no abnormalities. No 'ragged-red fibers' were noted in the trichromie stained 
section. The mitochondria were normal and no intramitochondrial inclu­
sions were seen. On light and electron microscopic studies of sural nerve 
and liver no abnormalities were noted. 
BIOCHEMICAL STUDIES 
MATERIALS AND METHODS 
Biochemical studies were performed in homogenized liver tissue obtained 
by needle biopsy, and two quadriceps muscle homogenates from biopsies 
obtained with a three-year interval. 
Pyruvate oxidation rate in liver tissue homogenate was studied by 
measuring 14C02 production from [l-14C]pyruvate according to Willems 
et al ( 1979). Pyruvate carboxylase activity was measured in liver homogenate 
as described by Utter and Keech (1963), with a regenerating system for 
acetyl-CoA according to Henning and Seubert (1964). Pyruvate oxidation 
rate and activity of citric acid cycle and respiratory chain were evaluated 
for muscle tissue by measuring '"СОг production from [l-l4C]pyruvate, 
[ l-14C]2-oxoglutarate and [U-14C]malate in a 600 g supernatant, as described 
by Bookelman et al (1978b). Succinate-cytochrome с oxidoreductase activity 
was estimated in SETH medium (Bookelman et al, 1978b) at 250C in the 
presence of 10 mM succinate, 2 mM potassium cyanide, 2 μg/ml rotenone 
and 50 μΜ cytochrome с as the final electron acceptor. The extinction 
was followed at 550 nm. An extinction coefficient of 21.1 тМЛсігГ1 was 
used (Van Gelder and Slater, 1962). Cytochrome с oxidase activity in muscle 
homogenate and isolated muscle mitochondria was measured according 
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to Cooperstem and Lazarow (1951). Cytochromes were assayed in isolated 
muscle mitochondria according to Bookelman et al (1978a). All oxidation 
rates and cytochrome determinations were performed in fresh tissue, the 
single enzyme measurements in samples stored at -70oC. Protein was assayed 
as described by Lowry et al (1951). The method of Parvin and Pande 
(1977) was used for determination of carnitine content in muscle homo­
genate. 
RESULTS 
In liver homogenate, [l-14C]pymvate oxidation was clearly decreased (Table 
2), while pyruvate carboxylase had a normal activity (29 nmol/min/mg 
protein; control range 13-40, n=16). In muscle homogenate, the oxidation 
of [l-14C]pyruvate, [U-14C]malate and [l-14C]2-oxoglutarate was markedly 
lowered under all incubation conditions tested (Table 2). These oxidation 
rates were not normalized in the presence of 25 μΜ cytochrome c, 1 mM 
NAD and 0.1 mM CoASH, added alone or in combination. Furthermore, 
normal values were found for the cytochrome levels and cytochrome с 
Table 2. "СОг production from various "C-labeled substrates in liver and muscle tissue ho-
mogenates of patient and controls 
Substrate Patient Controls No 
Liver [l-MC]pyruvate +malate 19 45-205 13 
Muscle* [l-14C]pyruvate + malate 
[l-NC]pyruvate + carnitine 
[l-NC]pyruvate + malate + malonate 
[U-HC]malate + pyruvate + malonate 
[U-14C]malate + acetylcamitine + malonate 
[U-14Clmalate + acetylcamitine + arsemte 
[l-14C]2-oxoglutarate 
* nmol 14C02/h/mg protein, ь determined in two specimens from biopsies obtained with a 3-
year interval 
Table 3. Contents of cytochrome b, с + с, and aaìy and activities of cytochrome с oxidase 
and succinate-cytochrome с oxidoreductase in isolated muscle mitochondria of patient and 
controls 
Patient Controls No. 
Cytochrome/)' 329 228-424 14 
Cytochrome с + с," 516 365-923 14 
Cytochrome ja," 543 271-543 14 
Cytochrome с oxidase1" 2.17 129-3 43 19 
Succinate-cytochrome с oxidoreductase" 110 75-186 7 
' pmol/mg protein, ь U/mg protein; ' nmol succinate metabolized/mm/g wet weight. 
80, 152b 
136, 164b 
76 
112, 189b 
126 
75 
86 
243-729 
221-838 
214-687 
390-1172 
352-1155 
172-492 
341-1229 
41 
39 
36 
39 
39 
36 
15 
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oxidase activity in isolated muscle mitochondria (Table 3). The activity 
of cytochrome с oxidase was also normal in liver and muscle homogenate. 
Muscle showed a normal activity of succinate-cytochrome с oxidoreductase 
(Table 3). Carnitine content of muscle was normal. 
DISCUSSION 
We reported on an eight-year-old girl with a mild spastic paraparesis, 
ataxia, exercise intolerance, and temporary deteriorations on intercurrent 
infections. Two sibs with similar clinical features died in the course of 
an intercurrent infection. One of them showed changes characteristic of 
SNE on neuropathologic examination. Considering the autosomal recessive 
mode of inheritance of SNE (Pincus, 1972) and the similarities in clinical 
picture of the three sibs, we concluded to the diagnosis of familial SNE. 
In our patient, lactate and pyruvate levels of serum and CSF showed 
an intermittent elevation, a finding that suggested a disturbance in pyruvate 
metabolism. Biochemical studies in liver and muscle tissue confirmed the 
existence of a defective pyruvate catabolism. 
In muscle homogenate, a decreased CO2 production rate from [1-
14C]pyruvate either in the presence of malate or carnitine as an acetyl-
CoA acceptor was found, indicating that the defect is not localized in 
the citric acid cycle. The decreased 14C02 production rate obtained with 
[U-14C]malate in the presence of acetylcarnitine as acetyl-CoA donor 
succinate-
pyruvate 
malate 
N. 
/ 
NADH 
*-| cyt.., [—»O; 
cytoplasmic ADP cytoplasmic ATP 
Fig 2. Simplified scheme of the mitochondrial respiratory chain, and synthesis and transport 
of ATP. 
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indicates that the defect is not localized in the pyruvate dehydrogenase 
complex (PDHc). The findings summarized in Table 2 can only be explained 
in terms of a defect in the mitochondrial electron transport chain, ATP-
ADP translocator or Fi-ATPase (Fig 2). The afore mentioned conclusion 
is based on a previous observation that in human muscle homogenate 
malate and carnitine are equally effective as an acetyl-CoA acceptor, and 
pyruvate and acetylcarnitine as an acetyl-CoA donor (Bookelman et al, 
1978b,c). As examination of the cytochrome content and succinate-
cytochrome с oxidoreductase activity did not reveal abnormalities, only 
the first functional unit of the respiratory chain may be defective: the 
NADH dehydrogenase (Fig 2). Theoretically, lack of NAD or CoASH 
could also cause low oxidative capacity of the mitochondria. We could 
exclude leakage of these cofactors out of the mitochondria as a cause 
of the defect because exogenous NAD plus CoASH did not normalize 
oxidation rates. 
Several authors have pointed to the association of SNE with disorders 
of oxidative metabolism. Since the initial publication of a pyruvate 
carboxylase (PC) deficiency in association with Leigh syndrome (Hommes 
et al, 1968), others reported the same finding (Grover et al, 1972; Tang 
et al, 1972; Gruskin et al, 1973; Grobe et al, 1975; Maesaka et al, 1976; 
Van Biervliet et al, 1980; Gilbert et al, 1983). Only a few reports, however, 
link PC deficiency with pathologically proven SNE (Hommes et al, 1968; 
Tang et al, 1972; Van Biervliet et al, 1980; Gilbert et al, 1983), and even 
in these cases methods and interpretation of the findings remain contro­
versial (Atkin et al, 1979; Murphy, 1981). A review of the literature on 
PC deficiency (Baal et al, 1981; De Vivo and Uziel, 1983) shows that (severe) 
PC deficiency can occur without evidence of SNE. 
Deficiencies of pyruvate decarboxylase (Farmer et al, 1973; Blass et al, 
1976; Hansen et al, 1982; Ohtake et al, 1982; Toshima et al, 1982) and 
defective activation of PDHc (DeVivo et al, 1979; Sorbi and Blass, 1982) 
have been reported in patients with SNE. The clinical manifestations of 
PDHc deficiency correlate wih the degree of impairment of activity (Blass, 
1979). The paucity of correlative studies between deficient activity of PDHc 
and corresponding pathology makes it difficult to define the place of SNE 
in the spectrum of PDHc deficiency. 
Defects of the respiratory chain have also been reported in Leigh 
syndrome. In 1977, Willems et al described the absence of cytochrome 
ааг and of cytochrome с oxidase activity in muscle tissue of a patient 
with SNE. Recently, Miyabayashi et al (1983) reported two siblings with 
cytochrome с oxidase deficiency, one of whom died of SNE. They 
demonstrated deficiency of cytochrome с oxidase activity in fibroblasts, 
liver, muscle and brain. Deficiencies of cytochrome с oxidase activity are 
also associated with the syndromes of fatal infantile mitochondrial my-
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opathy with renal dysfunction (Van Biervliet et al, 1977), benign infantile 
mitochondrial myopathy (DiMauro et al, 1983), trichopoliodystrophy 
(Menkes' disease) (French et al, 1972), and progressive poliodystrophy 
(Alpers' disease) (Prick et al, 1983; Gabreëls et al, 1984). 
In 1969, Pincus et al discovered an in vitro inhibition of the mitochondrial 
enzyme thiamine pyrophosphate-adenosine triphosphate phosphotransfer-
ase by urine and blood of a patient with SNE. The absence of thiamine 
triphosphate (TTP) in the brain of their patient led them to hypothesize 
that SNE was caused by this 'inhibiting factor'. Low values of TTP in 
SNE brains, roughly correlating with the sites of the brain lesions, were 
reported by the same author (Pincus et al, 1976). The hope that the urine 
inhibitor test would provide an unequivocal antemortem diagnosis of SNE 
has not been fulfilled. The urine test proved to have a 6% false-positive 
rate and in six out of twenty-nine patients no inhibiting factor could be 
demonstrated (Pincus et al, 1974). 
There are several reports on NADH-Coenzyme Q oxidoreductase com-
plex deficiencies (Morgan-Hughes et al, 1979; Busch et al, 1981; Land 
et al, 1981a,b; Prick et al, 1981; Morgan-Hughes, 1982). In contrast to 
the patients described by Morgan-Hughes et al (1979), Land et al (1981a) 
and Prick et al (1981), our patient shows no histochemical or ultrastructural 
abnormalities in muscle tissue. 
The presence of a mitochondrial myopathy in combination with an 
encephalopathy in our patient makes her fit into the concept of mito-
chondrial encephalomyopathies (Shapira et al, 1977). Defects in oxidative 
metabolism in SNE, however, have also been shown in fibroblasts, liver 
and kidney. So, SNE is more than an encephalomyopathy: it is a multi-
system disorder affecting derivatives of all three germinal layers. The 
disorder is associated with a disturbance in energy metabolism localized 
in the mitochondria. 
Le Coultre and Ebels (1976) first used the term mitochondriopathy in 
a case of Canavan's disease. Walter (1981) proposed the concept of 
mitochondriopathy and he distinguished between a primary and a secondary 
form. On the analogy of this concept, SNE is a mitochondriopathy, 
manifesting as a distinct encephalopathy with well-characterized neuro-
pathologic criteria and a defect of oxidative metabolism. 
The recognition of distinct syndromes certainly has heuristic value, but 
the ultimate classification must depend on identification of etiology and 
pathophysiology of the individual disorders. 
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ABSTRACT 
A-16-year-old girl shows delayed psychomotor development. In the infantile 
period, exercise intolerance, cerebellar signs, deteriorations on intercurrent 
infections, and disturbances of breathing and cardiac rhythm become 
manifest. From age 7 there is a chronic progressive psychomotor dete­
rioration. Hypotonia, a bilateral pyramidal and cerebellar syndrome, and 
a mild epilepsy develop. Pyruvate and lactate levels are elevated in CSF, 
and lactate content is elevated in urine. There is an abnormally high rise 
of lactate levels on moderate exercise and an abnormal response to pyruvate 
loading. Quadriceps muscle biopsies obtained at age 10 and 16 years show 
ragged-red fibres, and a decreased cytochrome с oxidase activity and 
cytochrome ааъ content. Cytochrome с oxidase activity in fibroblasts is 
normal. Clinical signs and symptoms in association with a disturbance 
of mitochondrial energy metabolism led us to a diagnosis of most probable 
Leigh syndrome. 
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INTRODUCTION 
In the clinical spectrum of mitochondrial myopathies Petty et al' identified 
three subgroups: 1) chronic progressive external ophthalmoplegia (CPEO) 
and limb weakness, 2) proximal weakness with fatigability, 3) predominantly 
or exclusively central nervous system (CNS) disease. The recognition that 
CNS disease is a prominent feature in a subgroup of the mitochondrial 
myopathies prompted Shapira et al2 to expand the concept of mitochondrial 
myopathy to mitochondrial encephalomyopathy. This latter group of 
disorders encompasses the syndromes of Alpers,3 Leigh,4 dysmyelination,5 
myoclonus epilepsy associated with 'ragged-red fibres' (MERRF)6 and a 
syndrome indicated by the acronym MELAS (mitochondrial myopathy, 
encephalopathy, lactic acidosis, and stroke-like episodes).7 
We present a girl with a mitochondrial encephalomyopathy and a clinical 
diagnosis of most probable Leigh syndrome and a partial cytochrome с 
oxidase deficiency of muscle. 
CASE REPORT 
Our patient is the youngest child of healthy non-consanguineous parents. There is one healthy 
sib The oldest sib died at age 12 after an accident. Family history reveals no neurodegenerative 
disorders Two sibs of the father are suffering from epilepsy Pre-, pen- and postnatal periods 
of the index patient are uneventful. Psychomotor development is delayed She is able to 
sit without help at age 18 months and walk at age 3 years. She speaks her first words 
at age 2% years. Motor performance is poor and deteriorations with often slow recovery, 
are noted on intercurrent infections During these periods of deterioration, frequent sighing, 
tachy- and bradypnea, and tachy- and bradycardia are evident. A few times she manifests 
a partial oculomotor nerve paresis on the left, that subsides within one week. A progressive 
exercise intolerance becomes evident At age 5 years, neurological examination reveals 
myopathic and cerebellar signs, active tendon reflexes and flexor plantar responses. Total 
IQ (WISC-R) is 95. At age 7 years, a slowly progressive psychomotor deterioration sets 
in, and absence-like epileptic manifestations appear, that are treated with ethosuccimide. 
At age 10 years, she is referred to our department On examination we see a mentally 
retarded girl, with normal height, weight and skull circumference There are no degenerative 
stigmata General physical examination is normal. On neurological examination there is 
a generalized hypotonia, muscle wasting, and proximal muscular weakness There is an 
increased lumbar lordosis, recurvation of the knees and a positive Gowers' sign. Facial 
expression is poor with a mild bilateral ptosis, and speech is monotonous and dysarthnc. 
Cerebellar involvement is evident by ataxia of rump and extremities, and marked dysdi-
adochokinesis. Tendon reflexes are hyperactive with spontaneous ankle clonus and bilateral 
Babinski signs 
A steady slowly progressive deterioration of the neurological status is seen in the following 
years She is 16 years old now and total IQ is 53. She has been free of seizures and without 
anti-epileptic medication for the last 4 years 
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ELECTROPHYSIOLOGICAL AND RADIOLOGICAL INVESTIGA­
TIONS 
Electroencephalogram shows focal (right temporal) and generalized epi­
leptic discharges. Electromyography and nerve conduction velocities are 
normal. Somatosensory, brainstem auditory and visual evoked potentials 
are within the normal ranges. Radiograms of skull, chest, hand and vertebral 
column, cerebral computed tomography scan and cerebral nuclear magnetic 
resonance scan are normal. Electrocardiogram is normal and the echo­
cardiogram shows no signs of cardiomyopathy. 
LABORATORY INVESTIGATIONS 
Routine haematological parameters, serum electrolytes, serum pH, рСОг 
and bicarbonate, serum protein, protein- and Immunoelectrophoresis, 
ammonia, lipids, short-chain fatty acids, lipoproteins and carnitine (total 
and free) are normal. Other studies reveal no abnormalities of renal, thyroid, 
parathyroid and adrenal functions. Serum enzymes, creatine kinase, serum 
levels of vitamins Bi, Вб, Bi2 and folic acid, serum levels of zinc, manganese, 
copper and ceruloplasmin, phytanic acid, uric acid, and activities of 
lysosomal enzymes in leucocytes are all normal. There are no acanthocytes. 
Syphilis, tuberculosis, sarcoidosis and systemic lupus erythematosus are 
ruled out by appropriate studies. Neurotropic virus antibody titers are 
not elevated in serum and cerebrospinal fluid (CSF). Urinalysis, urinary 
organic acids and amino acids, and urinary excretion of heavy metals are 
normal. Serum levels of glucose, pyruvate, lactate, /J-hydroxybutyrate and 
acetoacetate, their ratios, and responses of glucose, pyruvate and lactate 
to oral glucose loading (1.75 g/kg) are in the normal ranges. Lactate 
excretion is elevated in one 24-hour urine sample (131 pmol/mmol creatine, 
normal <100). The McArdle/Fischbein ischaemic exercise test8 yields a 
normal rise of serum lactate and ammonia levels. Moderate exercise 
(walking for a few minutes) gives a rise of serum pyruvate to 335 μτηοΐ/ 
1 (normal 60-155 μιηοΐ/ΐ under resting conditions) and of serum lactate 
to 6480 μτηοΙΑ (normal 460-1720 μτηοΙΛ under resting conditions), the 
lactate-pyruvate ratio is 18.2 (normal up to 15) and serum pH remains 
normal with a base excess of-3.9. An intravenous pyruvate loading test9'10 
(500 mg/kg) shows an abnormal response in that there is a rise of the 
lactate level after 5 minutes postinfusion to a maximum at 15 minutes. 
CSF cell number, protein content, protein- and Immunoelectrophoresis, 
and the levels of glucose, /i-hydroxybutyrate and acetoacetate are normal. 
The levels of pyruvate (222 дтоі/і, normal 85-132 μπιοΐ/ΐ) and lactate 
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(1900 μτηοΐ/l, normal 1200-1600 μπιοΐ/ΐ) are elevated with a normal lactate-
pyruvate ratio. 
HISTOPATHOLOGICAL STUDIES 
Quadriceps muscle biopsies are performed at the age of 10 and 16 years. 
Histopathological studies show no abnormalities except for the occurrence 
of ragged-red fibres in both biopsies. The cytochrome с oxidase (COX) 
stain shows a normal aspect in most fibres, but the ragged-red fibres show 
a strongly increased activity (Fig 1). Electronmicroscopy reveals no struc­
tural abnormalities of the mitochondria, and crystal-like inclusions do not 
occur. COX activity is normal in all fibres investigated (Fig 2). 
BIOCHEMICAL STUDIES 
MATERIALS AND METHODS 
In fresh homogenate of quadriceps muscle obtained by biopsy at age 10 
Fig 1. Cytochrome с oxidase stain. The fibres show a normal activity except for the ragged-
red fibre in the middle, that shows a strong increase of activity (bar = 50 μηι). 
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Fig 2. Electronmicrograph of section stained for cytochrome с oxidase activity. Normal 
reactivity is seen in all mitochondria (x60,000). 
years, pyruvate oxidation rate and activities of citric acid cycle and 
respiratory chain are evaluated by measuring '"ССЬ production from [1-
14C]pyruvate and [U-14C]malate.11 ATP production by muscle homogenate 
is measured according to Ruitenbeek et al.12 The activity of COX13 is 
measured in muscle homogenate and in isolated mitochondria. Cytochrome 
content is measured in isolated mitochondria.14 Protein is assayed according 
to Lo wry et al.15 
At age 16 years a quadriceps muscle specimen is obtained by needle 
biopsy. Carnitine content,16 and activities of COX,13 citrate synthase,17 
succinate-cytochrome с oxidoreductase18 and NADHiCb oxidoreductase19 
are measured, after storage of the muscle at -70oC. 
Oxidative metabolism is also evaluated in cultured fibroblasts by meas­
uring 14C02 production rate from [l-14C]pyruvate and [2-14C]pyruvate,20 
and the activities of COX12 and citrate synthase.17 
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RESULTS 
Table 1 contains the biochemical findings in both muscle specimens. 14C02 
production rates from [l-14C]pyruvate and [U-14C]malate by muscle ho­
mogenate are slightly diminished. ATP + CrP production with pyruvate 
as substrate is also decreased. The ratio of the ATP + CrP production 
to the arsenite sensitive pyruvate oxidation is normal. Total carnitine 
content (carnitine + acylcarnitines) is normal in muscle homogenate. The 
specific activity of COX in muscle homogenate and in isolated mitochondria 
is about 20% of the mean control value.This enzymatic defect is associated 
with a lack of cytochrome ааз. The ratio of the content of this protein 
of the COX complex to the content of cytochrome b and с + c\ is diminished 
(0.59 : 1 : 1.20; control ratio 1.08 : 1 : 1.52). 
UC02 production rates from [l-14C]pyruvate and [2-14C]pyruvate by 
fibroblasts, and the activities of COX and citrate synthase are normal. 
DISCUSSION 
We describe a 16-year-old girl with a slowly progressive degenerative 
neurological disorder characterized by myopathy, mental retardation, 
pyramidal, cerebellar and ocular signs. Frequent sighing, marked fluctu-
Table 1. Results of biochemical studies in the 600 g supernatant of the two muscle tissue spe­
cimens 
Oxidation 
[l-^Clpyravate + malate 
[l-,4C]pyruvate + carnitine 
[U-14C]malate + pyruvate + malonate 
[U-14C]malate + acetylcarmtine + malonate 
[U-14C]malate + acetylcarmtine + arsenite 
ATP Metabolism 
ATP + CrP production from pyruvate 
ATP + CrP production / pyruvate oxidation 
Enzyme activities 
Citrate synthase 
Cytochrome с oxidase 
Succinate cytochrome с oxidoreductase 
NADH O2 oxidoreductase 
1
 nmol 14C02/hr/mg protein,
2
 nmol/hr/mg protein,3 mU/mg protein,4 nmol cytochrome с 
reduced/min/mg protein,5 nmol NADH oxidized/min/mg protein 
Patienl 
1980 
208' 
237' 
270' 
343' 
196' 
20752 
10.0 
36' 
1986 
41' 
41 
8.74 
15.35 
Controls 
Range 
273-705 
266-941 
320-996 
317-1155 
198-274 
3354-9993 
8 8-15 0 
48-146 
73-284 
10-33 
4 5-23 
Mean ± SD 
473 ±117 
504 ±169 
621 ±211 
575 ±220 
294 ± 8 0 
No. 
20 
20 
20 
20 
19 
5910±2168 20 
11.8 ± 1 . 8 
77 ± 3 3 
194 ± 9 2 
18±7 
13±7 
20 
18 
39 
9 
7 
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ations of respiratory and cardiac rate, and long-lasting deteriorations on 
intercurrent infections are other clinical characteristics. 
Laboratory investigations show an elevation of lactate excretion in 24-
hour urine. Lactate concentration shows an abnormal increase on moderate 
exercise, and after pyruvate loading. In CSF, levels of pyruvate and lactate 
are elevated. These findings are suggestive of a defect in pyruvate me-
tabolism in this patient. 
At the age of 10 and 16 years quadriceps muscle biopsies are performed 
for histochemical and biochemical studies. Histochemical studies show 
ragged-red fibres. Biochemical studies show a slight decrease of 14C02 
production from pyruvate and malate, and a decrease of ATP production 
from pyruvate to one-third of the mean control value. COX activity in 
muscle homogenate as well as in isolated muscle mitochondria is decreased 
to 20% of the mean control value. These data and the lack of cytochrome 
au) protein point to a disturbance of mitochondrial oxidative metabolism 
at the level of COX. Involvement of the central nervous system (CNS) 
and elevation of pyruvate and lactate in CSF make it likely that the same 
defect is present in CNS. Although the disorder has a multisystem character, 
no defect could be detected in fibroblasts. 
In various patients with partial or complete COX deficiency, an overall 
decrease " or complete lack ' of histochemical reactivity of COX have 
been reported. Apparently the residual activity of COX in our patient 
is sufficient for a normal light- and electronmicroscopic appearance. 
COX deficiency clinically presents in a heterogeneous fashion. COX 
deficiency of muscle can manifest as a fatal infantile myopathy26 with27"34 
or without24'35"38 DeToni-Fanconi-Debré syndrome or as a benign spon-
taneously remitting myopathy of infancy.21,39 COX deficiency has also been 
reported in two types of mitochondrial encephalomyopathies: the syndro-
mes of Alpers40 and Leigh.22'25,39,41,42 Complete lack of histochemically 
demonstrable COX activity was reported in individual fibres in patients 
with chronic progressive ophthalmoplegia, but biochemical studies most 
often revealed normal COX activity.43,44 The deficiency of COX described 
in Menkes' kinky hair disease45 has a secondary nature, due to secondary 
deficiencies of copper dependent enzymes, one of which is COX. 
Our patient fits in with the clinical picture of Leigh syndrome46 (Table 
2) and we have made a clinical diagnosis of Leigh syndrome in our patient. 
Recently, a patient with a childhood encephalomyopathy with COX 
deficiency in muscle and platelets, resembling our patient, was reported 
by Angelini et al.23 This patient, an 8-year-old boy, had muscle wasting 
with proximal weakness, ataxia and mental impairment, but no pyramidal 
signs. There was parental consanguinity in this case, pointing to an 
autosomal recessive mode of inheritance. 
In other patients with Leigh syndrome, the deficiency of COX was present 
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+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
78 
69 
69 
61 
47 
39 
39 
37 
36 
IS 
Table 2. Clinical data of our patient compared with results of a literature study of 173 Leigh 
syndrome patients 
Patient Literature (%) 
Ocular signs 
Respiratory signs and symptoms 
Hypotonia 
Pyramidal signs 
Exercise intolerance 
Cerebellar signs 
Decompensation on infection 
Mental retardation/deterioration 
Seizures 
Cardiac signs and symptoms 
in skeletal muscle, heart muscle, brain, kidney, liver and cultured fibro­
blasts.47 Normal enzyme activities have been reported in liver tissue,25 and 
in liver tissue and cultured fibroblasts47 of Leigh patients with a cytochrome 
с oxidase deficiency of muscle. 
There are strong indications for the existence of tissue-specific isoforms 
of the complex enzyme COX,48 that might explain the differential invol­
vement of tissues. The apoprotein consists of multiple subunits, 3 of which 
are encoded by mitochondnal DNA, whereas the rest is encoded by nuclear 
DNA.4 9 As mitochondrial DNA is maternally transmitted,50 a non-men-
delian type of inheritance is possible in cases of COX deficiency. ' However, 
this has until now not been documented in respiratory chain defects, and 
autosomal recessive inheritance seems most probable. 
To elucidate etiologic mechanisms, enzyme abnormalities will have to 
be clarified at the molecular level with modern techniques of immuno-
cytochemistry and molecular genetics. Immunodetection allows identifi­
cation of the enzyme subunit composition. The amount of immunologically 
reacting protein was normal in two Leigh patients with COX deficiency41,52 
and diminished38 or absent52 in patients with a fatal myopathy with or 
without renal dysfunction. As human mitochondrial DNA has been fully 
sequenced,53 it is likely that mutations can be demonstrated at DNA level 
within a few years. Definition of biochemical errors at the molecular level 
will disclose different molecular defects of COX that constitute the basis 
of the different phenotypic expressions of the enzyme deficiency. 
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ABSTRACT 
Four siblings with Leigh's syndrome are described. The diagnosis was 
confirmed by pathological examination in one case. Chemical and bio-
chemical investigations of serum and urine revealed no abnormalities of 
pyruvate metabolism, but all patients had marked elevations of CSF 
pyruvate and lactate concentrations. In three of the siblings, [l-14C]pyruvate 
oxidation rates were normal in fibroblasts and leucocytes. In one patient, 
extensive biochemical and histochemical studies of liver and muscle tissue 
revealed no mitochondrial dysfunction. A defect of oxidative metabolism 
restricted to brain seems probable. 
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INTRODUCTION 
The diagnosis of subacute necrotizing encephalomyelopathy or Leigh's 
syndrome rests on pathological findings. Sharply demarcated areas of 
spongy necrosis with capillary and glial proliferation and relative sparing 
of the neurons, localized in the grey matter of mid- and hindbrain, constitute 
the most prominent histological features (16). Clinical signs and symptoms 
show considerable variation and are non-specific (16,24). The mode of 
inheritance is autosomal recessive (16,24). Biochemical investigations have 
revealed associations with several defects of oxidative metabolism 
(11,15,37,40). 
In our cases of familial Leigh's syndrome a defect of oxidative metabolism 
was probably restricted to the brain. 
CASE REPORTS 
The family consists of two healthy, unrelated parents and their four children, 
all suffering from a degenerative neurological disorder (Fig 1). 
Case 1 
Apart from slow psychomotor development, the patient's hrstory was uneventful At age 
6 years, his mental development appeared to be normal Movements were clumsy. There 
was pes cavus The tendon reflexes were hypoactive, Achilles tendon reflexes were absent. 
In the following years, his gait became ataxic and he often fell An action tremor of the 
upper extremities developed The legs became hypertonic with bilateral Babinski signs Pin­
prick and vibration sense of the legs diminished With intercurrent infections there was clinical 
η 
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Fig 1. Pedigree of the family. 
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deterioration from which he took months to recover fully During such phases, the patient 
showed periodic bradycardia and tachycardia and tachypnoea Electroencephalography (EEG) 
showed a generalized slowing of background activity, and nerve conduction velocity studies 
and electromyography (EMG) showed a slight axonal polyneuropathy of the legs. 
When aged 17 years, he died suddenly of respiratory arrest in the course of an intercurrent 
infection, dunng which he developed a tachycardia of ISO beats/mm. 
Pathological examination. The brain weighed 1,370 g and showed no macroscopic abnor­
malities On microscopical examination, sharply demarcated areas of spongy necrosis were 
situated symmetrically in the tegmentum of the brain-stem (from the caudal mesencephalon 
to the facial nerve nuclei) They were characterized by astroglia proliferation and capillary 
dilatation and proliferation with relative neuronal spanng. Identical lesions were found 
bilaterally in the thalamus. The medulla oblongata showed no abnormalities, except for 
capillary dilatation in the nuclei dorsales vagi In the cerebellum, there was glial proliferation 
in the dentate nuclei. The spinal cord showed marked myelin loss in the medial dorsal columns 
where the fibres originate from the lower extremities. On the basis of these pathological 
findings the diagnosis of Leigh's syndrome was made. 
Case 2 
After a normal psychomotor development, this patient went through a 3-month penod of 
fever of unknown ongin at age 3 years In this penod, walking difficulties developed and 
gait detenorated until he could no longer walk, owing to a severe spastic paraparesis with 
hyperactive tendon reflexes and Babinski signs. Recovery was slow and it took 1 year to 
reach the pre-morbid psychomotor level, but a rapid fatigability on exercise remained. 
At age б years, dunng an attack of tonsillitis, he became apathetic, mute and ataxic. 
Hyperventilation and respiratory alkalosis developed. The respiratory rate normalized in 
a few months, but after that time penodic irregular breathing was seen. Recovery was only 
partial Motor retardation became evident. There was a choreoathetosis and dysdiadocho-
kmesis. Muscle tone and reflexes were normal; plantar responses remained extensor. With 
intercurrent infections, there was always temporary deterioration 
At age 10 years, a cerebellar dysarthna with pronounced dysdiadochokinesis was noted. 
Gait became more ataxic Muscle tone was low and reflexes were hypoactive with Babinski 
signs. 
At age IS years, there was a hypotonic paraparesis with absent tendon reflexes of the 
legs, extensor plantar responses and severe impairment of gait. Periods of hypothermia (32°-
340C) occurred. 
The patient is now 24 years old. Full scale IQ is 70. He cannot walk without help. There 
is generalized muscular atrophy. He has a hypotonic tetraparesis with total areflexia, and 
ataxia of trunk and extremities, cerebellar dysarthna, hypermetna and intention tremor. 
Sensation is diminished distally in the extremities EEG shows diffuse encephalopathy with 
predominance of delta and theta activities Nerve conduction velocity studies and EMG 
show an axonal polyneuropathy Cerebral computed tomography (CT) scanning and cerebral 
angiography are normal. 
Case 3 
Psychomotor development was normal and medical history was uneventful until, at age 
9 years, after an intercurrent infection, the patient insidiously developed walking difficulty 
and clumsiness of fine movements. 
At age 13 years, a paraparesis and difficult micturition developed in the course of an 
intercurrent infection After initial improvement, a few months later, following a rubella 
inoculation, a bilateral oculomotor nuclear paresis became manifest. Respiration became 
irregular, there were bilateral pyramidal and cerebellar signs A few weeks later, her condition 
detenorated rapidly A bulbar paresis developed into a total flaccid paralysis in 2 weeks. 
Artificial respiration was necessary for a month A sural nerve biopsy specimen showed 
active Wallenan degeneration of myelinated and unmyelinated fibres, with massive loss of 
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fibres. Recovery was only partial Since this time, the patient has been confined to a wheelchair. 
In the following years, there have been several penods of detenoration dunng metabolic 
stress. Penodic bradycardia and tachycardia were noticed with tachypnoea. 
The patient is now 23 years old and functions on a moderately retarded mental level 
Respiration is spontaneous There is total incontinence. Vision is unimpaired despite bilateral 
optical atrophy There is divergence of the left eye, and eye movements are jerky with loss 
of smooth pursuit. There is a pseudobulbar paresis and a hypotonic paralysis of the legs. 
The arms have some residual motor function, which is further impaired by intention myoclonus 
and ataxia. Tendon reflexes are negative with Babinski plantar responses. Sensation is 
diminished distally in the legs. EEG shows a progressive diffuse encephalopathy EMG and 
nerve conduction velocity studies show an axonal polyneuropathy Cerebral CT scan is normal 
Case 4 
From age 4 years on, this patient insidiously developed neurological signs and symptoms, 
starting with easy fatigability and impairment of fine movement. Through the years there 
has been a slow, but steady progression, with stepwise detenoration dunng intercurrent 
infections In this patient, periods of tachypnoea, bradycardia and tachycardia, and hypo­
thermia were also present. 
The patient is now 20 years old and functions on a normal mental level She can manage 
the activities of daily life independently of others Outdoors, she is confined to a wheelchair. 
Speech shows a cerebellar dysarthria There is hypotonic tetraparesis with absent tendon 
reflexes and extensor plantar responses Ataxia of trunk and extremities, and an intention 
tremor indicate cerebellar involvement Sensation is unimpaired. EEG shows a diffuse 
encephalopathy EMG and cerebral CT scan are normal. 
LABORATORY INVESTIGATIONS 
Routine haematological parameters, serum electrolytes, serum pH, pCO: 
and bicarbonate, serum protein, NH3, lipids and lipoproteins were normal. 
There were no acanthocytes. Other studies revealed normal liver, renal, 
thyroid, parathyroid and adrenal function tests, serum enzymes, serum 
levels of vitamin Bi, Вб, Bu and folic acid, serum copper and ceruloplasmin, 
phytanic acid, uric acid, amino acids, and lysosomal enzyme activities in 
leucocytes. Syphilis, tuberculosis, sarcoidosis and lupus erythematosus were 
ruled out by appropriate studies. Neurological virus antibody titres and 
toxoplasma antibody titres were normal in serum and cerebrospinal fluid 
(CSF). Urinalysis, urinary organic acids and amino acids, and urinary 
excretion of heavy metals were normal. Serum glucose, pyruvate and lactate, 
and responses of glucose, pyruvate and lactate to oral glucose loading 
(1.75 g/kg) and 24-h urinary lactate excretion were all in the normal ranges. 
In case 2, prolonged fasting for 24 h resulted in a normal rise in serum 
lactate and pyruvate, and a normal stimulation of ketogenesis (17). Also 
in case 2, the intravenous alanine loading test (500 mg/kg) (12) yielded 
normal results. The results of the intravenous pyruvate loading test (8), 
however, were abnormal (Figs 2,3). 
CSF cell count was normal in all patients. In cases 1 and 2, CSF protein 
content was elevated: 580 and 436 mg/1 respectively (normal <350 mg/ 
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Fig 2. Patient 2: pyruvate response to pyruvate loading (500 mg sodium pyruvatye/kg body 
weight is administered in a penod of 10 mm using a 0.91 M sodium pyruvate solution (8)). 
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Fig 3. Patient 2. lactate response to pyruvate loading (for details see legend to Fig 2). 
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1). Protein electrophoresis and Immunoelectrophoresis patterns of all 
patients were normal, as were the levels of glucose and minerals. CSF 
pyruvate and lactate levels were elevated in all patients; the lactate/pyruvate 
ratio was elevated in cases 2 and 4 (Table 1). 
BIOPSY STUDIES 
In case 2, biopsies were performed on quadriceps muscle and liver at age 
24 years. Histochemical studies were performed in muscle tissue. Bioche­
mical studies were performed on liver and muscle homogenates. 
MORPHOLOGICAL STUDIES 
Histochemical studies of quadriceps muscle showed the presence of atrophic 
angulated fibres, indicative of denervation. There were no signs of lipid 
myopathy. In the trichromie stained section, no 'ragged-red' fibres were 
seen. No ultrastructural studies were performed. 
BIOCHEMICAL STUDIES 
Pyruvate carboxylase activity was measured in liver tissue homogenate 
(35). The activities of the enzymes cytochrome с oxidase, citrate synthase, 
succinate-cytochrome с oxidoreductase and carnitine palmitoyltransferase 
(at 0.8 mM palmitoylcarnitine) were measured in liver and/or muscle tissue 
(4,13,29,32). Pyruvate oxidation rate, and activities of citric acid cycle and 
respiratory chain enzymes were evaluated in muscle homogenate by 
measuring "СОг production from [l-14C]pyruvate and [U-14C]malate (2). 
ATP metabolism was investigated after inhibition of adenylate kinase ac­
tivity (28). Carnitine content was measured in muscle homogenate (23). 
Protein was assayed according to the method of Lowry et al (18). 
In cases 2-4, pyruvate oxidation and citric acid cycle activities in 
leucocytes and fibroblasts were determined by measuring '"СОг production 
from [l-14C]pyruvate and [2-14C]pyruvate (41). 
Table 1. CSF levels of lactate and pyruvate, and the ratio lactate/pyruvate in all four cases 
Lactate" 
Pyruvate' 
Ratio L/P 
Case 1 
4125 
225 
9.9 
Case 2 
3760 
201 
18.7 
Case3 
2440 
200 
12.2 
Case 4 
4250 
211 
20.1 
Controls 
(n=200) 
1200-1600 
85-132 
up to 15 
' μιηοΙ/Ι. 
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Table 2. Activities of mitochondrial enzymes* in liver and muscle tissue of case 2 
Substrate 
Liver 
Citrate synthase 
Cytochrome с oxidase 
Pyruvate carboxylase 
Muscle 
Citrate synthase 
Cytochrome с oxidase 
Succinate-cytochrome с oxidoreductase 
Carnitine palmitoyltransferase 
Case 2 
7 6 
33 
91 
112 
83 
8 2 
0 25 
Controls 
Range 
11-46 
28-60 
13-40 
27-77 
73-284 
11-35 
0 42-0 97 
Mean ± SD 
27.4 ± 1 4 3 
41 8 ± 1 0 9 
26 1 ± 8 4 
44 7 ± 1 5 0 
194 ± 9 2 
1 8 ± 7 
0 62 ± 0 15 
No 
12 
7 
16 
18 
39 
14 
14 
* mU/mg protein 
Table 3. U C 0 2 
genates of cas« 
Substrate 
production' from [1-
: 2 and controls 
l4C]pyruvatí : and [U-
Patient 
14C]malate in 
Controls (r 
Range 
muscle tissue homo-
i=19) 
Mean ± SD 
[l-14C]pyruvate + malate 2 04 1 89-8 74 3 53 ± 1 73 
[l-14Clpyruvate + carnitine 2 75 1 89-9 60 3 68 ± 1 91 
[U-14C]malate + pyruvate + matonaie 2 20 181-10 12 4 69 ± 2 41 
[U-l4Clmalate + acctylcamitine + malonate 2 24 1 61-8 69 4 29 ±225 
[U-l4C]malate + acctylcamitine +arsenite 1 27 1 06-4 63 2 20 ± 1 08 
* nmol/hr/mU cytochrome с oxidase 
RESULTS. 
Activities of the mitochondrial enzymes measured in liver and muscle tissue 
were all in the low-normal range (Table 2). Studies of [l-l4C]pyruvate 
and [U-14C]malate oxidation by intact muscle mitochondria revealed normal 
oxidation rates (Table 3). The ratio of the number of moles ATP + CrP 
produced per mole pyruvate oxidized amounted to 8.7 (control range: 8.8 
- 15.0; n=20). Carnitine content (total and non-esterified) was normal in 
muscle tissue. [l-MC]pyruvate and [2-14C]pyruvate oxidation rates in 
leucocytes and fibroblasts (cases 2-4) were all within the normal ranges. 
DISCUSSION 
We have described a family in which all of four sibs are afflicted with 
a degenerative neurological disorder. The oldest sib (case 1) died at age 
17 years in the course of an intercurrent infection, and on pathological 
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examination the typical features of subacute necrotizing encephalomye-
lopathy or Leigh's syndrome were found. Leigh's syndrome is transmitted 
as an autosomal recessive trait (19) and familial occurrence is not rare 
(16,24). Therefore, in our opinion the diagnosis can be considered esta-
blished in the other sibs. A mitochondrial type of inheritance (9) would 
explain better the occurrence of the disorder in all four of the children, 
but the mother is healthy and her family history gives no evidence of 
myopathic or degenerative neurological disease. The signs and symptoms 
of our patients and the chronic progressive course with exacerbations, 
mostly on intercurrent infections, have been described in Leigh's syndrome 
(6). 
Histochemical studies of muscle tissue revealed no abnormalities, in 
particular no signs of mitochondrial myopathy, e.g. ragged-red fibres or 
lipid myopathy. Ragged-red fibres, however, have only rarely been reported 
in Leigh's syndrome (5). Ultrastructural studies were not performed. 
Laboratory investigations revealed a marked elevation of CSF pyruvate 
and lactate levels with normal serum levels in all patients. 
Biochemical studies in liver and muscle tissue of case 2 revealed 
moderately low activities of all mitochondrial enzymes (Table 2). This 
finding indicates a low mitochondrial content in both tissues and not a 
specific enzyme deficiency. This is in accordance with the normal amount 
of pyruvate and malate that can be oxidized by muscle mitochondria, 
as well as the normal amount of ATP produced from the substrates (Table 
3). Although the oxidative capacity may be somewhat limited per gram 
of muscle, it is obviously not so seriously that it results in lactate 
accumulation in the blood. Direct measurement of pyruvate carboxylase 
in liver tissue demonstrated a normal activity when compared with the 
other mitochondrial enzymes. A pyruvate dehydrogenase complex (PDHc) 
deficiency can be excluded in the present patient as [l-14C]pyruvate is 
oxidized at a normal rate. Normal 14C02 production by [l-^Cjpyruvate 
is only possible if there is normal PDHc activity. 
Mitochondrial function being normal in muscle, liver, leucocytes and 
fibroblasts, it seems most probable that there is a disturbance of pyruvate 
metabolism, as indicated by the marked elevation of CSF pyruvate and 
lactate levels, which is restricted to the brain. The elevated levels of pyruvate 
and lactate after intravenous pyruvate loading can be explained by long-
term immobilization, generalized muscular atrophy, limitation of oxidative 
capacity of muscle (as discussed above) and decrease of cerebral pyruvate 
oxidation. A cerebral biopsy for exact localization of the site of the 
biochemical defect was not performed. 
Several biochemical disorders of mitochondrial function have been 
described in Leigh's syndrome. Reports of associations with pyruvate 
carboxylase deficiency (14,15,33,36) and a disturbance of the thiamine 
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triphosphate synthesis system (25, 26) have been controversial. There have 
been reports of subacute necrotizing encephalomyelopathy associated with 
cytochrome с oxidase deficiency (20,40). Recently, a tissue specificity of 
cytochrome с oxidase was demonstrated that might explain the differential 
involvement of tissues (e.g. the central nervous system in our patients) 
in cytochrome с oxidase deficiency (21,42). A deficiency of NADH 
dehydrogenase was reported in two patients (37,38). The most consistent 
biochemical finding in Leigh's syndrome, however, seems to be an ab­
normality of PDHc. Decreased PDHc activities (1,10,11,22,34) and defective 
PDHc activation (3,7,31) have been reported. In a patient with Alpers' 
syndrome a deficiency of pyruvate dehydrogenase restricted to the brain 
has been demonstrated (27). In a recent report, however, Sheu and Blass 
(30) were unable to demonstrate a significant difference in the activity 
of pyruvate dehydrogenase phosphate phosphatase, the enzyme that ac­
tivates PDHc by phosphorylation, in cultured skin fibroblasts of five 
patients with Leigh's syndrome compared with normal control cell lines. 
In view of a biochemical disorder of mitochondrial function in Leigh's 
syndrome, the concept of mitochondriopathy (as proposed by Walter (39)) 
seems appropriate in subacute necrotizing encephalomyelopathy. However, 
the pathophysiology of Leigh's syndrome, especially the regional selective 
vulnerability, i.e. the predilection for specific brain structures in the 
expression of a biochemical defect, is still unknown. 
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GENERAL DISCUSSION 
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This study provides a review of the literature data concerning Leigh 
syndrome, adding the results of own clinical, neurophysiological, and 
biochemical investigations in patients with this syndrome. It provides data 
and arguments to answer the questions raised in the first chapter: 
1. Can a better characterization of the clinical picture of Leigh syndrome 
be achieved? 
2. Is it possible to distinguish clinically distinct subgroups within the 
spectrum of Leigh syndrome? 
3. What is the contribution of technical (neurophysiological, neuroradio-
logical and biochemical) investigations to diagnosis and to insight into 
the pathophysiology of Leigh syndrome? 
4. Is it possible to formulate better criteria for a diagnosis of Leigh 
syndrome durante vitam? 
Pathophysiological and therapeutic aspects and future perspectives will 
also be discussed in this chapter. 
RESULTS AND ANSWERS TO THE QUESTIONS 
Can a better characterization of the clinical picture of Leigh 
syndrome be achieved? 
The median age at onset of the disease in the 173 patients from the literature 
is 0.9 years, and the median age at death is 2.1 years. In the juvenile 
group, median time of survival after onset of the disease is 5.5 years versus 
0.9 years in the neonatal, early infantile, and infantile groups. The male 
: female ratio is 3 : 2, but with increasing age at onset there is an increasing 
preponderance of males over females, up to 4 : 1 in the juvenile group, 
which is significantly deviant from the expected 1 : 1 ratio. We have no 
explanation for this phenomenon. The mode of inheritance of Leigh 
syndrome is generally considered to be autosomal recessive, but an X-
linked mode of transmission might explain the male preponderance. 
Signs and symptoms, both at onset and in the course of the disease 
(the latter for different age groups) are presented in Chapter II. Feeding 
problems, motor retardation, hypotonia, eye signs and symptoms, mental 
retardation, seizures, and respiratory problems are seen most frequently 
at onset (Table 3, Chapter II). Eye signs and symptoms, respiratory 
problems, hypotonia, pyramidal signs, motor retardation, feeding problems, 
exercise intolerance, deterioration on infections, cerebellar signs, mental 
retardation, seizures, extrapyramidal and cardiac signs are frequently 
encountered in the course of the disease (Table 4, Chapter II). 
Respiratory and cardiac signs and symptoms, pyramidal and cerebellar 
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signs, and especially the decompensation/deterioration during infectious 
episodes have been noticed more frequently in our patient group than 
in the patients reported in the literature (Table I, Chapter IV). It is evident 
that it is not one separate sign or symptom but the combination of signs 
and symptoms that may point to Leigh syndrome. 
Is it possible to distinguish clinically distinct subgroups within 
the spectrum of Leigh syndrome? 
For practical purposes the patients reported in the literature have been 
divided into 4 subgroups according to age at onset, although these subgroups 
appear to represent no separate clinical entities. The group with the juvenile 
age at onset can be separated from the rest, in that the disease runs a 
much more protracted course in these children and median survival is 
much longer than in the other groups (Table 2, Chapter II). The patients 
with a very rapidly progressive course of the disease clinically present in 
a rather uniform way with epileptic seizures and acute coma, ending in 
death within a few days. The more subacute and protracted the disease, 
the more manifold the clinical signs and symptoms. From the case studies 
reported in the literature we were not able to separate any subgroup with 
a characteristic clinical presentation. But in our patient group we found 
3 patients with a very similar clinical picture consisting of hypokinesia 
and rigidity (Chapter III). The importance of this finding is, that in the 
differential diagnosis of infantile and juvenile parkinsonism Leigh syndrome 
must be taken into account, and that hypokinesia and rigidity in a child 
warrant investigation of pyruvate metabolism. 
What is the contribution of technical investigations to diagnosis 
and to insight into the pathophysiology of Leigh syndrome? 
Neurophysiological investigations 
The value of neurophysiological studies in Leigh syndrome is assessed 
in 12 patients (Chapter IV). As neurophysiological studies (electroenceph-
alogram, electromyogram, nerve conduction velocity studies and evoked 
potentials) rarely show abnormalities specific for a certain disease, it is 
not surprising to find no specific abnormalities in our patients. But the 
yield of neurophysiological abnormalities in our patients is surprisingly 
low and especially the lack of evoked potential abnormalities is striking 
(Table 4, Chapter IV). In our patients there is a relatively late onset and 
a chronic, slowly progressive course of the disease; clinical examination 
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points to pathology not of the afferent nervous system structures but 
especially of the efferent structures. This might explain the paucity of 
neurophysiological abnormalities in the patients we studied. 
Radiological investigations 
A radiological abnormality in Leigh syndrome becoming increasingly 
recognized is the finding of bilateral hypodense areas in the basal ganglia, 
especially the putamina, on CT or MRI. Two of our patients show these 
hypodensities (Chapter III), whereas 4 other proven Leigh patients do 
not show the abnormality. So these lesions on CT or MRI are not obligatory, 
nor pathognomic of Leigh syndrome, as they are found in other pathological 
conditions (Chapter III). However, if these lesions are present the possibility 
of Leigh syndrome should be considered. An interesting finding in MRI 
investigation of our patients was the fact that the calculated Ti values 
of the thalamus of two patients were prolonged while the images were 
not abnormal. It might, therefore, be useful to calculate the Ti and T2 
values of clinically relevant areas, even if MRI pictures are not abnormal, 
in patients suspected of Leigh syndrome. 
Biochemical investigations 
Leigh syndrome is associated with several defects of pyruvate metabolism 
and of the respiratory chain (Chapter II). Chemical studies of pyruvate 
metabolism in our patients (determination of pyruvate and lactate levels 
in serum and cerebrospinal fluid (CSF), of lactate in a 24-hour urinary 
sample, and of glucose, pyruvate, and lactate after oral glucose loading) 
often point to a disturbance of pyruvate metabolism (Table 2, Chapter 
V). In the literature, data on chemical studies of pyruvate metabolism 
in Leigh patients are relatively scarce. But in the patients in whom lactate 
and pyruvate are determined in body fluids abnormalities are often found 
(Table 5, Chapter II). The most important abnormal parameters in our 
patients are the levels of pyruvate and lactate in CSF, whereas the pyruvate 
and lactate levels in serum are only rarely elevated in resting state (Table 
2, Chapter V). The intravenous pyruvate loading test, performed in 9 
patients with Leigh syndrome and 23 control subjects, proved to be a 
valuable diagnostic tool to detect disturbances in pyruvate metabolism 
(Chapter V). By constructing a tolerance region for normal controls we 
made the test suitable for diagnostic purposes (Fig 1, Chapter V). The 
intravenous pyruvate loading test gives no additional information when 
routine investigations indicate a disturbance of pyruvate metabolism; but 
when these investigations are inconclusive, while at the same time there 
is a strong clinical suspicion of Leigh syndrome, the intravenous pyruvate 
loading test can be of diagnostic value. 
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The case studies of our own patients with Leigh syndrome reveal 
interesting facts. A defect of NADH dehydrogenase was established in 
two patients (Chapters VI and VII) and suspected in one patient (Chapter 
VIII). This biochemical defect was hitherto only reported in patients with 
muscular complaints and in a patient with Alpers' disease (Chapter VI). 
In one patient we found a defect of cytochrome с oxidase (Chapter IX). 
The association between Leigh syndrome and cytochrome с oxidase 
deficiency has been described by several authors, but cytochrome с oxidase 
deficiency has also been associated with several other heterogeneous clinical 
syndromes with variable biochemical expression in different organs (Chap­
ter IX). The last case study describes four sibs with Leigh syndrome (Chapter 
X). No abnormalities of pyruvate metabolism or of the respiratory chain 
were found in liver and muscle tissue, but the marked elevation of pyruvate 
and lactate levels in CSF points to a disturbance of pyruvate metabolism 
restricted to brain. 
Is it possible to formulate better criteria for a diagnosis of 
Leigh syndrome durante vitam? 
Despite the lack of characteristic signs and symptoms, and despite the 
existence of some overlap, the clinical picture of Leigh syndrome differs 
clearly from those of the other mitochondrial encephalomyopathies. It 
is, in our opinion, possible to come to the diagnosis of Leigh syndrome 
durante vitam when the following conditions are present: 
- clinical signs and symptoms, 
- bilateral hypodense areas in the basal ganglia region on CT or MRI, 
- association with a defect of pyruvate metabolism or respiratory chain, 
- autosomal recessive mode of inheritance. 
SOME PATHOPHYSIOLOGICAL CONSIDERATIONS 
The pathophysiology of Leigh syndrome so far has not been clarified. 
Radiological studies (CT, MRI) and chemical studies can have important 
contributions to the diagnosis, but both techniques provide little insight 
into the pathophysiology. 
Morphological mitochondrial abnormalities have been frequently ob­
served in patients with defects of the respiratory chain or of the energy 
transducing system.1 The structural mitochondrial alterations are not 
specific for any type of disorders, and no correlation has been found between 
type of morphological mitochondrial alteration and a certain enzyme 
deficiency. 
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In many patients with Leigh syndrome defects of pyruvate metabolism 
and the respiratory chain have been reported. Defects of the pyruvate 
dehydrogenase complex (PDHc) and cytochrome с oxidase (COX) may 
be etiopathogenic factors in Leigh syndrome.2 A causal link of a pyruvate 
carboxylase deficiency with Leigh syndrome seems unlikely (Chapter VIII). 
In favour of a relationship between PDHc deficiency and Leigh syndrome 
is the pathological similarity between Leigh syndrome and Wernicke's 
encephalopathy, the latter being associated with a deficiency of thiamine 
(vitamin Bi), a cofactor of PDHc. 
The striking clinical deterioration of Leigh patients in periods of 
infections, inoculations or traumas, all of which are events leading to an 
increased energy demand, is compatible with the concept of deficiencies 
of enzymes involved in oxidative metabolism. Without metabolic stress 
the residual enzyme activity is sufficient for normal mitochondrial or cellular 
functioning, but with increasing energy demands the system decompensates 
at its weakest link (the deficient enzyme) and clinical symptoms become 
manifest. 
The fact that deficiencies of PDHc, NADH dehydrogenase and COX 
all affect the capacity of mitochondrial oxidative metabolism might explain 
the occurrence of one climcopathological entity (Leigh syndrome), based 
on these different defects (Fig 3, Chapter II). But defects of PDHc, NADH 
dehydrogenase and COX have also been reported in association with several 
other clinical syndromes: PDHc deficiency in Alpers' disease, hypomy-
elination, and spinocerebellar ataxias; NADH dehydrogenase deficiency 
in patients with a clinical myopathy and with Alpers' disease; and COX 
deficiency in early infantile, rapidly progressive, fatal myopathy with and 
without renal dysfunction, a benign infantile myopathy, and Alpers' disease. 
According to Blass,3 in PDHc deficiency the clinical picture seems to show 
a positive correlation with the degree of residual activity of PDHc, while 
in NADH dehydrogenase and COX deficiency such a correlation has not 
been demonstrated. 
The mitochondrial encephalomyopathies are multisystem disorders. The 
biochemical abnormalities have been detected in various tissues, e.g. muscle, 
liver, brain, kidney and cultured fibroblasts. However, in most patients 
the defects are expressed only in skeletal muscle and brain tissue. Ex­
ceptionally, defects restricted to brain have been published4 (the family 
described in Chapter X). The presence of a biochemical abnormality does 
not mean that there are always clinical correlates, e.g. a biochemical defect 
of muscle can be established in a patient who does not show clinical 
myopathy. In patients with an encephalomyelopathy there is often such 
a 'biochemical' mitochondrial myopathy. 
Insight into the biochemical defect at a molecular level has to be gained 
to be able to explain the different phenotypic expressions of the enzyme 
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deficiencies. In COX deficiency the different tissue-specific isozymes of 
COX might explain the differential involvement of tissues, which may 
constitute one of the causes of the various clinical syndromes associated 
with deficiency of this enzyme. 
THERAPY 
Many therapeutic strategies have been reported in patients with disturbances 
of pyruvate metabolism or the respiratory chain (see Chapter II). As soon 
as the diagnostic investigations were completed, all our patients received 
a combination of thiamine (3 χ 100 mg) and lipoic acid (3 χ 20 mg), 
both cofactors of PDHc, and riboflavin ( 3 x 5 mg), a precursor of the 
flavin moiety of flavoproteins (see Chapter II). The results of this therapy 
have not been evaluated consistently by means of a clinical trial, nor by 
comparing results of chemical and biochemical studies before and during 
therapy. 
In order to evaluate the efficacy of drug treatment regimens in this 
group of disorders, prospective controlled trials will have to be performed 
in patients with identified biochemical defects. As the incidence of these 
disorders is very low, a multicenter approach will be necessary. 
ANTENATAL DIAGNOSIS 
Of the various abnormalities found in the mitochondrial (encephalo)-
myopathies only a restricted number of enzyme deficiencies can be 
demonstrated in fibroblasts.5 The activities of cytochrome с oxidase and 
the pyruvate dehydrogenase complex can be determined in both chorionic 
villi and fibroblasts, and thus antenatal diagnosis of defects in these enzymes 
is possible, if the defects come to expression in these cells. Besides other 
advantages of the use of chorionic villi, the technical problems in deter­
mining the activities of the respiratory chain are fewer in the case of 
chorionic villi than in fibroblasts. 
Robinson et al6 claim that it is possible to detect deficiencies of NADH 
dehydrogenase and cytochrome с oxidase in cultured fibroblasts of all 
patients in whom chemical studies point to a deficiency of the respiratory 
chain. However, in patients with (encephalo)myopathies, in whom distinct 
enzymatic defects were established in muscle, we found no decreased enzyme 
activities in fibroblasts and chorionic villi. This limits, of course, the 
possibilities for antenatal diagnosis. 
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FUTURE PERSPECTIVES 
Several recent and future developments will have their impact on the 
diagnosis of Leigh syndrome and the insight into its pathophysiology. The 
increasing resolution of CT and MRI will enable detection of the often 
very small lesions in the brainstem, that may constitute the only mor-
phological abnormalities in Leigh syndrome. 
A very promising new development is the in vivo phosphorus magnetic 
resonance spectroscopy (31P-NMR) of muscle, that already permits the 
identification of a variety of metabolic disorders of muscle7,8 and the 
monitoring of therapeutic improvements in mitochondrial (encephalo)-
myopathies.9 Rapid, non-invasive diagnosis of disturbances of mitochon-
drial functioning will probably result from the further development and 
application of 31P-NMR spectroscopy. 
Positron emission tomography (PET) has already enabled in vivo study 
of cerebral glucose metabolism in normal brain and in several neurological 
disorders in a quantitative way.10 Improvement of spatial resolution (from 
7-8 mm at present to 2-3 mm in the future), and reduction of processing 
time per event, so that rapid changes in (patho)physiological parameters 
can also be recorded with accurate assignment to small cerebral structures, 
will contribute to more insight in the pathophysiology of Leigh syndrome. 
The quantitative analysis of the metabolism of therapeutic substances 
labeled with positron-emitting radionuclides will permit in vivo monitoring 
of therapy. Perhaps PET will help to solve the problem of selective regional 
vulnerability of certain brain structures. 31P-NMR spectroscopy and PET 
will enable the clinician to make the diagnosis in affected but still 
asymptomatic sibs of Leigh patients. Such technical possibilities will be 
of great value in genetic counseling. 
Biochemical investigations in various tissues are being used to identify 
enzyme deficiencies of pyruvate metabolism or respiratory chain in Leigh 
syndrome and other mitochondrial (encephalo)myopathies. With use of 
modern techniques of immunocytochemistry and of molecular genetics 
attempts are made to disclose the abnormalities at the molecular level. 
Probably this will solve the problems of tissue and organ specificity of 
some enzyme deficiencies and of the different phenotypic expressions of 
certain enzyme deficiencies. Of course, also therapy will benefit by exact 
localization of the molecular defect. 
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SUMMARY 
This study of Leigh syndrome is focusing mainly on the clinical and 
biochemical aspects of the disorder. 
In Chapter II the results of a literature study of 173 patients with proven 
Leigh syndrome are summarized. This group of patients is divided into 
four subgroups according to age at onset: neonatal (0-4 weeks), early 
infantile (4 weeks-1 year, infantile (1-4 years) and juvenile (4-16 years). 
Sex ratio, duration of the disease, and most important signs and symptoms 
at onset and in the course of the illness are surveyed. The results of technical 
studies (neurophysiological studies, radiological studies, and chemical and 
biochemical studies) and their significance are discussed. An overview of 
the pharmacotherapeutical regimens and strategies in this group of disorders 
is presented. The main conclusion of this study is, that it is possible to 
come to a diagnosis of 'most probable' Leigh syndrome durante vitam 
based on 1) signs and symptoms, 2) autosomal recessive mode of inheritance, 
3) association with a defect of pyruvate metabolism or respiratory chain, 
and 4) bilateral hypodense areas in the basal ganglia region on CT or 
MRI. 
In Chapter III three patients are reported in whom hypokinesia and 
rigidity are the most prominent clinical manifestations of Leigh syndrome. 
The importance of investigating mitochondrial energy metabolism in 
children with parkinsonism is stressed. 
In Chapter IV the results of neurophysiological studies (electroenceph­
alogram, electromyogram, nerve conduction velocity studies, visual evoked 
potentials, brainstem auditory evoked potentials, and median nerve so­
matosensory evoked potentials) in 12 patients are presented. No specific 
abnormalities are found and it is concluded that neurophysiological studies 
at least in our patients - a subgroup with a relatively late onset and a 
chronic progressive course of the disease - do not contribute to the diagnosis 
of Leigh syndrome. 
Chapter V contains the results and implications of an intravenous 
pyruvate loading test in 9 patients with Leigh syndrome. The pyruvate 
loading test can have diagnostic value in cases where there is a strong 
clinical suspicion while determinations of lactate and pyruvate levels in 
body fluids are not conclusive. 
In Chapters VI, VII and VIII case studies are presented of two patients 
with an established (Chapters VI and VII) and one patient with a suspected 
(Chapter Vili) NADH dehydrogenase deficiency. Such a defect of the 
respiratory chain was hitherto not reported in Leigh syndrome. 
In Chapter IX a patient is described with a clinical diagnosis of Leigh 
syndrome and a cytochrome с oxidase deficiency in muscle. This defect, 
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which is associated with several clinical syndromes, has been reported in 
a number of Leigh patients. 
Chapter X contains a report of four siblings with Leigh syndrome 
associated with a probable defect in oxidative metabolism restricted to 
brain. 
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SAMENVATTING 
Deze studie betreffende het syndroom van Leigh is voornamelijk gericht 
op de klinische en biochemische aspecten van de aandoening. 
In Hoofdstuk II worden de resultaten weergegeven van een literatuur-
studie van 173 patiënten waarbij het syndroom van Leigh is vastgesteld. 
Deze groep patiënten is verdeeld in vier subgroepen naar leeftijd bij het 
begin van de ziekte: neonataal (0-4 weken), vroeg-infantiel (4 weken-1 jaar), 
infantiel (1-4 jaar) en juveniel (4-16 jaar). Er wordt een overzicht gegeven 
van de sex-ratio, de duur van de periode tussen vaststellen van de ziekte 
en het overlijden, en de belangrijkste klinische verschijnselen bij het begin 
en in het verloop van de ziekte. De resultaten en de betekenis van technische 
onderzoeken (neurofysiologisch, radiologisch, chemisch en biochemisch 
onderzoek) worden gepresenteerd en besproken. Er wordt een overzicht 
gegeven van de farmakotherapeutische mogelijkheden bij deze groep van 
aandoeningen. De voornaamste conclusie van dit onderzoek is dat het 
mogelijk is om durante vitam tot een diagnose van 'zeer waarschijnlijk' 
syndroom van Leigh te komen op basis van: 1) klinisch beeld, 2) autosomaal 
recessieve erfelijkheidsmodus, 3) stoornis in het pyravaatmetabolisme of 
in de ademhalingsketen, en 4) bilaterale afwijkingen in de basale ganglia 
opCTofMRI . 
In Hoofdstuk III worden 3 patiënten besproken waarbij hypokinesie 
en rigiditeit de belangrijkste klinische manifestaties van het syndroom van 
Leigh vormen. Het belang van het onderzoek van het mitochondriële 
energiemetabolisme bij kinderen met parkinsonisme wordt benadrukt. 
In Hoofdstuk IV worden de resultaten weergegeven van neurofysiologisch 
onderzoek (elektroencefalografie, elektromyografie, bepaling van de ge-
leidingssnelheid van zenuwen en evoked potentials) bij 12 patiënten uit 
de Nijmeegse kliniek met het syndroom van Leigh. Er worden geen 
specifieke afwijkingen gevonden. Geconcludeerd wordt dat het neurofy-
siologisch onderzoek in ieder geval bij onze patiënten - een subgroep met 
een relatief laat begin van de aandoening en een chronisch progressief 
beloop - geen bijdrage levert aan de diagnose. 
In Hoofdstuk V worden de resultaten en implicaties besproken van een 
intraveneuze pyruvaatbelastingstest bij 9 patiënten met het syndroom van 
Leigh. Deze test is ontworpen om het pyravaatmetabolisme te onderzoeken. 
De intraveneuze pyruvaatbelastingstest kan diagnostische waarde hebben 
in gevallen waar klinisch een sterke verdenking bestaat op het syndroom 
van Leigh, waarbij metingen van laktaat en pyruvaat in lichaamsvloeistoffen 
geen duidelijke indicatie geven omtrent het al of niet bestaan van een 
stoornis in het pyravaatmetabolisme. 
In Hoofdstukken VI, VII en VIII wordt de studie beschreven van twee 
patiënten (Hoofdstukken VI en VII) met een bewezen en van één patiënt 
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(Hoofdstuk VIII) met een waarschijnlijke deficiëntie van het NADH 
dehydrogenase. Dit defect van de ademhalingsketen was tot nu toe nog 
niet beschreven bij het syndroom van Leigh. 
In Hoofdstuk IX wordt een patiënt beschreven met een klinische diagnose 
van het syndroom van Leigh en een cytochroom с oxidase deficiëntie van 
het spierweefsel. Dit defect, dat geassocieerd is met verschillende klinische 
syndromen, is beschreven bij een aantal patiënten met het syndroom van 
Leigh. 
In Hoofdstuk X worden vier kinderen uit één gezin beschreven met 
het syndroom van Leigh, met waarschijnlijk een stoornis in het oxidatieve 
metabolisme welke beperkt is tot het centrale zenuwstelsel. 
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der Putt Lyceum te Eindhoven, studeerde hij van 1972 tot 1979 geneeskunde 
aan de Katholieke Universiteit te Nijmegen. Het kandidaatsexamen en het 
doctoraal examen werden cum laude behaald. 
Van juli 1979 tot september 1984 volgde hij de opleiding tot het 
specialisme zenuw- en zielsziekten: de 3-jarige A-opleiding neurologie aan 
de Kliniek voor Neurologie van het St. Radboudziekenhuis te Nijmegen, 
opleiders Drs. J.J. Prick -ad interim- en Prof.Dr. B.P.M. Schulte, en de 
2-jarige A-opleiding psychiatrie aan de Psychiatrische Instituten van de 
Godshuizen te 's Hertogenbosch, opleider Dr. G.J. Zwanikken. 
Vervolgens werd de opleiding gevolgd ter verkrijging van de aantekening 
klinische neurofysiologie op de Afdeling Klinische Neurofysiologie van 
de Kliniek voor Neurologie van het St. Radboudziekenhuis, opleider 
Prof.Dr. S.L.H. Notermans. 
Sinds 1 januari 1985 is hij werkzaam als neuroloog-klinisch neurofy-
sioloog in het Ignatiusziekenhuis te Breda, in associatief verband met 
M.A.M. Bomhof, M.E. Dorren, W.A.C. Schijns (tot september 1985) en 
J.P.M. Stroy (vanaf september 1985). 
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STELLINGEN 
behorende bij het proefschrift 
LEIGH SYNDROME 
in het openbaar te verdedigen 
op 9 oktober 1987 
des namiddags te 3.30 uur 
door 
P.M.M. VAN ERVEN 
1. Op basis van klinische verschijnselen, bilaterale afwijkingen in de basale 
ganglia op cerebrale CT scan en MRI, associatie met een stoornis in 
het pyruvaatmetabolisme en een autosomaal recessieve erfmodus kan men, 
durante vitam, de diagnose 'zeer waarschijnlijk' syndroom van Leigh 
stellen. 
- dit proefschrift 
2. Als de gehalten aan pyruvaat en laktaat in serum en liquor cerebrospinalis, 
de laktaatuitscheiding in 24-uurs urine en de resultaten van de orale 
glucosetolerantietest en van de pyruvaatbelastingstest normaal zijn, is 
de pyruvaatoxidatie van spier- en hersenweefsel ongestoord. 
- dit proefschrift 
3. Klinisch-neurofysiologische onderzoeksmethoden dragen niet bij tot het 
stellen van de diagnose syndroom van Leigh. 
- dit proefschrift 
4. Bij kinderen met een hypokinetisch-rigide syndroom moet de diagnose 
syndroom van Leigh overwogen worden en dient het pyruvaatmetabolisme 
onderzocht te worden. 
- dit proefschrift 
5. Het hypokinetisch-rigide syndroom op kinderleeftijd wordt vaak niet 
herkend en men stelt dan ten onrechte meestal de diagnose spastische 
tétraplégie bij een infantiele encephalopathie. 
6. De therapie van de (akute) hernia nuclei pulposi (HNP) bestaat uit absolute 
bedrust gecombineerd met analgetica en spierrelaxantia. Wertheim Salo-
monson stelde in 1911 reeds, hoewel de HNP in zijn tijd nog niet bekend 
was: "tegen massage bij versehe gevallen der neuralgia ischiadica dient 
met nadruk te worden gewaarschuwd". 
- Wertheim Salomonson JKA. Amsterdam, Scheltema en Holkema's Boekhandel, 1911, 
ρ 315. 
7. In de Chinese Volksrepubliek zijn de incidentie en prevalentie van 
cerebrovasculaire aandoeningen gelijk aan die in Westerse landen, doch 
om onbekende redenen is het aantal intracerebrale bloedingen (44%) veel 
groter dan in Westerse landen gemiddeld gezien wordt (12%). 
- Li S-c, et al. Neurology 1985;35:1708-13. 
8. Bij patiënten met een asymptomatische carotissouffle is het geven van 
uitgebreide informatie omtrent mogelijke symptomen van voorbijgaande 
ischemische aanvallen van belang, want "although the risk of cerebral 
ischemic events is highest in patients with severe carotid artery stenosis, 
in most instances even these patients do not have strokes without some 
warning". 
- Chambers BR, et al. N Engl J Med 1986;315:860-5. 
9. Huidafwijkingen (pruritus, pigmentafwijkingen en hyperkeratotische ver-
anderingen) worden gezien bij ongeveer 30% van de patiënten met 
hersentumoren. 
- Andreev VC, Petkov I. Br J Dermatol 1975;92:675-8. 
10. Bij onderzoek naar de nauwkeurigheid van citaten en referenties in 
medische tijdschriften (waaronder de Lancet, New England Journal of 
Medicine en British Medical Journal) bleek, dat 24% van alle referenties 
onjuist geciteerd werd. Vele onwaarheden worden op deze manier ge-
accepteerde feiten. 
- De Lacey G, et al. Br Med J 1985;1:557-9. 
11. Het om budgettaire redenen onthouden van medische zorg aan bepaalde 
groepen patiënten door ziekenhuisdirekties of medici is ten principale 
onjuist. Het betreft hier geen medische doch een politieke keuze. Laat 
de politiek zich duidelijk uitspreken omtrent wie in de toekomst wèl 
en wie géén behandeling mag verwachten. 
12. Door het grotendeels negeren van risicofaktoren m.b.t. het ontstaan van 
ziekten, geeft de Nederlandse bevolking impliciet aan vertrouwen te 
hebben in de beoefenaars van de geneeskunst hier te lande. 



